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Abstract 
 
Breast cancer is the most common cancer in the UK, but despite recent encouraging increases in 
survival rates, is still the second most common cause of cancer death in women in the UK. To try to 
reduce systemic toxicity during treatment of cancer patients, a plethora of targeted therapies are in 
various stages of development.  PARP inhibitors have been shown to be particularly effective in 
BRCA-deficient cells, making them a contender as a personalised therapy. One of the challenges for 
targeted therapies is that of resistance, which limits the extent of benefit to the patient. The work 
described in this study continues previous work within our laboratory, investigating the PARP 
inhibitor olaparib in a conditional mouse model of BRCA2-mutated human breast cancer. 
The data presented here establish a correlation between histological tumour type and response to 
olaparib therapy, with poor responders classified exclusively as mesenchymal-like metaplastic 
spindle cell carcinomas (MSCC). This suggests that further patient stratification is required when 
deciding on whether this therapy may be suitable, and may explain why not all patients with BRCA-
mutated breast cancer have benefitted from olaparib therapy in current clinical trials. 
Investigation of olaparib resistance in this study indicated that several currently proposed 
mechanisms of resistance were not pertinent to the Brca2/p53 model, hence novel mechanisms 
were sought. Histopathological analysis of resistant tumours showed that the majority were MSCCs, 
representing a significant change in the proportion compared to an untreated cohort. Other 
resistant tumour types had epithelial morphology, but showed an increase in expression in some 
mesenchymal-like genes compared to untreated cohorts, suggesting that mesenchymal features 
may be important in causing resistance to olaparib. 
A similar tumour model, incorporating the additional deletion of E-cadherin, was used to investigate 
whether lack of this protein in tumours affected response and resistance to olaparib therapy. Loss of 
Cdh1 led to an increase in invasive ductal carcinomas of no special type (IDC-NST) and the absence of 
MSCCs, suggesting that genetic loss of expression does not drive the formation of mesenchymal-like 
tumours. Correlating with this, loss of E-cadherin did not drive epithelial-to-mesenchymal transition 
in these tumours and had no effect on response to olaparib therapy or resistance to the inhibitor. 
Taken together, the data presented in this thesis suggest that MSCCs have an intrinsic resistance to 
olaparib therapy, and tumours which initially respond to olaparib therapy harness or acquire certain 
mesenchymal characteristics in order to develop resistance during treatment.  
1 
 
1. Introduction 
1.1 Mammary gland 
1.1.1 Structure and Architecture 
The female mammalian mammary gland functions to produce and secrete milk to nourish 
progeny. The milk is supplied by an exterior nipple which is connected to an interior 
network of epithelial ducts. The epithelial ducts branch throughout the fat pad, which 
comprises of adipocytes, fibroblasts, immune cells, neurons and blood vessels. In humans 
the nipple is connected to numerous epithelial ducts and pregnancy initiates the formation 
of alveoli, the sites of milk production. A collection of alveoli connected to one terminal duct 
is termed a terminal duct lobular unit (TDLU) (Figure 1.1A). 
The epithelial ducts are comprised of two cellular layers surrounding a central lumen (Figure 
1.1C) (Howard and Gusterson 2000). The inner layer of epithelial cells are termed luminal 
cells. These cells have an apical-basal polarity, are connected to adjacent luminal cells via 
tight junctions and are characterised by the expression of genes such as cytokeratin (CK) 8 
and CK18. Approximately a third of the luminal cells express the oestrogen receptor (ER), 
enabling them to respond to oestrogen. The outer layer of cells surrounding the duct lumen 
are the basal cells. These cells are located between the luminal cells and the basement 
membrane and are characterised by the expression of CK5, CK14 or p63. Within this basal 
layer reside the myoepithelial cells, which contain features of both epithelial and smooth 
muscle cells and can be characterised by the expression of markers such as smooth muscle 
actin (SMA). These cells contract in response to the hormone oxytocin during lactation. The 
basement membrane functions to provide structural support for the epithelial cells and is 
composed of extracellular matrix proteins such as type IV collagen, fibronectin and laminin 
(Richert et al. 2000). 
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1.1.2 Key differences between the human and mouse mammary glands 
Although the structure and development of the mammary glands in humans and mice are 
very similar, and studying the mouse mammary gland has achieved important advances in 
the knowledge of human mammary gland morphogenesis and disease, there are key 
differences between the two species. These include: (i) sexual dimorphism occurs during 
puberty in humans while in mice it occurs in utero; (ii) humans have one pair of mammary 
glands whereas mice have five; (iii) in humans the nipple is connected to multiple ducts and 
the alveoli are clustered in discrete TDLUs, whereas in mice the nipple is connected to one 
primary duct and the alveoli are located throughout the ductal network (Figure 1.1B) (Hovey 
et al. 2002). In addition the TDLUs in humans are encapsulated by intralobular stroma, 
which is predominantly composed of fibroblasts, and is bordered by a second, denser 
intralobular layer. In comparison the stroma in the mouse mammary gland is mainly 
composed of adipocytes (Howard and Gusterson 2000). 
1.1.3 Changes during development  
The mammary gland is a unique tissue in that the majority of its development occurs post-
embryonically. The female mouse mammary gland undergoes dramatic morphological 
changes during puberty, pregnancy, lactation and involution (Figure 1.2A). At birth the 
interior mammary gland is composed of a rudimentary ductal structure (Richert et al. 2000). 
Oestrogen and progesterone initiate epithelial proliferation during puberty, creating 
secondary ducts, whose branching and elongation initiate from terminal end buds (TEBs), 
which are located at the growing tip of the duct. TEBs contain two cell types: cap cells and 
body cells. Cap cells compose the outer layer of the terminal end bud and form the basal 
cells, whereas the body cells form multilayers in the duct lumen and give rise to luminal cells 
(Figure 1.2B) (Williams and Daniel 1983; Hennighausen and Robinson 2005).  The TEBs 
continue to cause ductal branching and elongation until they reach the capsule at the end of 
the mammary fat pad or become surrounded by other ducts, where they then regress to 
form terminal ducts (Howard and Gusterson 2000). Each oestrous cycle results in the 
formation of alveolar buds, but in the absence of pregnancy-related hormones these buds 
regress (Howard and Gusterson 2000). Rising levels of hormones such as prolactin, 
oestrogen and progesterone during pregnancy initiates further ductal branching and  
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Figure 1.1 Structure of epithelial ducts within the mammary gland. (A) The human 
mammary gland. (B) The mouse mammary gland. (C) Epithelial duct structure. TDLU: 
terminal ductal lobular unit. 
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Figure 1.2 Post natal development of the mouse mammary gland. (A) Changes in structure in pre-pubertal, pubertal, adult, pregnant, 
lactating and involuting mammary gland in mice. TEB: terminal end buds. (B) TEB structure. Figure adapted from Hennighausen and Robinson, 
2005
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differentiation of the alveolar buds into alveoli. During lactation milk is produced in the 
alveoli and the contractile myoepithelial cells function to move the milk towards the nipple. 
Once lactation ceases the mammary gland undergoes a high rate of apoptosis and 
remodelling, a process known as involution, resulting in the morphology of the ductal 
network returning closely to the pre-pregnancy state (Howard and Gusterson 2000).   
 
1.1.4 Mammary gland cell hierarchy 
Cell hierarchy in the mammary gland remains controversial, with conflicting ideas as to 
whether the epithelial cell lineages arise from bipotent or unipotent stem cells (Figure 1.3A-
B).  Transplantation studies of small numbers of, or even single basal cells have been shown 
to regenerate entire mammary epithelial trees (Shackleton et al. 2006; Stingl et al. 2006), 
demonstrating the presence of bipotent stem cells in the basal layer. In contrast a study by 
Van Keymeulen and colleagues suggested that the luminal and basal lineages are uncoupled 
and are produced from distinct unipotent stem cell populations (Van Keymeulen et al. 
2011). The in 2012, a study used lineage tracing to suggest that the epithelial cell lineages 
are maintained by unipotent stem cells during puberty and homoeostasis (van Amerongen 
et al. 2012). Cellular differentiation during pregnancy was also investigated in this study, 
with results suggesting that bipotent stem cells are able to produce both the luminal and 
basal lineages, and that alveolar cells differentiate from the luminal progenitor (Figure 1.3C). 
Following this, in early 2014 a study by Rios et al supported the bipotent theory by showing 
evidence of bipotent stem cells in the adult mouse mammary gland located in the basal 
layer (Rios et al. 2014). 
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Figure 1.3 Theories of Mammary gland cell hierarchy. (A) The mammary gland initially develops from a multipotent stem cell, then during 
puberty and adulthood the basal and luminal cells are maintained by unipotent stem cells. (B) In adults the epithelial lineages are maintained 
by bipotent stem cells. (C) During pregnancy bipotent stem cells are able to give rise to both epithelial lineages and alveolar cells are 
differentiated from luminal progenitors. 
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1.2 Breast cancer 
1.2.1 Incidence and survival 
Breast cancer is the most common cancer in women in the UK, with almost 50,000 being 
diagnosed in 2010 (http://www.cancerresearchuk.org). Breast cancer is also the second 
most common cause of cancer death in women in the UK; however, despite the high 
incidence five year survival rates are increasing, currently at 85.1% 
(http://www.cancerresearchuk.org). The incidence of breast cancer in males is much lower, 
with around 400 being diagnosed in 2010. Factors that have been shown to increase the risk 
of breast cancer include: increased age, family history of the disease, obesity, high alcohol 
consumption, and exposure to hormone replacement therapy. There is also evidence to 
suggest that breast cancer risk can be reduced by both breastfeeding and an increased 
number of live births (Beral et al. 2002). 
1.2.2 Progression of Breast cancer 
The predominant location of breast tumour initiation in humans is in the TDLUs (Wellings et 
al. 1975). Breast cancer is thought to progress from hyperplasia to metastatic cancer via a 
series of stages (Mallon et al. 2000); Figure 1.4). The initial stage of epithelial hyperplasia is 
followed by atypical hyperplasia, which is the proliferation of epithelial cells with nuclear 
and morphological abnormalities. Atypical hyperplasia can result in ductal carcinoma in situ 
(DCIS), where the lumen is filled with abnormal epithelial cells. Once cells invade through 
the basement membrane and into the surrounding stroma it is classed as invasive breast 
cancer. Invasive cells can then enter the lymphatic or vasculature system and metastasise to 
secondary sites in the body. In humans, breast cancer metastasis via the lymphatic and the 
vascular system, with the most common sites of metastasis being lymph nodes, lung and 
bone, however in the mouse metastasis is predominantly through the vascular system 
(Mallon et al. 2000).  
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Figure 1.4 Progression of breast cancer. Epithelial hyperplasia (A) can progress to atypical hyperplasia (B), which can be followed by ductal 
carcinoma in situ (C). Invasive cancer (D) occurs when the abnormal cells penetrate through the basement membrane and invade the 
surrounding tissue. Cells can then enter the lymphatic or vasculature system and metastasise to other tissues.  
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1.2.2.1 Epithelial to mesenchymal transition 
To progress from DCIS to invasive breast cancer it is thought that epithelial cells undergo 
epithelial to mesenchymal transition (EMT) (Choi et al. 2013). During EMT epithelial cells 
lose their apical-basal polarity and acquire mesenchymal characteristics, such as spindle-
morphology and increased migration and invasion. The acquisition of these characteristics 
changes a tumours ability to become invasive and metastatic. To create secondary tumours 
following metastasis it is thought that these mesenchymal cells then undergo mesenchymal-
to-epithelial transition (MET) (Chaffer et al. 2006). 
EMT is required for processes such as embryogenesis and wound healing and involves the 
loss of adheren and tight junctions and reorganisation of the cytoskeleton. To achieve 
mesenchymal transition epithelial cells repress the expression of CDH1 (epithelial cadherin 
(E-cadherin)), resulting in the loss of cell-cell junctions, and increase the expression of genes 
such as CDH2 (neural cadherin (N-cadherin)) and VIM (Vimentin), which make cells more 
motile and invasive, and also genes such as MMP2 (metalloproteinase 2) which cause 
changes to the extracellular matrix (ECM) and increase the invasive potential of the cells 
(reviewed in (Xu et al. 2009)). As well as these differences in gene expression cells 
undergoing EMT can be characterised by increased expression of EMT-associated 
transcription factors, such as SNAIL, SLUG, ZEB1/2 and TWIST. The expression of these 
transcription factors are induced by signalling from transforming growth factor beta 1 (TGF-
β1) (Figure 1.5).  
TGF-β1 is produced by the tumour microenvironment and binds to a heteromeric complex 
of two type I and two type II transmembrane serine-threonine kinase receptors. Binding of 
TGF-β1 to the complex causes the phosphorylation of the type I receptors by the type II 
receptors, resulting in the subsequent phosphorylation and activation of SMAD2 and 
SMAD3 by the type I receptors. Phosphorylated SMAD2 and SMAD3 then form trimers with 
SMAD4, allowing translocation of the complex into the nucleus, where it regulates 
transcription of target genes.  
EMT can also be induced by other pathways such as the Wnt (Yook et al. 2005), Notch 
(Timmerman et al. 2004), integrin (Kim et al. 2006) and AKT pathways (Grille et al. 2003). 
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Figure 1.5 TGF-β Signalling. Binding of TGF-β to the type I (red) and type II (green) receptors 
causes the phosphorylation and activation of Smad2/3. Smad 4 is then recruited and the 
complex translocates to the nucleus where it causes changes in target gene expression, for 
example inducing the expression of Snai1 and Snai2. Figure adapted from Xu et al. 2009. 
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1.2.3 Breast cancer heterogeneity 
Breast cancer is an extremely heterogeneous disease, with tumours showing inter- and 
intra-heterogeneity. There are numerous ways to classify breast tumours, ranging from 
cellular morphology to gene expression. These classification systems help to stratify breast 
cancers into groups for determination of prognosis and treatment. 
1.2.3.1 Histopathological classification 
Histopathological classification involves the examination of haematoxylin and eosin (H&E)-
stained sections to analyse characteristics and morphological features of the cells within the 
tumour. There are many different histopathological types of human breast cancer which can 
be broadly classified into epithelial, mesenchymal and fibroepithelial tumours (Mallon et al. 
2000; Lakhani et al. 2012). There are numerous subgroups within each of these 
classifications. In humans invasive breast tumours are predominantly classed as invasive 
ductal carcinoma of no special type (IDC-NST). These tumours are classified by the exclusion 
of characteristics which would classify them as other histopathological types; therefore they 
are a heterogeneous group of tumours. Although mammary tumours from genetically 
engineered mouse models display a number of differences to those in humans they have 
shown to have similar molecular and morphological features (Cardiff et al. 2000). 
1.2.3.2 Grade 
The grading system of Bloom and Richardson (Bloom and Richardson 1957) classifies breast 
tumours into 3 grades, with grade 1 indicating the best prognosis and grade 3 the worst. 
This grading system comprises of three components that are each given a score from 1-3. 
The first component is tubule formation, which is indicative of the amount of differentiation 
within the tumour, with a score of 1 if glandular structures compose over 75% of the 
tumour, 2 if they make up 10-75% and 3 if they compose less than 10%. The second 
component is nuclear pleomorphism, with a score of 1 denoting small and regularly shaped 
nuclei, 2 if there is a moderate change in size and shape, and 3 if there are multinucleated 
cells with a large variation in size and shape. The final component is mitotic index, which 
involves counting the number of mitotic cells in 10 high power fields to create an average.  If 
using a 20x objective, a score of 1 is given if 0-9 mitotic nuclei are counted, 2 if 10-19 are 
counted and 3 if over 19 are counted. The three scores are added together to give a final 
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total which correlates with the grade: grade 1 corresponds to a score of 3-5, grade 2 to a 
score of 6-7 and grade 3 to a score of 8-9.  
1.2.3.3 Stage 
Breast cancers can also be classified into stages, with the most widely used system being the 
TNM staging system (published by American joint committee on cancer/Union for 
international cancer control). This involves three components: the size of the tumour and 
whether it has spread into the surrounding tissues (T), whether it has metastasised to the 
lymph nodes (N), and whether it has metastasised to distant parts of the body (M). The 
components are then combined to produce a stage, which are classified as 0-IV.  
1.2.3.4 Molecular classification 
1.2.3.4.1 Receptor status 
Breast tumours can be classified on the expression of three receptors: oestrogen receptor α 
(ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 
(HER2). These three receptors are not only used as a classification system, but are also 
targets for cancer treatment.  
Around 75% of human breast cancers are ER positive (+). There are two isoforms of the 
oestrogen receptor, α and β, which are expressed from two different genes. Currently only 
the α isoform is used for breast cancer classification. ER is a nuclear transcription factor 
which is expressed in around a third of luminal cells in the normal mammary gland. Binding 
of the steroid hormone oestrogen to the receptor causes a conformation change, allowing 
receptor dimerisation and binding to response elements in DNA resulting in expression of 
target genes. The ER pathway stimulates growth in normal breast epithelial cells and in 
tumour cells. The amount of ER positivity within a tumour is predictive of response to 
endocrine therapy. The PR receptor mediates the effects of the steroid hormone 
progesterone. There are two isoforms of the receptor which are expressed from the same 
gene: A and B. PR is expressed in around 65% of human breast cancers. PR is an oestrogen-
regulated gene and was originally used in breast cancer as an indicator of an intact ER 
pathway. Studies have now shown that PR status can also be predictive of therapy, with 
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ER+/PR+ tumours responding better to a targeted ER therapy than ER+/PR negative (-) 
tumours (Bardou et al. 2003).  
HER2 is a member of the epidermal growth factor receptor (EGFR) family. It is a 
transmembrane receptor which is activated upon ligand binding and causes the activation of 
the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
cascades. 20-30% of human breast cancers overexpress the HER2 receptor, with the 
majority caused by gene amplification, and these tumours can also express ER and PR. 
HER2+ tumours tend to be aggressive and patients have a poor prognosis compared to 
those with HER2- tumours. Tumours that are negative for ER, PR and HER2 are termed triple 
negative tumours. They account for around 15% of human breast cancers and are 
associated with a high mitotic index, earlier onset and poor prognosis.  
1.2.3.4.2 Gene expression 
Breast tumours can be classed into intrinsic subgroups based on their gene expression 
profiles (Perou et al. 2000b; Sorlie et al. 2001) and are first classified for ER status.  
ER+ breast tumours express genes that are characteristic of luminal cells (for example CK18, 
CK8 and E-cadherin) and commonly contain epithelial cells which are positive for PR. ER+ 
breast tumours are the most common intrinsic subgroup of breast cancer (Gusterson et al. 
1984; Carey et al. 2006), accounting for around two thirds of cases, and can be split into two 
further groups: luminal A and luminal B. Luminal A tumours tend to be PR+/HER2- whereas 
luminal B tumours tend to be PR+/HER2+. Luminal A is twice as common as luminal B and 
these two groups can also be distinguished by the expression of proliferation markers, 
which are more highly expressed in luminal B tumours (Cheang et al. 2009). Patients with 
luminal A tumours have a better prognosis than those with luminal B. 
ER- tumours are categorised into four subgroups: HER2+, basal, claudin-low and normal-like. 
HER2+, ER- breast tumours also tend to be PR-, express low levels of genes characteristic to 
luminal cells and account for around 5-10% of breast cancers (Carey et al. 2006). Basal 
breast cancers make up 15-20% of breast cancers, express genes that are characteristic to 
basal cells (for example CK14, CK5, EGFR and p63) and are mainly triple negative (Perou et 
al. 2000b; Sorlie et al. 2001).  
14 
 
12-14% of breast tumours are of the claudin-low subtype, which show similar gene 
expression patterns to basal tumours but are characterised by the low expression of cell-cell 
adhesion genes (e.g. those that encode claudin 3, 4, 7 and E-cadherin) and high expression 
of EMT genes (e.g. those that encode vimentin and twist) (Prat et al. 2010). They also show 
high expression of immune response genes, low expression of proliferation markers, high 
frequency of medullary and metaplastic features and are enriched for stem cell markers and 
cells with stem-cell-like characteristics (Creighton et al. 2009; Hennessy et al. 2009; Prat et 
al. 2010).  
Normal-like breast tumours show high expression of genes that are characteristic of basal 
cells, adipose cells and other non-epithelial cells and low expression of luminal genes, 
although there is controversy over whether this is a genuine subgroup or an artefact of 
contaminating stromal tissue.  
The different intrinsic subgroups of breast cancer are linked to prognosis, with luminal A 
patients having the best prognosis and those with basal-like or HER2+ tumours having the 
worst (Sorlie et al. 2001). 
1.2.3.4.2.1 Origin of intrinsic groups 
One hypothesis for the existence of intrinsic subgroups in breast cancer is that tumours 
arise from different epithelial populations. The clonal evolution theory states that each 
subgroup is determined by which particular cell along the mammary cell hierarchy the 
tumour originates from, and that all cells within the tumour are capable of tumour 
formation (tumour initiating cells). Gene expression analysis studies have suggested that all 
breast tumours originate from the luminal differentiation hierarchy, with ER+ tumours 
arising from mature, differentiated luminal cells, HER2+/ER- tumours and basal tumours 
originating from luminal progenitors and claudin-low tumours arising from the mammary 
stem cells (Figure 1.6A) (Lim et al. 2009; Prat and Perou 2011). In contrast a recent study 
showed that tumours deriving from the same cell-of-origin in a particular mouse model 
displayed different molecular features and spanned a broad range of molecular signatures, 
suggesting that intrinsic subtype does not necessarily reflect its cell-of-origin (Melchor et al. 
2014). 
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A criticism of the clonal evolution theory is whether all tumour cells are tumour initiating 
cells. The cancer stem cell theory states that only a subpopulation of cells within the tumour 
are tumour initiating cells and that these cells have similar characteristics to mammary stem 
cells. This theory opens up two hypotheses for intrinsic subgroup origination: either the 
mammary stem cells are the cells of origin for all the subgroups, or cells along the epithelial 
differentiation hierarchy acquire stem cell-like characteristics which enable them to initiate 
tumour development (Figure 1.6B-C). 
1.2.3.4.3 Targeted treatments 
The presence of intrinsic subgroups of breast cancer suggests that targeted, personalised 
therapy may be critical for efficient tumour treatment and patient survival. Unlike 
conventional chemotherapy, which has traditionally targeted any highly proliferative cells, 
targeted therapy involves the administration of treatments which target a specific signalling 
pathway, hopefully resulting in low systemic toxicity. An example of a targeted treatment in 
breast cancer is tamoxifen, a competitive ER inhibitor; which has been very successful in 
patients with ER+ breast cancers. Following the success of tamoxifen, other therapies that 
target the ER pathway are also available, including aromatase inhibitors.  
Another example of a targeted treatment for breast cancer is the anti-HER2 monoclonal 
antibody trastuzumab, which perturbs HER2 signalling by targeting the extracellular domain 
of its receptor and hence is effective in HER2+ breast cancers. It has been shown to increase 
survival in around 30% of HER2+ breast cancer patients, and response is further increased 
when used in combination with certain chemotherapeutics (Baselga 2001). However 
patients can quickly relapse and exhibit resistance. Drugs such as lapatinib, which target 
multiple members of the EGFR family, are also useful in HER2+ patients. 
There are currently no targeted therapies for basal breast cancers. As the majority of basal 
breast cancers are triple negative, hormone-based therapies, such as tamoxifen and 
trastuzumab, are ineffective. A potential target for basal breast cancers is the epidermal 
growth factor receptor (also known as HER1), as it is overexpressed in up to 80% of these 
tumours. Monoclonal antibodies, such as certuximab, and inhibitors of receptor 
phosphorylation, for example gefitinib, have been trialled in basal breast cancers to perturb
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Figure 1.6 Origin of different intrinsic subgroups of breast cancer from cells along the luminal differentiation hierarchy. (A) In the clonal 
evolution theory each tumour type originates from a different cell type. The cancer stem cell theory states that either (B) all tumour types 
originate from the stem cells, or (C) they originate from different cell types that have acquired stem cell characteristics. Figure adapted from 
Prat and Perou 2011. 
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EGFR signalling; however, patients have shown only a modest response (Modi et al. 2006; 
Carey et al. 2008; Green et al. 2009). It is clear that a better understanding of the molecular 
processes involved in basal breast cancers is required so that new targets can be discovered.  
 
1.2.4 Drug resistance 
A recurring problem with cancer treatment is that of drug resistance, which limits clinical 
benefit. Hence it is imperative that the mechanisms of drug resistance are discovered and 
explored to ensure the effectiveness of these important therapies. Tumours can exhibit 
intrinsic or acquired resistance. ‘Classical’ resistance mechanisms include rapid metabolism 
or excretion of the drug, poor absorption and alteration of the drug target (reviewed in 
(Gottesman 2002; Stewart 2007). Mechanisms can also confer resistance to multiple, 
unrelated drugs. This is termed multidrug resistance and mechanisms include decreased 
uptake of drugs into the cell and up-regulation of P-glycoproteins (P-gps), which are energy-
dependent drug efflux pumps (reviewed in (Gottesman 2002)).  
Studies have shown that tumour cells with stem cell-like characteristics are more resistant 
to chemotherapy, with characteristics such as high expression of P-gps and anti-apoptotic 
factors, such as Bcl-2 and sonic hedgehog (Mimeault et al. 2008). This small population of 
cells are termed cancer stem cells (CSCs). It is hypothesised that these cells cause tumour 
relapse by surviving conventional cancer treatments, therefore therapies that specifically 
target the CSCs could be a more effective approach to treating cancer (Figure 1.7). 
 
 
 
 
 
 
18 
 
 
 
 
 
 
 
 
 
Figure 1.7 Targeting cancer stem cells as a therapeutic strategy. Cancer stem cells (CSC, 
blue cells) may be resistant to conventional chemotherapies, allowing tumour relapse. CSC 
therapies could prevent tumour relapse and cause tumour regression, possible in 
combination with conventional chemotherapy. 
 
1.3 Inherited breast cancer 
1.3.1 Incidence  
Cancer which originates from the inheritance of a mutated gene is termed inherited cancer. 
Inherited breast cancer is thought to account for around 10% of all breast cancer cases. The 
most commonly mutated genes in inherited breast cancer are the genes that encode the 
breast cancer type 1 susceptibility protein (BRCA1) and the breast cancer type 2 
susceptibility protein (BRCA2). Patients with a family history of breast cancer can receive 
genetic screening to search for common mutations in the BRCA genes. If the patient is found 
to carry a BRCA mutation then preventive measures are available, including mastectomy 
which can reduce the risk by approximately 90% (Hartmann et al. 1999; Rebbeck et al. 
2004).  
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1.3.2 BRCA1 and BRCA2 structure and function 
The BRCA1 and BRCA2 genes are expressed in the late G2 and S phases of the cell cycle and 
are located on chromosomes 17q21 and 13q12-13. Both proteins are located in the nucleus 
and are expressed ubiquitously. BRCA1 is an 1863 amino acid protein with a RING finger 
domain at its N-terminus and a BRCA1 C-terminal repeat (BRCT) domain at its C-terminus 
(Figure 1.8). The BRCT domain is composed of a repeated sequence of 100 amino acids and 
facilitates the binding of BRCA1 to other proteins. BRCA1’s DNA binding ability is 
hypothesised to be facilitated by the BRCT domain, however current studies are conflicting 
(Yamane et al. 2000; Paull et al. 2001). The RING finger domain is the binding site for the 
BRCA1-associated RING domain protein 1 (BARD1). The BRCA1-BARD1 heterodimer is 
hypothesised to be involved in protein ubiquitination as the dimer possesses ubiquitin ligase 
activity (Xia et al. 2003). BRCA1 also contains a nuclear localisation signal (NLS), and a 
transcriptional activation domain, which is located close to the BRCT domain (Figure 1.8).  
BRCA2 is a 3418 amino acid protein. It contains similar domains to BRCA1 such as a 
transcriptional activation domain, DNA binding sequences and a NLS; however BRCA1 and 
BRCA2 have different localisations of these domains within their protein structures (Figure 
1.8). BRCA2 contains eight BRC repeats that have variable spacing, such that the repeat 
region spans around 1000 amino acids, which are vital for its role in DNA repair. 
BRCA1 and BRCA2 are unrelated proteins involved in the homologous recombination (HR) 
pathway of DNA repair. This pathway repairs DNA double stranded breaks (DSBs) using the 
sister chromatid as a template, enabling an error-free mechanism of DNA repair. In vitro and 
in vivo homologous mutants for Brca1 and Brca2 show a reduction in HR mediated DNA 
repair and the human pancreatic adenocarcinomas cell line CAPAN-1, which contains a 
heterozygous mutation for BRCA2, shows a dramatic reduction in HR (Goggins et al. 1996); 
demonstrating that the BRCA proteins are required for efficient HR repair. BRCA1 has two 
major roles within the HR pathway; (1) it forms part of a multi-protein complex, named the 
BRCA1-associated genome surveillance complex, which surveys the genome for DNA 
damage and is involved in the signalling of downstream proteins for repair; (2) it is recruited 
to sites of DSBs, where its phosphorylation by ataxia telangiectasia mutated protein (ATM) 
causes the formation of a multi-protein complex including BARD1 and BRCA2, resulting in 
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the recruitment of BRCA2 to the site of the DNA damage. BRCA2 binds to the DNA 
recombinase RAD51 via its BRC repeats and functions to recruit and facilitate its loading 
onto DNA, which is required for the strand invasion step of HR (Yuan et al. 1999). 
The BRCA1 and BRCA2 genes are multifunctional proteins. As well as their roles in HR BRCA1 
has been shown to have additional roles in ubiquination, apoptosis, chromatin remodelling 
and cell cycle checkpoint regulation, whereas BRCA2 has been shown to have roles in 
cytokinesis and centrosome location (reviewed in (Powell and Kachnic 2003))  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Protein structures of BRCA1 and BRCA2. Both proteins contain a transcriptional 
activation domain, a nuclear localisation signal (NLS) and a DNA binding domain. BRCA1 
contains a RING finger domain at its N terminus and a BRCT domain at the C terminus. 
BRCA2 contains BRC repeats in the middle of the protein which are essential for its function 
in the HR pathway. Figure adapted from Powell and Kachnic 2003. 
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1.3.3 The Homologous Recombination pathway of DNA repair 
DSBs can be caused by reactive oxygen species (ROS) created by cellular metabolism, 
exogenous components such as ultraviolet light, and unrepaired single stranded breaks 
(SSBs) in DNA. The HR pathway occurs during the S and G2 phases of the cell cycle and 
ensures error-free repair of DBSs in DNA by using the sister chromatid as a template (Figure 
1.9). The pathway begins with 5’-3’ resection of the DNA sequence surrounding the break 
site by the mitotic recombination 11 (MRE11)-RAD50-Nijmegan breakage syndrome 1(NBS1) 
(MRN) complex, creating single stranded overhangs. In this process NBS recognises the DSB, 
and the complex recruits phosphorylated CtBP-interacting protein (CtIP) which activates the 
exonuclease activity of MRE11. MRE11 then resects the DNA.  
BRCA2 is recruited to the site of DNA damage by the multiprotein complex generated by the 
phosphorylation of BRCA1. Partner and localiser of BRCA2 (PALB2) then stabilises and 
anchors the protein to the DNA, allowing BRCA2 to facilitate the loading of RAD51 onto the 
single stranded DNA, by displacing Replication protein A (RPA), a protein that binds to single 
stranded DNA, thereby preventing RAD51 binding. RAD51 exists as a hexomeric protein ring 
and polymerises on the single stranded DNA to form a right-handed helical polymer 
filament, known as a presynaptic filament (Yu et al. 2001). This filament holds the DNA in an 
extended conformation.  
Accessory factors such as the SWI/SNF proteins RAD54 and RAD54b aid the invasion of the 
coated single stranded DNA into the sister chromatid, creating a D-loop structure. Homology 
in the sister chromatid is searched for by random collisions. Once homology is found the 
DNA is extended by DNA polymerases. From this point of the HR pathway there are two 
different models:  the double-strand break repair (DSBR) model and the synthesis-
dependent strand annealing (SDSA) model. In SDSA the new strand is released from the 
sister chromatid and anneals to the 3’-end of the DSB. This enables the other strand of DNA 
to use the new strand as a template for DNA synthesis and complete the DSB repair. In DSBR 
both DNA strands use the sister chromatid as a template for DNA synthesis. This results in a 
duplex structure containing two Holliday junctions. These Holliday junctions are then 
resolved by BLM helicase and topoisomerase IIIα to give either non-crossover or crossover 
products (Figure 1.9). 
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Figure 1.9 The HR pathway. The pathway begins with 5’-3’ resection of the DNA strands to 
create single strand overhangs. RPA binds to the single stranded DNA and is removed by 
BRCA2 so that RAD51 can bind to the single strand overhangs and polymerises to form a 
right-handed helical polymer filament. This filament aids strand invasion into the sister 
chromatid to form a D-loop structure. DNA extension then begins, using the sister chromatid 
as a template. From this point the pathway can either use the SDSA model (A) or the DSBR 
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model (B). The SDSA model only results in non-crossover products whereas the DSBR model 
produces either non-crossover or crossover products. Figure adapted from (Sung and Klein 
2006). 
 
1.3.4 BRCA genes and breast cancer 
BRCA mutated breast cancers account for around 25% of inherited breast cancer cases 
(http://www.cancerresearchuk.org). Mutations in BRCA1 and BRCA2 genes results in up to 
85% chance of developing breast cancer and also increases the risk of ovarian, prostate and 
pancreatic cancer. In patients who have inherited mutations in their BRCA1 or BRCA2 genes, 
loss of heterozygosity at the second allele results in a deficiency in the HR pathway, 
resulting in the cell becoming reliant on error-prone pathways of DNA repair, such as the 
non-homologous end joining pathway (NHEJ). The NHEJ pathway occurs throughout the cell 
cycle and ligates the DNA strand together at the site of the break, thereby occasionally 
causing deletions or mutations. With a deficient HR pathway cells can accumulate further 
mutations that contribute to the cancer phenotype, eventually causing the cells to become 
tumourigenic. Patients with BRCA mutated breast cancer often also contain mutations in 
genes that encode proteins involved in cell cycle arrest, for example around 90% of patients 
have inactivating mutations in TP53 (p53) (Crook et al. 1997; Crook et al. 1998). The loss of 
the cell cycle arrest allows proliferation with the presence of DNA damage, allowing tumour 
cells to evade cell death. 
The majority of BRCA1 mutated tumours are classified as triple negative basal tumours 
whereas the majority of BRCA2 mutated tumours are similar to sporadic ER+ luminal 
tumours (Laakso et al. 2005). Currently all patients with BRCA mutated breast cancer are 
given the same treatments as patients with sporadic breast cancer. 
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1.4 Poly(ADP-ribose) polymerase (PARP)  
1.4.1 PARP-1 
The Poly (ADP-ribose) polymerase 1 (PARP-1) gene is located at locus 1q41. PARP-1 is an 
113kDa protein which has a nuclear localisation and is expressed in all nucleated cells 
except neutrophils. PARP-1 consists of three domains; an N-terminal DNA binding domain, a 
central auto-modification domain and a C-terminal catalytic domain (Figure 1.10). These 3 
domains can be further divided into six modules, A-F (Demurcia and Demurcia 1994). 
Module A is located at the N-terminus of the protein and contains two Cys-Cys-His-Cys zinc 
fingers. These are the binding sites of DNA and the second has been shown to be important 
for SSB recognition. Domain B contains a nuclear localisation signal and a caspase 3-cleavage 
site, which is utilised during apoptosis to prevent the depletion of NAD+ and ATP+. Domain C 
contains a third zinc finger which has a role in enzyme activation. Domain D contains specific 
glutamate and lysine residues that are the sites of ADP-ribose addition, and a BRCT domain, 
which is hypothesised to be involved in protein-protein interactions. Domain E contains a 
WGR domain, which function is currently unknown, and domain F contains the PARP 
catalytic motif: histidine and tyrosine residues which are important for NAD+ binding and a 
glutamate which is needed for enzymatic activity. PARP-1 knockout mice are viable and 
show mild phenotypes but have been shown to be sensitive to chemically-induced genomic 
stress, are susceptible to diet-induced obesity and are resistant to diabetes and 
inflammation (deMurcia et al. 1997; Masutani et al. 1999; Shall and de Murcia 2000; 
Devalaraja-Narashimha and Padanilam 2010).  
PARP-1 functions in the base excision repair (BER) pathway, which repairs SSBs in DNA. This 
pathway uses the complementary strand of DNA as a template and PARP-1 is thought to act 
as a DNA damage sensor, recruiting proteins involved in the process to the site of the SSB, 
such as XRCC1 (El-Khamisy et al. 2003). The exact role of PARP-1 in this pathway remains 
controversial. Probably the most widely excepted concept is that the protein functions at 
the first stages of the pathway, binding to DNA at the site of the SSB, where the enzyme 
becomes activated and catalyses the addition of poly (ADP-ribose) (PAR) to itself, utilising 
NAD+ as a substrate. Studies on whether PARP-1 binds to DNA as a monomer or a dimer are  
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Figure 1.10 PARP protein structure. PARP-1 is split into six modules, A-F. PARP-2 and PARP-3 
are the smallest of the group and have a similar structure. PARP-4 is the largest of the group 
and contains an MVP-binding domain which is required for the protein to interact with other 
VAULT proteins. PARP-5a and PARP-5b have a similar protein structure, both containing 
ankyrin repeats and the PARP catalytic motif. PARP-5a also contains a His-Pro-Ser rich 
domain (HPS) at the N terminus. Figure adapted from (Burkle 2005) and (Giansanti et al. 
2010). 
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conflicting (Eustermann et al. 2011; Loeffler et al. 2011; Ali et al. 2012; Langelier and Pascal 
2013). The resulting negative charge created by PAR results in the recruitment of proteins 
involved in the subsequent steps of the BER pathway, such as XRCC1 and DNA polymerase 
β. Further addition of PAR to PARP-1 creates a high negative charge, resulting in the protein 
being repulsed by the DNA. This causes PARP-1 to be released from the SSB site, which then 
allows recruited DNA repair proteins to access the site. Once PARP-1 has left the SSB, the 
ADP-ribose polymer chain is rapidly degraded by poly (ADP-ribose) glycohydrolase (PARG). 
In addition to this role, PARP-1 also causes changes in chromatin structure so that the site of 
the SSB is exposed for repair by catalysing the addition of ADP-ribose polymers to H1 and 
H2B histones. Other proposed roles of PARP-1 in BER include producing a source of ATP for 
the final steps of the pathway (Oei and Ziegler 2000) and the recognition and processing of 
stalled intermediates (Prasad et al. 2001). 
As well as its role in SSB repair PARP-1 is also hypothesised to be involved in other DNA 
processes such as transcription, methylation and DSB repair. Its role in DNA transcription 
comes from studies showing that PARP-1 can effect chromatin structure, interact with 
transcription factors such as COX-2 and OCT1, and the presence of PARP-1 at the majority of 
promoters of actively transcribing genes in MCF-7 cells (Nie et al. 1998; Krishnakumar et al. 
2008; Lin et al. 2011). PARP-1 has also been shown to regulate the DNA (cytosine-5)-
methyltransferase 1 protein (Dnmt1), by protecting its promoter against epigenetic silencing 
(Caiafa et al. 2009), suggesting a role in DNA methylation. It has also been proposed that 
PARP-1 may have roles in both the NHEJ and the HR pathways of DSB repair as studies have 
shown that PARP-1 competitively inhibits NHEJ and promotes the activation of MRE11 and 
NBS, both of which are involved in the DNA resection step of the HR pathway (Haince et al. 
2008; Bryant et al. 2009). These roles in HR mediated DSB repair however,  are not thought 
to be essential, as PARP null cells in vitro do not have drastic defects in the HR pathway 
(Schultz et al. 2003). PARP-1 is also hypothesised to have roles in DNA-independent 
processes such as inflammation, which is thought to be linked to its coactivator activity for 
NFB (Hassa and Hottiger 2002; Hassa et al. 2003). 
Excessive DNA damage leads to PARP-1 over-activation, resulting in cell death through 
either NAD+ depletion or the caspase-independent mechanism of parthanatos. The 
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parthanatos pathway involves PAR polymers, generated by the over activation of PARP-1, 
migrating to the cytosol and causing the release of apoptosis-inducing factor (AIF) from 
mitochondria (Yu et al. 2002). AIF then translocates to the nucleus and causes chromatin 
condensation and large scale DNA fragmentation, resulting in cell death. 
PARP-1 has been found to be overexpressed in a number of cancers, for example malignant 
lymphoma, hepatocellular carcinoma, cervical cancer and colorectal cancer (Fukushima et 
al. 1981; Hirai et al. 1983; Tomoda et al. 1991; Shiobara et al. 2001). In breast cancer, PARP-
1 overexpression is more common in high grade basal and triple negative tumours 
(Goncalves et al. 2011; Rojo et al. 2012). 
1.4.2 BER pathway 
The BER pathway occurs in the G1 phase of the cell cycle, and causes removal and 
replacement of damaged bases within DNA (Figure 1.11). BER is thought to function as a 
series of independent steps, with a damaged base first recognised from the DNA backbone 
by DNA glycosylase, due to cleavage of the N-glycosidic bond. The resulting base-less site is 
termed an abasic or AP site. APE1 endonuclease then cleaves the phosphodiester bond 5’ to 
the AP site, creating a single stranded break. PARP-1 is thought to recognise this single 
stranded break and recruit the repair proteins XRCC1, DNA polymerase β and DNA ligase III 
by poly-ribosylating itself. At this point BER may take one of two routes depending on 
whether DNA polymerase β can remove the 5’ sugar phosphate (Figure 1.11). Short patch 
BER occurs when DNA polymerase β is successful and subsequently adds a new nucleotide, 
corresponding with the template strand of DNA.  The new nucleotide is then sealed into 
position by DNA ligase III, with XRCC1 acting as a scaffold for these reactions. Long patch 
BER occurs when DNA polymerase β is unable to remove the 5’ sugar phosphate; instead, 
DNA polymerase δ/ε removes the group and adds a number of nucleotides into the gap, 
creating a flap. This flap is removed by 5’-flap endonuclease 1 (FEN-1) and DNA ligase I seals 
the resulting gap in the DNA. If the BER pathway is unsuccessful the SSB will still be present 
in the S phase of the cell cycle, resulting in the formation of DSBs due to replication fork 
collapse. 
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Figure 1.11 The BER pathway. When a damaged base is identified, DNA glycosylase removes 
it from the nucleotide to produce an abasic site (AP site). APE1 creates a single stranded 
break in the DNA by cleaving the phosphosugar backbone. PARP-1 recognises and binds to 
the single stranded break. PARP-1 adds polymer chains of ADP-ribose to itself which results 
in the recruitment of XRCC1, DNA polymerase β (pol β) and DNA ligase III (L III). The DNA is 
either repaired by these proteins (A) or by DNA polymerase δ/ε (Pol δ/ε), FEN1 and DNA 
ligase I (B). Figure adapted from (Dianov 2011) 
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1.4.3 PARP family 
After the discovery of PARP-1 the sequence of its catalytic domain was utilised to search for 
related proteins; 16 were found, although not all have been shown to have the ability to 
create PAR, with some members only able to perform mono (ADP-ribose) transfer  (Kleine et 
al. 2008). Due to the differences in catalytic function between members of the family, a new 
nomenclature has been suggested, which would re-name the proteins ADP-ribosyl 
transferases (Hottiger et al. 2010).  
PARP-2 is the only other member of the family to share PARP-1’s ability to detect SSBs and 
recruit repair proteins to the sites of damage (Ame et al. 1999; Schreiber et al. 2002). Its 
role in SSB repair was discovered due to residual PARP activity in PARP-1 deficient mice 
(Ame et al. 1999). Whereas PARP-1 knockout mice show only mild phenotypes PARP-
1/PARP-2 double knockout mice are embryonically lethal (de Murcia et al. 2003). It is 
thought that PARP-1 performs around 90% of poly (ADP)-ribosylating activity for DNA repair, 
with PARP-2 accounting for the remaining 10% (Schreiber et al. 2002). PARP-2 is located at 
14q11.2 and alternative splicing results in two isoforms of the protein. The PARP-1 and 
PARP-2 proteins have 69% similarity in their C terminal catalytic domains; however the DNA 
binding domain of PARP-2 does not contain any zinc fingers (Figure 1.10) and does not bind 
as efficiently to single stranded breaks in DNA when compared to PARP-1 (Ame et al. 1999; 
Berghammer et al. 1999). 
PARP-3 is thought only to perform mono(ADP-ribose) transfer (Loseva et al. 2010). Unlike 
PARP-1 and PARP-2, PARP-3 is not ubiquitously expressed, but limited to certain tissues, e.g. 
the brain, spinal cord and epithelial cells lining the ducts of the prostate, liver and pancreas.  
It has a similar protein structure to PARP-2 (Figure 1.10), but has not been shown to be 
involved in the BER pathway. Its exact roles are unknown but it has been shown to localise 
to the centrosome and associates with polycomb proteins (Augustin et al. 2003; Rouleau et 
al. 2007). PARP-3 has also been implicated in DSB repair, where it is hypothesised to 
cooperate with PARP-1; however, deletion of PARP-3 does not compromise survival after 
DNA damage (Boehler et al. 2011), suggesting that, like PARP-1, PARP-3’s role in DSB repair 
is not essential. 
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PARP-4 is the largest member of the family and is a component of the cytoplasmic VAULT 
complexes, along with major vault protein, telomerase protein component 1 and 
untranslated RNAs. These large complexes are thought to function in cellular transport (van 
Zon et al. 2003). Due to its inclusion in the VAULT complex, PARP-4 is also termed vPARP. It 
contains a BRCT domain at the N-terminus, the PARP catalytic motif near the centre of the 
protein and motifs that allow the formation of multiprotein complexes, such as the major 
vault protein-binding domain (Figure 1.10).  
PARP-5a and PARP-5b are also termed Tankyrase 1 and Tankyrase 2. These proteins are 
thought to be involved in regulation of telomeres and are components of the human 
telomeric complex. Tankyrase 1-mediated ADP-ribosylation of telomeric repeat-binding 
factor 1 (TRF1) has been shown to cause its release from telomeres, resulting in telomere 
elongation (Smith and de Lange 2000). Due to their similarities in structure (Figure 1.10) 
Tankyrase 2 is hypothesised that they perform a similar function. The remaining members of 
the PARP family have not been extensively studied and their functions are currently 
unknown. 
1.4.4 PARP inhibitors 
The first generation PARP inhibitors were created in the early 1990s and were based on the 
benzamide structure of NAD+ due to its ability to inhibit PARP activity. The majority of PARP 
inhibitors are designed to competitively inhibit the catalytic domain of PARP-1, preventing 
the NAD+ substrate from entering the catalytic site. Second and third generation PARP 
inhibitors were later designed to improve potency and were based on the structure of 
tricyclic benzimidaole carboxamides. PARP inhibitors were initially proposed as 
chemosensitisers, but in 2005 two preclinical papers showed that BRCA deficient cells were 
highly sensitive to PARP inhibition compared to wild type cells (Bryant et al. 2005; Farmer et 
al. 2005). PARP inhibitors selectively cause death in cells that are BRCA deficient through a 
process known as synthetic lethality; this means that deficiency in either BRCA1/2 or PARP-1 
alone is not essential for cell survival, but deficiency in both is lethal (Figure 1.12). Although 
the exact mechanism is uncertain, the most common theory is following PARP-1 inhibition, 
unrepaired SSBs result in DSBs due to replication fork collapse, and in BRCA deficient cells 
these DSBs cannot be repaired efficiently and the accumulation of genomic damage reaches 
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above the threshold and results in cell death (Bryant et al. 2005). In BRCA proficient cells 
DSBs are repaired by the HR pathway resulting in cell viability. Due to the selectivity of PARP 
inhibitors for BRCA deficient cells they have the potential of being utilised as a selective, low 
toxicity, personalised treatment for patients with BRCA mutated cancers.  
PARP inhibitors have also been proposed to be suitable for treatment of non-BRCA mutated 
breast cancers, such as tumours deficient in other components of the HR pathway (McCabe 
et al. 2006) and triple-negative breast cancer. Triple-negative breast cancer contains similar 
characteristics to BRCA1 mutated cancers, termed BRCAness. Mutations in the BRCA1 gene 
are rare in sporadic breast cancers; however, its expression is reduced in around 15% of 
sporadic breast cancer by hypermethylation of the BRCA1 promoter (Turner and Reis-Filho 
2006), suggesting that the loss of BRCA1, and hence the HR pathway, has a role in cancer 
development in triple negative breast cancers. Interestingly there is a similar phenomenon 
with BRCA2 in which the EMSY gene, which encodes a suppressor of BRCA2 expression, is 
amplified in 13% of sporadic breast cancers (Hughes-Davies et al. 2003) This hypothesis 
suggests that PARP inhibitors may be an effective treatment for triple-negative breast 
cancers, giving this intrinsic subgroup of breast cancer a selective treatment strategy, of 
which there are currently none. Indeed the PARP inhibitor iniparib showed promising phase 
II results when combined with the chemotherapeutic agents gemcitabine and carboplatin in 
patients with triple-negative breast cancer (O'Shaughnessy et al. 2011), but a phase III trial 
failed to show any difference in progression-free and overall patient survival (Guha 2011). 
Since then iniparib has been criticised as a PARP inhibitor due to its mechanism of inhibition, 
which differs from that of other PARP inhibitors, and its failure to inhibit poly(ADP-ribose) 
polymers in vitro (Patel et al. 2012). This suggests that there is still a possibility of other 
PARP inhibitors being utilised to treat patients with triple-negative breast cancer. 
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Figure 1.12 Synthetic lethality between BRCA1/2 and PARP-1. (A)  In a normal cell in which 
both PARP-1 and BRCA1/2 (BRCA) are functional, a SSB is repaired efficiently and the cell is 
viable. (B) In a BRCA mutated cell the HR pathway is dysfunctional, but the presence of an 
active PARP-1 protein keeps the cell viable due to repair via the BER pathway. (C) Normal 
cells that have been treated with PARP inhibitor will have a dysfunctional BER pathway but 
the HR pathway repairs the DSB so that the cell remains viable. (D) Cancer cells with BRCA 
mutations which have been treated with PARP inhibitors will have dysfunctional HR and BER 
pathways, meaning their DNA cannot be repaired efficiently, resulting in cell death. Adapted 
from (Guha 2011). 
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PARP inhibitors have also been shown to induce cell death in tumour cells that have no 
defects in DNA repair, such as PTEN mutant cells and HER2+ breast cancer cells (Mendes-
Pereira et al. 2009; Nowsheen et al. 2012), widening the therapeutic potential of these 
drugs. Currently there are numerous PARP inhibitors in clinical trials, either as a 
monotherapy or in combination with other chemotherapeutics (Table 1.1).  
1.4.4.1 Olaparib 
Olaparib (4-(3-4-fluorophenyl) methyl-1(2H)-one) is an oral PARP inhibitor initially 
developed by KuDOS Pharmaceuticals but since 2006 has been the property of AstraZeneca. 
It is a competitive inhibitor and has been shown to inhibit PARP-1, -2 and -3 (Menear et al. 
2008), Oplustilova et al, unpublished). Olaparib entered clinical trials in 2005 for breast 
cancer, and a phase III trial is currently being planned. A phase I trial in which patients were 
given doses of olaparib ranging from 10mg once daily for two weeks to 600mg twice daily 
for three weeks showed a 47% response rate in patients with BRCA-mutated tumours and 
no response in patients that did not contain BRCA mutations (Fong et al. 2009). From the 
phase I trials the maximum tolerated dose of olaparib was set to 400mg twice daily. A phase 
II trial of olaparib-monotherapy showed a 41% response rate in patients with BRCA 
mutations that were given 400mg twice daily and 22% with 100mg twice daily (Tutt et al. 
2010). Toxicity has been mild throughout the trials and reduced in comparison to 
chemotherapeutics. The most frequent side effect are grade 1 and 2 nausea and fatigue but 
grade 3 mood alteration, fatigue and somnolence and grade 4 thrombocytopenia have also 
been reported (grades from the Common Terminology Criteria for Adverse effects). All 
toxicities resolved after drug discontinuation.  
Olaparib is also in clinical trials for ovarian cancer. Phase II clinical trials have shown 
response rates of 33% in patients with BRCA mutated ovarian cancer treated with a PARP 
inhibitor (Audeh et al. 2010) but also 24% in patients without BRCA mutations  (Gelmon et 
al. 2011). This suggests that olaparib could be used to treat sporadic ovarian cancers. To 
support this a phase II clinical study in high-grade sporadic serous ovarian cancer showed a 
41% response rate in patients who received 400mg olaparib twice daily (Gelmon et al. 
2011), suggesting that in ovarian cancer olaparib may be successful in treating both BRCA-
mutated and non-BRCA-mutated tumours. 
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Table 1.1 Examples of PARP inhibitors currently in clinical trials. Adapted from (Yap et al. 2011) 
Agent Company Route of Administration Tumour type Combination studies Clinical status 
AZD2281/ Olaparib AstraZeneca Oral BRCA associated breast 
tumours 
 
 
BRCA associated ovarian 
tumours 
- 
 
Cisplatin and gemcitabine 
 
- 
 
Paclitaxel and Carboplatin 
Phase II-III 
 
Phase II 
 
Phase II 
 
Phase II 
ABT888/ Veliparib Abbott Oral Metastatic melanoma 
 
Leukaemia, pancreatic 
 
Glioblastoma 
 
Leukaemia, lymphoma 
 
BRCA associated breast 
tumours 
Temozolmide 
 
- 
 
Temozolmide 
 
Cyclophosphamide  
 
Temozolmide 
 
Phase I 
 
Phase I 
 
Phase II-III 
 
Phase I  
 
Phase II 
 
BSI-201/ Iniparib BiPar/Sanofi Intravenous Glioblastoma 
 
Breast tumours 
 
Lung tumours 
 
BRCA associated ovarian 
tumours 
Temozolmide 
 
Gemcitabine and carboplatin 
 
Gemcitabine and cisplatin 
 
Gemcitabine and carboplatin 
Phase I-II 
 
Phase II 
 
Phase II 
 
Phase III 
AG014699 Pfizer Intravenous Advanced solid tumours 
 
BRCA associated breast and 
ovarian tumours 
Temozolmide 
 
   - 
Phase I 
 
Phase II 
MK-4827 Merck Oral Ovarian, prostate tumours 
 
BRCA associated tumours 
- 
 
- 
Phase I 
 
Phase I 
CEP-9722 Cephalon  Oral Solid tumours - 
Temozolmide 
Phase I-II 
Phase I 
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1.4.4.1.1 Olaparib Resistance 
Pre-clinical studies in Brca1 and Brca2 conditional knockout mice have shown mammary 
tumour regression with olaparib treatment; however continual daily treatment resulted in 
tumour relapse (Rottenberg et al. 2008; Hay et al. 2009). Clinical resistance has now also 
been reported (Barber et al. 2013). Tumour resistance is highly detrimental in the clinic so it 
is important to find the mechanism(s) of resistance. 
Preclinical studies investigating olaparib resistance have highlighted three possible 
mechanisms of resistance to olaparib: 1. up-regulation of the drug efflux pumps P-
glycoproteins (P-gps), shown in a subset olaparib-resistant tumours from Brca1 and Brca2 
conditional knockout mice (Rottenberg et al. 2008; Hay et al. 2009); 2. loss of p53-binding 
protein 1 (53BP1), resulting in reactivation of the HR pathway, shown in a subset of olaparib 
resistant tumours from Brca1 conditional knockout mice show (Jaspers et al. 2013); and 3. 
Reactivation of the HR pathway by secondary, activating mutations in the BRCA2 gene, 
shown in BRCA deficient cell lines and in two patients (Edwards et al. 2008; Barber et al. 
2013).  
1.5 Mouse models of Breast Cancer 
Mouse models are valuable in vivo tools which have greatly enhanced our understanding of 
breast cancer development and treatment. Mouse models are also critical in drug 
development and testing, producing analyses of drug efficacy and toxicity. The techniques 
developed by Capecchi, Evans and Smithies generated mice with targeted disruptions in a 
gene of interest, resulting in the targeted allele being permanently deleted or disrupted in 
every cell of the mice (Evans and Kaufman 1981; Doetschman et al. 1987; Thomas and 
Capecchi 1987). These models are termed constitutive knockout models and results in gene 
inactivation in every tissue and at every stage of development. Some genes involved in 
carcinogenesis are also required for development, meaning that constitutive knockout can 
result in embryonic or perinatal lethality. Analysing gene loss in a specific tissue may also be 
difficult in these mouse models as tumours can arise in other tissues. 
To circumvent the drawbacks of constitutive knockout models, conditional knockout 
systems have also been developed, enabling spatial and temporal control over expression of 
the gene of interest. The Cre-loxP system enables spatial control by the use of tissue specific 
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promoters (Figure 1.13). Where expressed, the Cre recombinase causes deletion of DNA 
sequences between specific recognition sites, termed ‘locus of crossover of bacteriophage 
P1’ (loxP) sites. These sites are not found endogenously in the mouse genome, and can 
therefore be utilised to specifically mutate genes of interest by flanking specific DNA 
sequences. Using embryonic stem cells two transgenic mice are created: one where the Cre 
transgene has been inserted into the mouse genome under the control of a tissue specific 
promoter, and another where the gene(s) of interest are flanked by loxP site. These mice 
are then used to perform a series of breedings to create mice that contain both the Cre 
transgene and the flanked gene(s) of interest.  
Mouse models of breast cancer utilise mammary-specific promoters, such as the mouse 
mammary tumour virus-long terminal repeat (MMTV-LTR), whey acidic protein (WAP), 
Cytokeratin 14 (K14) and β-lactoglobulin (BLG) promoters. These promoters vary in the 
location and specificity of expression: the WAP promoter is expressed in the alveolar cells of 
the mammary gland and in other tissues such as the brain, the K14 promoter is expressed in 
basal mammary cells but also in the skin, whereas the BLG promoter is specifically 
expressed in the ER- luminal mammary cells (reviewed in (Shen and Brown 2005)). The 
MMTV, WAP and BLG promoters are hormone-regulated, meaning that their expression 
increases during pregnancy and lactation. Inducible systems, such as the tetracycline-
controlled system, can be utilised to create temporal control; thereby removing the 
possibility of unwanted effects sometimes seen by constitutively active promoters.  
An alternative to genetically modified mice is transplantation of mouse or human cancer cell 
lines (xenograft). Like genetically modified mouse models, xenografts can be utilised to 
analyse breast cancer initiation, progression and response to therapy; however, as these 
mice are immune-compromised, the interaction of the immune system with cancer 
progression is absent. Due to the absence of one mouse model that completely 
encapsulates human breast cancer; the type of mouse model chosen for a particular study 
requires careful consideration. 
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1.5.1 Brca2/p53 Conditional knockout mouse model  
The Brca2/p53 conditional knockout mouse models human inherited breast cancer, utilising 
the CreLoxP system under the control of the BLG promoter, to conditionally knockout Brca2 
and p53 in the mammary gland. The BLG promoter encodes the whey milk protein β-
lactoglobulin, which is expressed preferentially in ER- luminal cells (Molyneux et al. 2010) of 
the mammary gland, thereby ensuring that Cre recombinase activity is specific to these cells 
(Watson et al. 1991). Expression from the BLG promoter is increased by the presence of 
pregnancy hormones but has also been shown to be active in virgin mice, with Brca2fl/f, 
p53fl/fl virgin mice developing tumours from six months of age (Hay et al. 2009). LoxP sites 
flank exons 9 and 10 of the Brca2 gene, truncating the protein before the critical BRC 
repeats in exon 11, and exons 2-10 of the p53 gene. These mice develop mammary tumours 
from 6-15 months of age, with the mean latency of 9 months (Hay et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Conditional knockout using the Cre loxP system. A mouse containing loxP sites 
flanking essential exons of the gene of interest is bred with a mouse that contains the Cre 
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Cre recombinase 
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recombinase gene under the control of a tissue-specific promoter. In the offspring the Cre 
recombinase results in the deletion of the DNA sequence flanked by the loxP sites. As the Cre 
recombinase is placed under a tissue-specific promoter this technology allows spatial 
control. 
1.6 Aims 
The two primary objectives of this thesis were to investigate whether different histological 
mammary tumour types, from a Brca2/p53 conditional knockout mouse model (section 
1.5.1), correlated with different responses to daily olaparib therapy, and to investigate the 
mechanism(s) of resistance to olaparib in this model. 
To address the first objective, untreated tumours from the mouse model were characterised 
by histopathology to analyse which tumour types were found in this model. Tumours 
displaying different initial responses to daily olaparib treatment were then classified by 
histopathology to investigate if tumour type is associated with response. This follows on 
from a study by Hay et al which showed that mammary tumours from Brca2/p53 conditional 
knockout mice showed varied initial responses to daily olaparib treatment (Hay et al. 2009).  
The rationale behind the second objective also arises from the study by Hay et al which 
showed that Brca2/p53 deficient mouse mammary tumours initially responded well to daily 
olaparib therapy but relapsed after long term treatment, possibly associated with up-
regulation of drug efflux pumps (P-gps) in a proportion of resistant tumours (Hay et al. 
2009). The second aim was therefore to use the same mouse model to address this 
hypothesis by inhibiting the P-gps in resistant tumours. Finally, as the up-regulation of P-gps 
was only shown in a subset of resistant tumours this suggests that other mechanisms of 
resistance exist in this mouse model, so other possible mechanisms of resistance were 
analysed using expression analysis to drive a non-directed approach. 
Following on from results obtained from the second objective, which suggested that EMT is 
involved in olaparib resistance, an additional aim was to analyse the effect of E-cadherin loss 
on histological tumour type and olaparib therapy. This was achieved by treating a 
Brca2/p53/Cdh1 conditional knockout mouse model with daily olaparib therapy, and 
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comparing the histopathology of untreated and olaparib-resistant tumours to those from 
the Brca2/p53 conditional knockout mouse model. 
 
 
 
40 
 
2. Materials and Methods 
 
2.1 Experimental animals 
The house mouse (mus musculus) was used as an experimental model in this work. All mice 
used were of outbred background. 
2.1.1 Genetic Mouse models 
Two different experimental mouse models were used. They were already established in the 
laboratory, and use Cre loxP technology to conditionally delete genes of interest in the 
mammary epithelium, using the BLG promoter to drive Cre expression, causing mammary 
tumour development without the need for induction by pregnancy. 
2.1.1.1 Brca2/p53 conditional knockout mice 
In BlgCre-Brca2f/f/p53f/f mice, exons 9-11 of the Brca2 gene and exons 2-10 of the p53 gene 
were flanked by loxP sites (Jonkers et al. 2001; Cheung et al. 2002). 
2.1.1.2 Brca2/p53/Cdh1 conditional knockout mice 
The Brca2/p53/E-cadherin conditional knockout mouse model (BlgCre-
Brca2f/f/p53f/f/Cdh1f/f), was created in our laboratory for a currently unpublished study, by 
crossing BlgCre-Brca2f/f/p53f/f mice with those carrying a Cdh1 allele, with exons 4-15 
flanked by loxP sites, (Derksen et al. 2006). 
2.1.2 Animal Husbandry 
All animals were housed according to UK Home Office Regulations. The mice were fed by 
Harlan standard diet and water was provided ab libitum. All experimental procedures were 
conducted in accordance with the UK Animals Act 1986 and current UK Home Office 
regulations. 
2.1.3 Experimental cohorts 
Mice were monitored weekly for palpable mammary tumours. Once detected, they were 
allowed to reach a size which would allow measurable growth or regression (around 
6mmx6mm), at which point olaparib treatment was initiated. The experimental tumour 
burden endpoints were if the tumour was close to causing blistering of the skin or starting 
to impair the animal’s movement, or if they became symptomatic of other disease. 
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2.1.3.1 Mammary tumour measurement  
Tumour measurement was initiated on the first day of treatment and was performed twice 
a week using manual spring-loaded callipers. Tumour volumes were calculated using the 
following equation: volume = length X (square of width)/2. Relative tumour volumes on 
each day were calculated by dividing the current tumour volume by the initial volume at the 
start of treatment. 
2.1.3.2 Experimental procedures 
All procedures on animals were conducted according to UK Home Office Regulations. 
Olaparib was administrated once daily at 100mg/kg by interperitoneal (IP) injection. 
Tariquidar was administrated IP once daily at 2mg/kg by, five times a week, 30 minutes 
before olaparib. 
2.2 Tissue preparation 
2.2.1 Tissue Dissection 
Mice were culled via cervical dislocation, according to UK Home Office Regulations. Upon 
dissection, mice were sprayed with 70% ethanol and mammary tumours were removed 
from under the skin. The majority of the tumour was used for fixation (section 2.4.2), with a 
small piece being snap frozen for RNA analysis (section 2.4.3). After the mammary tumours 
were removed, other organs were also removed from the mouse (liver, kidney, spleen, 
pancreas and lung) for fixation. 
2.2.2 Tissue Fixation 
Tissues were immediately placed into cold 10% neutral buffered formalin (Sigma). After 24 
hours the tissues were transferred to 70% ethanol at 4°C until paraffin embedding.  
2.2.3 Paraffin Embedding and Sectioning 
After fixation the tissues were removed from the 70% ethanol and placed in cassette (fisher) 
and processed using the automatic processor (Leica TP1050). In short, the tissues were 
dehydrated by incubation in increasing concentrations of ethanol (70% for 1 hour, 95% for 1 
hour, 2x 100% for 1 hour 30 minutes, followed by 100% for 2 hours),  followed by 2x xylene 
for 2 hours. They were then placed in liquid paraffin for 1 hour, twice for 2 hours, removed 
from the cassettes and embedded in paraffin by hand, and left to solidify. 
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In preparation for histological analysis (section 2.5), sections of embedded tissue were fixed 
onto slides, by cutting to 5µm using a microtome (Leica RM2135), placing on Poly-L-Lysine 
coated slides (PLLs) and baking at 58°C for 24 hours. 
The paraffin embedding and sectioning was performed by Derek Scarborough and Mark 
Isaac. 
2.2.4 Snap Frozen Tissue 
Small pieces of mammary tumour were placed into lockable microtubes, placed in liquid 
nitrogen until frozen and stored at -80°C until required. 
2.3 Histological analysis 
2.3.1 Immunohistochemistry 
2.3.1.1 Generic Protocol 
The generic protocol for immunohistochemistry is described below. For specific conditions 
for some parts of each immunohistochemistry, please refer to table 2. 
2.3.1.1.1 Dewaxing and rehydration of slides.  
Paraffin embedded tissue sections on PLL coated slides were dewaxed in xylene (2x 5 min, 
Fisher Scientific) and rehydrated by washing in decreasing concentrations of ethanol 
(Fishers Scientific): 2x 3 min in 100% ethanol, 1x 3 min 95% ethanol and 1x 3 min 75% 
ethanol. 
2.3.1.1.2 Antigen retrieval.  
Antigen retrieval was carried out to unmask the antigens. Slides were incubated in 
preheated citrate buffer (99.9°C, pH6 Thermo) in a water bath or pressure cooker for 20 
minutes. Slides were then left to cool for 30 min at room temperature. 
2.3.1.1.3 Prevention of endogenous staining.  
To prevent endogenous background staining, slides were incubated with a peroxidase 
blocking solution (Table 2.1), which inactivates the endogenous peroxidases, for 15 minutes 
at room temperature, followed by three 5 minute washes in washing buffer (Table 2.1). 
2.3.1.1.4 Serum block.  
The slides were blocked with serum diluted in wash buffer (Table 2.1), to block non-specific 
binding of antibodies, for 45 minutes at room temperature. The serum block was removed 
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and slides were incubated immediately with the primary antibody in serum/wash buffer. In 
the case of the 3 antibodies (CK18, CK14 and ERα) that used the mouse-on-mouse kit (MOM 
kit, Vector labs), the serum block was provided in the kit, and a subsequent blocking step 
was performed for 30 minutes with Dako protein block (Dako #x0909), before primary 
antibody incubation. 
2.3.1.1.5 Primary antibody.  
The slides were incubated overnight at 4°C with the primary antibody at an optimised 
concentration (Table 2.1). Antibodies were diluted in the same serum solution used in 
section 2.3.1.1.4. Unbound primary antibody was removed by three 5 minute washes in 
wash buffer. 
2.3.1.1.6 Secondary antibody.  
The slides were then incubated for 1 hour at room temperature with the secondary 
antibody (Table 2.1), followed by three 5 minute washes in wash buffer. Some secondary 
antibodies were pre-diluted antibodies conjugated to Horse Radish Peroxidase (HRP) 
(Envision plus kit, DAKO), which catalyses the reaction for signal visualisation, so a signal 
amplification step was not needed; however, most of the secondary antibodies were 
biotinylated, so a signal amplification step was required for visualisation (section 2.3.1.1.7). 
In such cases, the secondary antibody was diluted in the serum solution used in section 
2.3.1.1.4.  
2.3.1.1.7 Signal amplification.  
For protocols that used biotinylated secondary antibodies, the positive signal was amplified 
by incubating the slides for 30 minutes at room temperature with the Avidin-Biotin Complex 
(ABC) kit (Vector labs), made up 30 minutes before it was applied. This results in the HRP 
enzyme being bound to the secondary antibody. The reagent was then removed by 3 x 5 
minute washes in wash buffer. 
2.3.1.1.8 Visualisation of positivity.  
The substrate 3,3’-diaminobenzidine (DAB) was used to visualise the positive signal, due to 
its HRP-catalysed conversion to a brown colour. This was achieved using the DAB+ 
Chromogen reagent supplied in the EnVisionTM kit. The reagent was applied to the slides 
for 10 minutes, and then removed by three 5 minute washes with wash buffer. The slides 
44 
 
were counterstained in haematoxylin for 60 seconds, followed by a wash in running water 
for 5 minutes. The slides were dehydrated by washing in increasing concentrations of 
alcohol. Before the slides were mounted they were placed in xylene for 2x 5 minutes. 
2.3.1.2 Specific Conditions 
Specific conditions for each individual immunohistochemistry are shown in Table 2.1  
 
2.3.2 Analysis of immunohistochemistries 
All immunohistochemical stains, apart from Ki67, were scored as described in (Molyneux et 
al. 2010; Melchor et al. 2014) 
2.3.2.1 Ki67 scoring  
Ki67 levels were analysed by counting the number of positive cells per field, using 20X 
magnification, and finding the percentage from the total number of cells. 3 fields per 
tumour were counted and an average was calculated for each sample. 
2.3.3 Haematoxylin and Eosin staining 
To visualise mammary tumours for histopathology sections, nuclei were marked by 
haematoxylin and cytoplasm by eosin as follows: sections were dewaxed and rehydrated as 
described in 2.3.1.1.1. before submersion in Haemalum solution (R.A.Lamb) for 45 seconds, 
followed by a 5 minute wash in running tap water. The sections were placed in 1% Eosin 
solution (R.A.Lamb) for 5 minutes before two rounds of 15 second washes were performed. 
Slides were dehydrated and mounted as described in 2.3.1.1.8. 
The H&E staining was performed by Derek Scarborough and Mark Isaac. 
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Table 2.1 Optimised conditions for specific antibodies 
Target P63 Cytokeratin 18 Vimentin Cytokeratin 14 Oestrogen Receptor α SMA 
Commercial source of primary Ab  Abcam 
#ab735 
Progen 
#65028 
Santa Cruz 
#SC-7557 
Abcam 
#ab7800 
Vector Labs 
#VP-E613 
Abcam 
#ab5694 
Primary Ab raised in Mouse (mAb) Mouse (mAb) Goat (pAb) Mouse (mAb) Mouse(mAb) Rabbit (pAb) 
Antigen retrieval Boiling Citrate buffer, 20 
mins 
Boiling Citrate buffer, 20 
minutes 
Boiling citrate buffer, 
20 mins 
Boiling citrate buffer, 
20 mins 
Boiling citrate buffer, 
PC, 20 mins 
Boiling citrate 
buffer, 20  minutes 
Peroxidase Block 3% H2O2, 15 minutes 1/60 H2O2 in methanol, 
10 minutes 
3% H2O2, 15 mins 1/60 H2O2 in 
methanol, 10 minutes 
1/60 H2O2 in methanol, 
10 minutes 
3% H2O2,  15 
minutes 
Serum block 10% goat serum, 45 
minutes 
MOM blocking reagent, 1 
hour 
10% rabbit serum, 45 
mins 
MOM blocking 
reagent, 1 hour 
MOM blocking reagent, 
1 hour 
10% goat serum, 45 
mins 
Wash buffer 0.1% TBS/Tween 0.1% TBS/Tween 0.1% TBS/Tween 0.1% TBS/Tween 0.1% TBS/Tween 1xPBS 
Conditions of primary Ab 1/100, 4°C overnight 1:5, diluted in MOM 
diluent, 4°C overnight 
1/300, 4°C overnight 1/500, diluted in 
MOM diluent, 4°C 
overnight 
1/500 diluted in MOM 
diluent, 4°C overnight 
1/200, 4°C overnight 
Secondary Ab Anti-mouse labelled 
polymer-HRP-
conjugated (EnVision
TM 
kit ) 
Anti-mouse (MOM kit) Anti-goat biotinylated 
(Dako) 
Anti-mouse (MOM 
kit) 
Anti-mouse (MOM kit) Anti-rabbit 
biotinylated (Dako) 
Conditions of secondary Ab 1 hr, room temp 10 mins, room temp 1/100, 30 mins room 
temp  
10 mins, room temp 10 mins, room temp 1/500, 30 mins 
room temp 
Signal amplification N/A ABC kit (Vector labs) ABC kit (Vector Labs) ABC kit (Vector labs) ABC kit (Vector Labs) N/A 
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Target E-cadherin Twist Slug Ki67 
Commercial source of primary Ab  BD Transduction 
#610182 
Abcam 
#ab50887 
Cell Signaling 
#C19G7 
Vector Labs 
Primary Ab raised in Mouse  Mouse (mAb) Rabbit (mAb) Mouse (mAb) 
Antigen retrieval Boiling Citrate buffer, 20 
mins 
Boiling Citrate buffer, 20 minutes Boiling citrate buffer, 20 mins Boiling citrate buffer, 30 mins 
Peroxidase Block 3% H2O2, 10 minutes 3% H2O2, 10 minutes 3% H2O2, 10 minutes 3% H2O2, 20 minutes 
Serum block 5% goat serum, 30 minutes 5% rabbit serum, 30 minutes 5% goat serum, 30 minutes 20% rabbit serum, 20 minutes 
Wash buffer 0.1% TBS/Tween 0.1% TBS/Tween 0.1% TBS/Tween 0.1% TBS/Tween 
Conditions of primary Ab 1/300, 4°C overnight 1/500, 4°C overnight 1/100, 4°C overnight 1/20, 4°C overnight 
Secondary Ab Anti-rabbit biotinylated 
(Dako) 
Anti-mouse biotinylated (Dako) Anti-rabbit biotinylated 
(Dako) 
Anti-mouse biotinylated (Dako) 
Conditions of secondary Ab 30 mins room temp 30 mins room temp 30 mins room temp 30 mins room temp 
Signal amplification ABC kit (Vector labs) ABC kit (Vector labs) ABC kit (Vector Labs) ABC kit (Vector labs) 
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2.4 RNA analysis 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to 
quantify expression levels of genes in mammary tumours. RNA was extracted from stored 
frozen tissue, then used as a template to produce cDNA, which was then used to compare 
expression levels between cohorts (n=4 per cohort). 
2.4.1 RNA extraction 
Mammary tumour samples were defrosted and placed into homogenising lysing matrix D 
tubes (MP Biomedicals). 1ml of Trizol (Invitrogen) was added, and the samples were 
homogenised using a Precellys 24 Homogeniser (Bertin Technologies) at 7000 x g for 2 cycles 
of 25 seconds. After homogenisation, 200µl of chloroform was added to each sample and 
they were incubated on ice for 10 minutes, before centrifugation at 9500 x g for 15 minutes 
at 4°C. The clear supernatant was transferred to a 1.5ml microfuge tube and 600µl of 
isopropanol (Fisher) was added,mixed well and left on ice for 1 hour to precipitate nucleic 
acids. Samples were centrifuged at 9500 x g for 15 minutes at 4°C and the supernatants 
carefully discarded. The remaining pellets were washed with 500µl cold 75% ethanol, before  
re-centrifugation at 9500 x g for 5 minutes at 4°C. Supernatants were again discarded and 
the pellets left to air-dry at room temperature for 10 minutes before resuspension in 100µl 
of diethylprocarbonate (DEPC)-treated water at 65°C for 10 minutes. The samples were then 
DNase treated (section 2.4.2). 
2.4.2 DNase treatment 
DNase treatment was performed using the Turbo DNA-free kit (Life technologies). 1/10 
dilution of the buffer and DNase was added to the RNA and incubated at 37°C for 1 hour, 
before addition of an inactivating agent and further incubation for 10 minutes.  
2.4.3 RNA quantification 
RNA concentrations were determined by nanodrop analysis using an ND-1000 spectrometer 
(Labtech, UK).  
2.4.4 cDNA synthesis 
cDNA was made using superscript III reverse transcriptase (Invitrogen). A master mix was 
composed so that each sample contained 1µl Random primers (Invitrogen), 2µl 10mM dNTP 
mix, and 1µg RNA in RNase-free water. The mixtures were placed in nuclease-free 
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microcentrifuge tubes and incubated at 65°C for 5 minutes followed by 1 minute on ice. 
Another master mix was composed so that 8µl 5x first-strand buffer, 2µl 0.1M DTT, 2µl 
RNase-freewater and 1µl superscript III reverse transcriptase was added to each sample and 
incubated for 5 minutes at room temperature. The samples were then incubated at 50°C for 
60 minutes, before inactivation by incubation at 70°C for 15 minutes.  
2.4.5 qRT-PCR 
2.4.5.1 Taq-Man 
The expression of the majority of genes of interest was quantified using TaqMan assays 
(Applied Biosystems). These use predesigned probes, each containing one forward and one 
reverse primer for the gene of interest, with a fluorescent molecule and a quencher 
attached to the 5’ end. During thermo-cycling, Taq polymerase cleaves the fluorescent 
molecule, releasing it from the quencher and enabling fluorescent detection. 
Each sample for the qRT-PCR reactions were performed in duplicate, including no cDNA 
controls, in MicroAmp 96-well PCR plates with 0.1ml wells (Applied Biosystems). Each 
reaction contained 10ng cDNA, 10µl Taqman universal PCR mastermix (Applied Biosystems), 
1µl gene specific assay (Applied Biosystems; Table 2.2) and was made up to 20µl with DEPC-
treated water. β-actin was used as an internal control and the reactions carried out using 
the StepOne Plus Real-Time PCR System (Applied Biosystems), using the following cycling 
conditions: 50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds 
(denaturation) and 60°C for 1 minute (annealing/elongation). The data was collected 
automatically using StepOne software (Applied Biosystems). 
2.4.5.2 Syber Green 
Quantitation of gene expression of Grem1 was carried out using Syber Green assays. Using a  
MicroAmp 96-well PCR plate (Applied Biosystems) each reaction contained 10ng cDNA, 10µl 
SYBR green fast mix (Invitrogen), 1µl gene specific primers (Table 2.2) and was made up to 
20µl with DEPC-treated water. Each sample was performed in duplicate, including no cDNA 
controls, and β-actin was used as an internal control. The reactions were carried out using 
the StepOne Plus Real-Time PCR System (Applied Biosystems), using the following cycling 
conditions:  95°C for 20 seconds, then 40 cycles of 95°C for 3 seconds (denaturation) and 
60°C for 30 seconds. As with the TaqMan assays, data was collected automatically. 
49 
 
Table 2.2 Primer details for qRT-PCR analysis 
 
2.4.5.3 Analysis of data 
The data was examined prior to analysis to ensure there was no product in the ‘no cDNA’ 
controls, and that the replicates were comparable. Cycle time (CT) was automatically 
calculated by the software, and an average of the replicates from each sample was 
calculated manually. The difference in cycle time (∆CT) were calculated manually for each 
sample, normalising the reaction using the β-actin controls, then an average ∆CT was found 
for each cohort. The average ∆CT were then used to calculate the fold change of each gene 
(fold change = 2∆∆CT) between the different cohorts. The average ∆CT values were compared 
statistically to test for significant differences between the cohorts, using the Mann-Whitney 
U test. 
2.5 Pharmacokinetic and Pharmacodynamic analysis 
Tumours were removed from mice that were treated with either a single dose of 100mg/kg 
olaparib or vehicle, and taken 1 and 24 hours later, and from mice that were treated with 
daily 100mg/kg olaparib until the tumours became resistant. Pieces of mammary tumour 
were snap frozen (section 2.2.4) then stored at -80°C. The frozen tissue was sent to 
AstraZeneca, where they analysed the concentrations of olaparib in the samples by mass 
spectroscopy, as described in Hay et al. 2009. To analyse PARP-1 activity, PAR levels were 
analysed in the same samples by electrochemiluminecense, as described in Hay et al. 2009. 
SYBER Green Forward Primer sequence 
(5’-3’) 
Reverse primer sequence  
(5’-3’) 
Grem1 GACAAGGCTCAGCACAATGA ACTCAAGCACCTCCTCTCCA 
Taq Man Supplier 
Snail Applied Biosystems 
Sema3b Applied Biosystems 
Foxa3 Applied Biosystems 
Sox8 Applied Biosystems 
Pcolce2 Applied Biosystems 
Hmga2 Applied Biosystems 
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2.6 RNA sequencing 
Tumours that were either resistant to or responding to daily 100mg/kg olaparib therapy, 
were removed from mice, snap frozen (section 2.2.4) and sent to AstraZeneca. At 
AstraZeneca they extracted the RNA from the samples and performed mRNA sequencing 
(100bp paired-end sequencing) on the Illumina Hi-Seq platform, at 150-fold coverage. The 
reads were mapped onto the mouse genome using the software Tophat, and counts from 
the mapped reads were generated using software HTSeq (Anders et al. 2014). The 
differentially-expressed genes were identified using the DESeq R package 
(http://genomebiology.com/2010/11/10/R106). The output was reads per kilobase of 
transcript per million mapped reads (R.P.K.M), in which ranges of values correspond with 
level of expression (0-0.5 represents very low expression, 0.5-8 represents low expression, 
8-16 medium expression, 16-128 high expression, and above 128 very high expression). 
The genetic profiles of the samples were also compared to an EMT-signature, generated in-
house at AstraZeneca, which was composed by comparing cell lines exhibiting epithelial-like 
expression (e.g. high expression of CDH1 and low expression of VIM) with cell lines 
exhibiting mesenchymal-like expression (e.g. low CDH1 expression and high VIM 
expression).  
2.7 Mammosphere Assay 
The composition of the media used in this assay are shown in Table 2.3. 
2.7.1 Digestion and plating of single cells 
Following dissection, mammary tumour samples were placed in 15ml digestion media and 
finely minced in a tissue culture hood using a scalpel and forceps. The minced tumour was 
then transferred to 9ml heated (37°C) digestion media, mixed with 1ml collagenase solution 
and incubated at 37°C, with rigorous shaking, for 3 hours. The resulting clumps of cells were 
broken down to single cells by passing the solution through a 21G needle a number of times, 
followed by a 25G needle, and finally through 70µm and 40µm cell strainers. The solution 
was then centrifuged at 10,000 x g for 5 minutes, the supernatant discarded and the pellet 
resuspended in 5ml of red blood cell lysis buffer (Sigma) and left to incubate at room 
temperature for 5 minutes. This was followed by a further centrifugation at 10,000 x g for 5 
minutes, and once more the supernatant was discarded. The pellet was resuspended in 5ml 
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digestion media and centrifuged again at 10,000 x g for 5 minutes. Once the supernatant 
has been discarded, the pellet was resuspended in 5ml digestion media, and the number of 
cells per ml calculated using Trypan blue stain (Invitrogen) and a haemocytometer.  
The cells were seeded to a density of 10,000 cells per well, in sterile 6 well cell culture plates 
(Cellstar) coated in polyHEMA, with 4ml of heated (37°C) mammosphere growth media in 
each well. The plates were incubated at 37°C for 7 days, at which point mammospheres 
larger than 50µm in diameter were counted manually. 
2.7.2 Fixation of mammospheres 
All tips were rinsed in 0.3% BSA/PBS to prevent mammospheres sticking to them. Medium 
from the 6 well plates was collected into 50ml unskirted falcon tubes and centrifuged at 
7000RPM for 3 minutes. The supernatant were discarded and pellets resuspended in 1ml 
formalin. The samples were then incubated on ice for 30 minutes followed by a further 
centrifugation at 7000 x g for 3 minutes and subsequent resuspension of the pellets in 1ml 
70% ethanol. After incubation on ice for 30 minutes, the samples were centrifuged at 7000 x 
g for 3 minutes and the pellest resuspended in 90µl of heated (70°C) Histogel 
(ThermoScientific). The gel solution was pipetted into a specifically made mould, which was 
manufactured in the lab, and placed on top of parafilm to enable the gel to set in a 3D 
sphere. Once set, the sphere was removed from the mould and placed into 70% ethanol 
prior to paraffin embedding and sectioning (section 2.2.3) 
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Table 2.3 Details for making the solutions used in the mammosphere assay 
Digestion media Supplier 
450ml DMEM Life Technologies 
50ml Fetal Bovine Serum  Life Technologies 
5ml L-glutamine  Life Technologies 
5ml Penecillin Steptomycin  Life Technologies 
Mammosphere growth media  
500ml Mammary Epithelial cell growth 
media 
Lonza 
2ml of Human Recombinant EGF (100µg/ml) Sigma 
200µl of Gentamycin (50mg/kg) Sigma 
100µl of Hydrocortisone (5mg/ml)   Sigma 
500µl of Insulin (5mg/ml)   Sigma 
Collagenase solution 
Dissolve collagenase (Sigma) in DMEM media (Life Technologies) to a concentration of 
10mg/ml) 
PolyHEMA 
12g polyHEMA (Sigma) dissolved in 1L 95% ethanol. Place 1ml of solution into each well of 
plate and incubate the plate at 37°C for 48 hours 
 
2.8 Data analysis 
2.8.1 Graphical representation of data 
The raw data obtained from scoring, histopathology and qRT-PCR were inputted into Excel 
spreadsheets (Microsoft). All means, standard deviations and sums were calculated using 
the calculator functions and the graphical representation of data was produced in Excel. 
2.8.2 Comparison of means 
Statistical tests were carried out using the Minitab 17 statistical package (Minitab Inc.). To 
test for normal distribution, the Andersson-Darling normality test was used. As all the data 
collected was not normally distributed, the comparison of means was tested using the 
Mann-Whitney U test. Statistical significance was indicated if p≤0.05. 
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2.8.3 Survival analysis 
Survival data was also analysed using the Minitab 17 statistical package, with Kaplan-Meier 
plots used to present the data and significance analysed using the Wilcoxon test. Statistical 
significance was indicated if p≤0.05. 
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3. Characterisation of Brca2/p53-deficient murine mammary 
tumours and analysis of initial response to olaparib 
therapy 
3.1 Introduction  
Breast cancer is a disease composed of different histological and molecular subtypes, each 
having distinct clinical behaviours (Perou et al. 2000a; Sorlie et al. 2003; Reis-Filho and 
Pusztai 2011). Although human BRCA2-mutated mammary tumours display a variety of 
histological types, the majority are IDC-NSTs that are ER+ and have a luminal gene 
expression profile (Laakso et al. 2005; Larsen et al. 2013). The heterogeneity of breast 
tumours emphasises the need for targeted treatments, such as tamoxifen and herceptin. 
PARP inhibitors, such as olaparib, show selective toxicity to BRCA-deficient cells (Bryant et 
al. 2005; Farmer et al. 2005) and clinical trials have shown that around 40% of patients with 
BRCA mutations respond to daily olaparib treatment (Fong et al. 2009; Tutt et al. 2010). In 
accordance with this, a previous study using BlgCre-Brca2f/f/p53f/f mouse model showed 
that although the vast majority of tumours responded to olaparib monotherapy, the 
responses were variable (Hay et al. 2009), suggesting that further stratification may be 
required to determine therapeutic relevance.  
To investigate whether histological tumour type correlates with response to olaparib 
treatment, a detailed histopathological analysis of the tumours was performed using 
previously established criteria (Molyneux et al. 2010; Melchor et al. 2014) based on human 
breast tumour classification (Lakhani et al. 2012). Immunohistochemistry was used to 
analyse the luminal (CK18), and basal/myoepithelial (CK14, p63, SMA) cell populations. 
Vimentin staining was used as a marker of mesenchymal differentiation, its presence 
thereby indicating the potential occurrence of EMT. 
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3.2 Results 
3.2.1 Presence of four histopathological tumour types in the BlgCre-
Brca2f/f/p53f/f mouse model  
Examination of a cohort of 20 tumours from untreated mice identified four 
histopathological tumour types, based on H&E appearance and immunohistochemical 
staining: IDC-NST, metaplastic spindle cell carcinoma (MSCC), malignant 
adenomyoepithelioma (AME) and metaplastic adenosquamous carcinoma (ASQC) (Figure 
3.1 and Figure 3.2A-E). All IDC-NSTs showed high CK18 expression (60-85% positivity), and 
the majority showed <1% CK14 expression, with just two showing higher levels. Although 
the majority were negative for Vimentin, SMA and p63, there was occasional positivity but 
never more than 1%.   AMEs showed high expression of p63 in comparison to IDC-NSTs and 
MSCCs (Mann-Whitney U test, p<0.01) with 20-60% of cells staining positive. They also 
showed 20-45% positivity for CK18, variable staining for CK14 (1-60%) and Vimentin (1-50%). 
AMEs showed significantly higher expression of SMA compared to IDC-NSTs (Mann-Whitney 
U test, p=0.043), although staining was variable between tumours (1-55% positivity). ASQCs 
showed high expression of p63 and CK14 (60-80% positivity), and low expression of CK18 (1-
5% positivity), Vimentin (<1% positivity) and SMA (1% positivity). MSCCs showed 
significantly higher expression of Vimentin compared to IDC-NSTs and AMEs (Mann-Whitney 
U test, p=0.011 and p<0.01 respectively), with 70-80% of cells staining positive. Three 
MSCCs also showed very low levels of CK18 and CK14 expression (<1% of tumour cells) 
whilst one showed 40% positivity for CK18 and 15% positivity for CK14. All MSCCs had no 
detectable p63 staining. They also showed significantly higher expression of SMA compared 
to IDC-NSTs, with 15-45% of cells staining positive (Mann-Whitney U test, p=0.011). 
All tumours were ERα negative, although ERα positive cells could be observed in normal 
mammary epithelial ducts around the tumours (Figure 3.1). IDC-NSTs and AMEs were the 
most prevalent tumour types in this cohort, making up 35% and 40% respectively. MSCCs 
and ASQCs were less common, making up 15% and 10% respectively (Figure 3.2F). 
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Vimentin ERα 
AME 
IDC-NST 
MSCC 
ASQC 
SMA 
Figure 3.1 Representative 
pictures of 
immunohistochemical stains in 
untreated tumours. Four 
different tumour types were 
identified. H&E staining was used 
to analyse cellular morphology, 
CK18 to identify luminal cells, 
CK14, p63 and SMA to identify 
basal/myoepithelial cells and 
Vimentin to identify cells 
undergoing EMT. All tumours 
were ER negative, but positive 
cells were found in the normal 
mammary tissue (insert). Scale 
bars represent 50µm. 
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Figure 3.2 Immunohistochemical staining and histopathological tumour proportions of tumours from our BlgCre:Brca2f/f/p53f/f mouse 
model. Analysis of the percent of tumour cells stained for CK18 (A), CK14 (B), and p63 (C), Vimentin (D) and SMA (E). (F) Classification of 
tumours from this model revealed that the most common tumour types were IDC-NSTs and AMEs (n=20). * indicates p≤0.05 
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3.2.2 Characterisation of different responses to olaparib treatment 
Previous studies have shown that tumours arising in BlgCre-Brca2f/f/p53f/f mice show 
variable responses to olaparib therapy (Hay et al. 2009). Broadly, three types of responses 
were observed in these tumours: excellent responders, where the tumours showed a 
dramatic decrease in size within the first 30 days of treatment; moderate responders, where 
the tumours stopped growing within the first 30 days but did not decrease dramatically in 
size; and poor responders where the tumours continued to grow in size throughout 
treatment (Figure 3.3A). The majority of tumours from mice treated with daily 100mg/kg 
olaparib therapy show either a moderate (45%) or excellent (34%) response and poor 
responders are relatively rare (20%) (Figure 3.3B). To investigate whether this variability in 
response correlated to tumour type mice were treated with daily IP 100mg/kg olaparib and 
culled 30 days into treatment and tumours were classified by histopathology. Those with 
poorly-responding tumours were sometimes culled at an earlier time point due to the 
tumours reaching the designated experimental endpoint. 
Analysis of the tumours classified as poor responders showed that they were exclusively 
MSCCs which were histologically identical to untreated MSCCs (Figure 3.3C and Figure 3.4). 
Analysis of the tumours classified as moderate responders showed that the majority were 
either IDC-NSTs or AMEs (both accounting for 38.5%), whilst MSCCs accounted for the 
remaining 23% (Figure 3.3D). Unlike in the untreated cohort, responding IDC-NSTs showed a 
significant increase in Vimentin staining, with 20-40% of epithelial cells staining positive 
(Figure 3.4, Mann-Whitney  U test, p<0.01). The AMEs in this cohort showed similar p63, 
CK14 and Vimentin staining to untreated tumours; however, CK18 staining was reduced to 
less than 1% of the tumours cells. MSCCs from the moderate responder cohort were not 
composed exclusively of fusiform spindle cells: rather, each contained a small region of 
epitheloid morphology (Figure 3.4), with the epitheloid sections showing immunostaining 
patterns similar to those seen in untreated IDC-NSTs, and the spindle cell sections showing 
similar patterns to untreated MSCCs. 
Analysis of the tumours classified as excellent responders showed that the majority were 
IDC-NSTs, with the remainder being ASQCs (Figure 3.3E). All tumours in this cohort displayed 
a high proportion of tumour-associated stroma compared to the untreated groups  
N=2 
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Figure 3.3 Histopathological classification of tumours with different responses to daily 
100mg/kg olaparib therapy. (A) Response to olaparib therapy was classified into three 
categories shown by the representative RTV graph. (B) Analysis of response showed that 
moderate and excellent responders were predominant, whilst poor responders were rare. (C) 
All poor responders were classified as MSCCs (n=16), whilst the majority of moderate 
responders (D) were either IDC-NSTs (38.5%) or AMEs (38.5%), plus a lower proportion of 
MSCCs (23%) (n=13). (E) Excellent responders were predominantly IDC-NSTs (89%) with just a 
few ASQCs (11%) (n=18).  
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(Figure 3.4). Immunohistochemical staining showed that the epithelial cells in the treated 
ASQCs were indistinguishable from untreated ASQCs. However, all of the IDC-NSTs showed 
an increase in epithelial-like tumour cells staining positive for Vimentin compared to 
untreated IDC-NSTs (Figure 3.4; Mann-Whitney  U test, p<0.01). 
The presence of only MSCCs in the poor responder cohort, and their absence in the 
excellent responder cohort, strongly suggests that this tumour type is less sensitive to 
olaparib therapy in comparison to the other tumour types.  
3.2.3 MSCCs show EMT characteristics and low proliferation  
The significant increase in Vimentin staining in untreated MSCCs compared to untreated 
IDC-NSTs and AMEs suggested that cells in this tumour type were undergoing or had 
undergone EMT. To further investigate this, additional EMT markers (E-cadherin, Twist and 
Slug) were analysed in the different untreated tumour types by immunohistochemistry. 
MSCCs showed a significant decrease in the percentage of epithelial cells staining positive 
for E-cadherin (Mann-Whitney U test, p=0.02 and p=0.011) and a significant increase in 
levels of Twist (Mann-Whitney U test, p=0.014 and p<0.01) compared to IDCNSTs and AMEs 
(Figure 3.5 and Figure 3.6), which correlate with the increased Vimentin staining. The low 
number of ASQCs available for analysis did not allow for statistically significant differences in 
expression to be found; however, E-cadherin and Twist levels in these tumours showed 
similar levels to those seen in the IDC-NSTs and AMEs (Figure 3.5 and Figure 3.6).  Slug 
expression was significantly higher in AMEs when compared with IDC-NSTs or MSCCs (Figure 
3.5; Mann-Whitney U test, p<0.01 and p=0.011 respectively), with expression in the 2 ASQCs 
similar to that seen in the AMEs. This suggests that Slug expression may correlate with p63 
expression, as Slug staining is seen in the myoepithelial population of both AMEs and ASQCs 
and in normal mammary gland (Figure 3.6).  
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Figure 3.4 Representative pictures of tumours 
with different initial responses to daily 
olaparib therapy. Poor responders were 
exclusively MSCC, and all showed high 
Vimentin positivity. In the moderate responder 
group the epithelial cells in IDC-NSTs and AMEs 
show positivity for Vimentin and the MSCCs 
contain epithelial sections. Tumours in the 
excellent responder group showed a high 
amount of tumour-associated stroma. IDC-
NSTs in this group also show positivity for 
Vimentin. Scale bars represent 100µm. 
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ASQCs showed similar marker expression to AMEs: high levels of E-cadherin and Slug and 
low levels of Twist. Analysis of Snail expression by qRT-PCR showed no significant 
differences between IDC-NSTs, AMEs or MSCCs, although there was a trend for an increase 
of expression in MSCCs (Figure 3.5D). Snail expression was not analysed in ASQCs due to the 
low numbers of tumours of this type. 
Ki67 staining was used to investigate differences in proliferation between the tumour types. 
Again, ASQCs were not analysed due to the low numbers of tumours of this type. No 
significant difference was seen between the IDC-NSTs and AMEs; however MSCCs showed a 
significant decrease in the percentage of cells staining positive for Ki67 (Mann-Whitney U 
test p=0.014 and p<0.01, Figure 3.7). 
3.2.4 Vimentin staining correlates with response to olaparib 
Untreated IDC-NSTs showed very low levels of Vimentin-positive epithelial cells; however, 
tumours that are responding to olaparib show increased positivity (Figure 3.4). Vimentin 
staining was compared across IDC-NSTs showing different responses to olaparib and results 
showed that excellent responders had a significantly lower percentage of positive epithelial 
cells compared to moderate responders (Figure 3.8A; Mann-Whitney U test p<0.01). This 
suggests that levels of Vimentin staining in IDC-NSTs correspond with response to olaparib. 
As Vimentin is an EMT marker the same analysis was performed for E-cadherin, Twist and 
Slug (Figure 3.8B-D, Figure 3.9). Analysis of Slug expression showed no significant 
differences. E-cadherin expression showed no significant differences between untreated 
and moderate IDC-NSTs, but did show a significant decrease in moderate responders 
compared to excellent responders (Mann-Whitney U test, p=0.038). Although there were no 
significant differences in Twist expression between the excellent and moderate responder 
IDC-NSTs, both groups showed a significant increase compared to untreated IDC-NSTs 
(Mann-Whitney U test, p=0.046 and p=0.043 respectively). 
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Figure 3.5 EMT marker expression in the different tumour types. Analysis of the percent of tumour cells positive for E-cadherin (A), Twist (B) 
and Slug (C). (D) qRT-PCR showed no significant difference was found in Snail expression between IDC-NSTs, AMEs and MSCCs (n=4 per tumour 
type.) * indicates p≤0.05 
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Figure 3.6 
Representative pictures 
of EMT markers in 
untreated tumour types. 
Immunohistochemistry 
for E-cadherin, Twist and 
Slug in the different 
tumour types. Slug 
expression correlated 
with myoepithelial cells 
in the normal mammary 
tissue (insert). Scale bars 
represent 50µm. 
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Figure 3.7 Ki67 staining in IDC-NSTs, AMEs and MSCCs. (A) Representative pictures of Ki67 staining in untreated IDC-NSTs, AMEs and MSCCs. 
Scale bars represent 100µm. (B) Comparison of % Ki67 positive epithelial cells in the three tumour types (IDC-NSTs n=6, AMEs n=8,and MSCCs 
n=4). *indicates p<0.05. Error bars indicate standard deviation. 
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Vimentin levels across the three different responding tumour groups was also analysed to 
investigate whether positivity correlates with response to olaparib independently of tumour 
type. Corresponding with the Vimentin levels in IDC-NSTs, the tumours from the excellent 
responder cohort were found to have a significantly lower percentage of Vimentin positive 
epithelial cells when compared to moderate or poor responders, and tumours from the 
moderate responder cohort also had a significantly lower percentage compared to poor 
responders (Figure 3.10A; Mann-Whitney U test p<0.001 and p<0.001). E-cadherin, Twist 
and Slug levels were also analysed in these tumours (Figure 3.10B-D). Slug expression 
showed no significant differences between the three cohorts. Twist expression showed 
similar results to Vimentin expression with a significant increase in expression in poor 
responders compared to excellent and moderate responders (Mann-Whitney U test, p<0.01 
and p<0.01) but no significant difference between excellent and moderate responders. 
Levels of E-cadherin showed an inverse pattern to the vimentin staining, with expression 
being significantly higher in excellent responders compared to moderate and poor 
responders, and a significantly lower expression in poor responders compared to moderate 
responders (Mann-Whitney U test, p<0.01, p<0.01 and p<0.01). 
To determine whether alterations in vimentin expression in tumours were an early or late 
response to olaparib treatment, IDC-NSTs were analysed from mice either 1 or 24 hours 
after a single dose of 100mg/kg olaparib. Results showed that at both time points there was 
a significant upregulation of Vimentin staining compared to untreated IDC-NSTs (Mann-
Whitney U test p<0.01 and p<0.01, Figure 3.10A, Figure 3.4). No significant difference was 
found between the 1 and 24 hour treatment groups, although there was a trend for a 
decrease (Figure 3.10A). Expression of E-cadherin, Twist and Slug were also analysed in IDC-
NSTs from mice treated for 1 hour (Figure 3.10B-D and Figure 3.11); results showed no 
significant difference in E-cadherin and Slug staining but there was a significant increase in 
Twist staining compared to untreated IDC-NSTs (Mann-Whitney U test, p=0.028, Figure 
3.10C). 
 
 
68 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 EMT markers in IDC-NSTs. Comparison of the percentage of tumour cells positive for Vimentin (A), E-cadherin  (B) , Twist (C) and  
Slug (D) in untreated IDC-NSTs, IDC-NSTs treated with a single dose of 100mg/kg olaparib and taken either 1 hour (1 hour) or 24 hours (24 hour) 
later and IDC-NSTS showing an excellent or moderate response to daily 100mg/kg olaparib therapy. * indicates p≤0.05.  
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Figure 3.9 Representative pictures of EMT markers in IDC-NSTs. E-cadherin, Twist and Slug staining in untreated, excellent responders and 
moderate responders to daily 100mg/kg olaparib therapy classified as IDC-NSTs. Scale bars represent 50µm. 
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Excellent 
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Figure 3.10 EMT marker expression in different initial responses to olaparib therapy. Comparison of the percentage of tumour cells staining 
positive for Vimentin (A), E-cadherin (B), Twist (C) and Slug (D) in tumours showing different responses to daily 100mg/kg olaparib therapy. 
Circles represent IDC-NSTs, triangles ASQCs, squares AMEs and diamonds MSCCs. * indicates p≤0.05. 
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Figure 3.11 Pictures of EMT markers in IDC-NSTs treated with a single dose of 100mg/kg olaparib. Vimentin staining in IDC-NSTs taken after 1 
hour and 24 hours after a single dose of olaparib. IDC-NSTs taken after 1 hour of a single dose also show expression of Twist but retain high E-
cadherin staining and low Slug staining. Scale bars represent 50µm.  
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1 hour 
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3.3 Discussion 
3.3.1 Mammary tumours from our BlgCre-Brca2f/f/p53f/f mouse model show 
similarities in histology and gene expression to human tumours 
Characterisation of a cohort of untreated tumours from our BlgCre-Brca2f/f/p53f/f mouse 
model revealed four different histopathological tumour types. The proportions of these 
tumour types are similar to those seen in humans, where the majority of breast tumours are 
classified as IDC-NSTs (60-70%), and metaplastic carcinomas are quite rare (<1%) (Mallon et 
al. 2000; Al Sayed et al. 2006). In this study we have observed a high proportion of AMEs, 
which although rare in humans, are more common in rodent models (Mallon et al. 2000). All 
the tumours from our model were ER-negative. This suggests that, similar to another study 
in a BlgCre-Brca2f/f/p53f/f mouse model (Melchor et al. 2014), these mice are modelling the 
ER-negative subset of human BRCA2-mutated breast cancers, which account for around 13-
19% (Melchor and Benitez 2013). 
IDC-NSTs from our model showed a similar gene expression profile to luminal tumours (high 
CK18 and E-cadherin staining and low CK14, p63 staining), corresponding with the majority 
of human breast tumours (Mallon et al. 2000; Lakhani et al. 2012). AMEs also correlated 
with previous studies, showing positivity for luminal and basal markers that were distributed 
into abluminal and luminal cell layers (Mallon et al. 2000; Melchor et al. 2014). In 
agreement with previous studies, this work shows that the MSCCs generated in the model 
show similarities with claudin-low tumours with respect to expression of a number of 
proteins, including low expression of E-cadherin and Ki67 and high expression of EMT-
associated proteins such as Vimentin and Twist (Hennessy et al. 2009; Weigelt et al. 2009; 
Taube et al. 2010; Melchor et al. 2014). As metaplastic carcinomas are so rare in humans 
they tend to be grouped together; however, this work shows that MSCCs and ASQCs have 
differences in biological characteristics and clinical behaviour, suggesting that this 
heterogeneous group of tumours should be stratified for cancer treatment.  
3.3.2 MSCCs may have intrinsic resistance to olaparib therapy 
Clinical trials with olaparib in BRCA-mutated breast cancers have shown around 40% 
response rate (Fong et al. 2009; Tutt et al. 2010). In this study, analysis of tumours with 
different initial responses to olaparib therapy showed that poorly-responding tumours were 
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exclusively MSCCs. This correlates with human metaplastic breast carcinoma patients having 
a poor prognosis (Al Sayed et al. 2006; Hennessy et al. 2009) and is therefore of clinical 
relevance. These MSCCs were morphologically and immunohistochemically identical to 
untreated MSCCs, suggesting that patients with this tumour type would not benefit from 
olaparib therapy. One reason for this could be the low percentage of proliferating cells in 
the MSCCs, as PARP inhibitors have been shown to be more effective in the S phase of the 
cell cycle, suggesting that rapidly dividing tumours are more susceptible to these agents 
(Noel et al. 2006). Tumours that showed a moderate response to daily 100mg/kg olaparib 
therapy show higher percentages of Vimentin positive epithelial cells compared to tumours 
responding excellently, suggesting that the proportion of Vimentin-expressing epithelial 
cells within the tumour is indicative of the response to olaparib therapy. Analysis of other 
EMT markers showed no significant difference in Slug or Twist expression between 
moderate and excellent responders; however, moderate responders do show significantly 
lower expression of E-cadherin compared to excellent responders. Taken with the Vimentin 
levels, this may mean that some mesenchymal-characteristics affect olaparib response. 
Other studies have also shown a correlation between EMT markers, such as Vimentin, and 
response to cancer therapy, for example non-small cell lung cancer carcinoma (NSCLC) cell 
lines that express Vimentin were shown to be insensitive to EGFR kinase inhibition 
(Thomson et al. 2005). This study, together with the data presented here, suggests that cells 
that have undergone/undergoing EMT have mechanisms that confer resistance to multiple, 
unrelated drugs. To support this, a study investigating Adriamycin treatment on breast 
cancer cell lines found that, in a subpopulation of cells, treatment induced EMT, and that 
these cells displayed up-regulation of P-gps, multidrug resistance to chemotherapeutic 
agents and increased invasion (Li et al. 2009). This suggests that the mechanism of 
multidrug resistance could be the up-regulation of P-gps. 
The MSCCs in the moderate responder cohort differed from untreated MSCCs in that they 
also contained epitheloid sections, suggesting that these tumours may be going through a 
change in tumour type. This would correspond with the study by Li et al., which showed that 
epithelial cells treated in vitro with Adriamycin showed mesenchymal morphology, 
decreased expression of E-cadherin and up-regulation of Vimentin, suggesting that cells 
74 
 
under treatment are undergoing EMT (Li et al. 2009); therefore changing into mesenchymal 
cells, and could lead to the formation of MSCCs during treatment. 
3.3.3 Vimentin expression is induced at an early time point following olaparib 
treatment 
In comparison to an untreated cohort, a significantly higher percentage of Vimentin positive 
epithelial cells were seen in IDC-NSTs 1 hour after a single dose of 100mg/kg olaparib, 
suggesting that olaparib treatment induces its expression. Although there was no significant 
difference in positivity in IDC-NSTs 24 hours after a single dose, compared to 1 hour, there 
was a trend for a decrease, suggesting that Vimentin expression may reduce after an initial 
peak of expression. Another study analysing PARP-1 in endothelial cells showed that PARP 
inhibition in vitro resulted in a down-regulation of Vimentin (Isabel Rodriguez et al. 2013), 
suggesting that PARP inhibition has different effects in different cell types. 
Slug expression was not shown to differ in the various responses to olaparib, or at the early 
(1 hour and 24 hour) time points, suggesting that other EMT transcription factors are 
involved. IDC-NSTs treated with a single dose of olaparib and taken 1 hour later showed 
significantly higher percentage of Twist positive cells, but no significant difference in E-
cadherin. This suggests that Twist expression is also induced following olaparib treatment, 
and that changes in E-cadherin expression occurs at later time points. This work suggests for 
the first time that olaparib treatment in mammary tumours induces EMT at a very early 
time point. Other studies have shown treatment-induced EMT, for example cisplatin 
treatment in ovarian cancer cell lines (Ahmed et al. 2010; Latifi et al. 2011), suggesting that 
other cancer therapeutics also induce EMT. A study in breast epithelial cells showed that 
PARP-1 knockdown in vitro promoted EMT upon TGF-β stimulation, and suggested that 
PARP-1 regulates Smad-mediated transcription (Lonn et al. 2010), correlating with the 
increase in Vimentin seen upon olaparib treatment in the BlgCre-Brca2f/f/p53f/f mouse 
model. In contrast other in vitro studies suggest that PARP inhibition decreases the 
expression of EMT markers (McPhee et al. 2008; Rodriguez et al. 2011), meaning that, 
although the existing studies are conflicting, these studies suggest that PARP-1 has a role in 
regulating EMT, and therefore treatment with PARP inhibitors will also effect EMT. 
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3.4 Summary  
Mammary tumours arising from our BlgCre-Brca2f/f/p53f/f mouse model show similar 
proportions and immunohistochemical staining to human breast tumours. Response to daily 
olaparib therapy may be influenced by mesenchymal-characteristics, with MSCCs having an 
intrinsic resistance. Olaparib treatment may induce early stages of EMT. 
3.5 Further Work 
Further investigation into the different responses to olaparib therapy may shed some light 
as to why not all patients with BRCA-mutated breast cancers respond to olaparib therapy. It 
would be interesting to investigate whether Vimentin is part of the mechanisms that govern 
response. It would also be useful to further analyse the effect of olaparib treatment at the 
very early time points to understand the initial response.  
As this work suggests that MSCCs have an intrinsic resistance to olaparib it would be 
interesting to investigate the mechanism(s) that govern this. Discovering the mechanism(s) 
may give insight into how these tumours can be effectively treated or sensitised to therapy. 
This would have implications in the clinic as MSCCs have a poor prognosis. As metaplastic 
breast tumours and mesenchymal cells have been shown to be resistant to chemotherapies 
(Hennessy et al. 2006; Sayan et al. 2009) the next step in this project was to investigate 
whether olaparib-resistant tumours have MSCC/mesenchymal characteristics (chapter 4). 
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4. Investigating the mechanism of resistance to olaparib in 
BlgCre-Brca2f/f/p53f/f tumours 
 
4.1 Introduction 
Resistance is a recurring problem with targeted treatments in cancer, and is highly 
detrimental in the clinic, causing tumour relapse and rendering drugs ineffective, therefore 
emphasising the importance of discovering the mechanisms involved. Common mechanisms 
of resistance include increased expulsion of the drug from the cell, prevention of the drug 
entering the cell, modification of the drug target, increased cellular metabolism of the drug 
and compensation by changes in cellular signalling (reviewed in Gottesman 2002; Stewart 
2007). Although clinical trials have shown that olaparib can provide clinical benefit to some 
patients with BRCA-mutated breast cancer, resistance has been reported in preclinical 
mouse models (Rottenberg et al. 2008; Hay et al. 2009) and in two patients (Barber et al. 
2013). 
Currently there are three proposed mechanisms of resistance to olaparib that have been 
published. The first involves restoration of the HR pathway by secondary activating 
mutations in the BRCA2 gene, as reported in in vitro studies and also in two patients that 
became resistant to olaparib (Edwards et al. 2008; Barber et al. 2013). The second is the loss 
of 53BP1, as a study in Brca1-deficient tumours showed that a subset of tumours that 
became resistant to olaparib showed partial restoration of the HR pathway by loss of this 
protein (Jaspers et al. 2013). The third proposed mechanism of resistance is the 
upregulation of P-gps, which are transmembrane, energy-dependent pumps that efflux 
drugs out of the cell. Preclinical studies in both Brca1/p53 and Brca2/p53 conditional 
knockout mice showed upregulation of a number of P-gps in olaparib-resistant tumours 
compared to untreated tumours (Rottenberg et al. 2008; Hay et al. 2009), and inhibition of 
P-gps in the Brca1/p53 conditional knockout mouse model was shown to cause re-
sensitisation to olaparib (Rottenberg et al. 2008). The study in the Brca2/p53 mouse model 
showed that out of numerous multidrug resistance proteins, P-gps were the only ones found 
to be up-regulated in resistant tumours. 
77 
 
To further investigate the third proposed mechanism, studies have been performed where 
Brca1- and Brca2-deficient tumours were treated with a novel PARP inhibitor AZD2461, 
which has a lower affinity for P-gps compared to olaparib (Jaspers et al. 2013; Hay et al. 
unpublished; Oplustilova et al. unpublished). BlgCre-Brca2f/f/p53f/f tumour-bearing mice 
were initially treated with daily IP 100mg/kg olaparib, and when the tumours became 
resistant they were switched to 100mg/kg AZD2461 for five days per week by oral gavage. 
Results showed no effect on tumour relapse (Figure 4.1, Hay et al. unpublished data). To 
ensure that AZD2461 was effective as a first line therapy for these tumours, mice were 
treated with 100mg/kg AZD2461 by oral gavage five days per week and results showed that 
the tumours responded well, although long-term treatment again resulted in resistance on a 
similar timescale to that seen when mice were treated with daily IP 100mg/kg olaparib 
(Figure 4.1, Hay et al. unpublished data).  In comparison Brca1/p53 conditional knockout 
mice showed an increased survival with AZD2461 treatment compared to olaparib; 
however, resistance still occurred with long term therapy (Jaspers et al. 2013). 
To further investigate if the upregulation of P-gps is contributing to the resistance to 
olaparib in BlgCre-Brca2f/f/p53f/f tumours, the P-gp inhibitor Tariquidar was administered in 
combination with olaparib in mice with such tumours.  
To investigate whether olaparib-resistant tumours show differences in tumour type and 
immunohistochemical staining compared to untreated tumours, they were classified by 
histopathology using the same set of criteria outlined in chapter 3. 
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Figure 4.1 Brca2/p53-deficient tumours treated with AZD2461. (A) Mice were initially 
treated with daily 100mg/kg olaparib (red lines), then once tumours became resistant mice 
were switched to a follow-up therapy of oral 100mg/kg AZD2461, 5 days per week (black 
lines). (B) Mice were treated with 100mg/kg AZD2461 5 days per week (red lines) and 
compared to vehicle treatment (black lines). Experiment performed by Dr Trevor Hay. 
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4.2 Results 
4.2.1 Inhibition of P-gps has no effect on tumour relapse  
Previous studies involving mouse Brca2/p53 and Brca1/p53 breast cancer models 
hypothesised that upregulation of P-gps may at least partly contribute to olaparib resistance 
in such cancers (Rottenberg et al. 2008; Hay et al. 2009). Unpublished data from our 
laboratory showed that the novel PARP inhibitor AZD2461 had no effect on tumour relapse 
in BlgCre-Brca2f/f/p53f/f mice.  To further investigate the involvement of P-gps in resistance, 
the P-gp inhibitor Tariquidar was administered to mice with olaparib-resistant tumours. 
Tariquidar is a specific, non-competitive inhibitor of P-gps and studies in a Brca1/p53 
conditional knockout model have shown that olaparib-resistant tumours in these mice 
regained sensitivity to olaparib when combined with Tariquidar (Rottenberg et al. 2008). 
BlgCre-Brca2f/f/p53f/f mice were treated with 100mg/kg daily olaparib until the tumours 
became resistant, where they were then placed on a combination treatment of daily 
100mg/kg olaparib with 2mg/kg Tariquidar (given half hour before the olaparib) five days 
per week. Results show that the addition of Tariquidar had no effect on tumour relapse  in 
any of the tumours tested (Figure 4.2), adding further weight to the theory that up-
regulation of P-gps in this model is a consequence of treatment in a subset of tumours, but 
not a mechanism of resistance.  
4.2.2 Resistant tumours show a shift in histopathological phenotype 
Tumours from BlgCre-Brca2f/f/p53f/f mice that had become resistant to olaparib were 
classified by histopathology. These 51 tumours initially responded to daily IP 100mg/kg 
olaparib treatment but then relapsed until tumour burden made it necessary to cull the 
mice. Resistant tumours showed the presence of the same four tumour types as seen in the 
untreated cohort (Figure 4.3), but there was a dramatic change in their relative proportions 
(Figure 4.4; Chi squared test, p=0.05), with an increase in the proportion of MSCCs from 11% 
to 53%, and a reduction in the proportions of the other three tumour types compared to the 
untreated group. 
Although the same four tumour types were present in both cohorts, immunohistochemical 
analysis showed some differences in staining patterns (Figure 4.3, Figure 4.4 and Figure 4.5).  
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Figure 4.2 Analysis of tumours treated with Tariquidar. Mice were initially treated with 
daily 100mg/kg olaparib (red line) until tumours became resistant where they were switched 
to a combination follow-up therapy of 2mg/kg Tariquidar, administered 30 minutes before 
100mg/kg olaparib (black line).  
Resistant IDC-NSTs showed a significantly higher expression of Vimentin and CK14 and a 
significantly lower expression of CK18 compared to untreated IDC-NSTs (Mann-Whitney U 
test, p<0.01, p=0.039 and p=0.039, respectively). These tumours showed no significant 
differences in SMA or p63 staining. Resistant AMEs showed no significant difference in 
CK18, CK14, p63 or SMA staining but did show a significant increase in Vimentin positive 
cells compared to untreated AMEs (Mann-Whitney U test, p=0.041). Resistant MSCCs 
retained the same levels of Vimentin, SMA and p63 expression but similar to the MSCCs in 
the moderate responder cohort (see chapter 3), these tumours contained small regions with 
histopathological features similar to IDC-NSTs or AMEs. Compared to untreated MSCCs, 
resistant MSCCs showed a significantly higher expression of CK18 (Mann-Whitney U test, 
p=0.045) and a subset showed higher levels of CK14 staining, which may be due to the IDC-
NST and AME regions, but the spindle cells themselves also showed cytokeratin positivity.  
The one ASQC tumour showed similar staining patterns to the untreated ASQCs (Figure 4.3). 
Like untreated tumours, all tumours were shown to be ERα negative (Figure 4.3). 
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Figure 4.3 
Representative pictures 
of immunohistochemical 
stains in olaparib-
resistant tumours. 
Olaparib-resistant 
tumours were classified 
by histopathology. H&E 
stains were performed to 
analyse cell morphology, 
whilst CK18, CK14, p63 
and SMA were used to 
characterise different cell 
populations. Vimentin 
positivity marks 
mesenchymal cells and 
the ERα stain was 
performed to analyse ER 
receptor expression. 
Scale bars show 100µm. 
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Figure 4.4 Comparison of untreated and olaparib-resistant tumours. Histopathological classification showed untreated tumours (A) have a 
significant difference in proportions compared to olaparib-resistant tumours (B). Analysis of immunohistochemistry for CK18 (C) and CK14 (D), 
showing percentage of positive tumour cells, comparing untreated and resistant tumour types. *p≤0.05 
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 Figure 4.5 p63, Vimentin and SMA positivity in olaparib-resistant tumours. Analysis of p63 (A), SMA (B) and Vimentin (C) positivity in 
untreated and olaparib-resistant tumours. *p≤0.05 
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Tumours treated with AZD2461 monotherapy (n=15) and olaparib-resistant tumours which 
were followed up with either AZD2461 (n=25) or the Tariquidar/olaparib combination 
(n=27) were classified by histopathology to see if they were similar to olaparib-resistant 
tumours. Analysis of all three cohorts showed that the same tumour types were present in 
very similar proportions in all cohorts, with MSCCs predominating (Figure 4.6), and showed 
similar staining patterns to tumours that had become resistant to olaparib monotherapy.  
Proliferation in resistant tumours was analysed by Ki67 staining. Resistant IDC-NSTs (n=9) 
and AMEs (n=3) showed no significant difference in percentage of Ki67 positive cells 
compared to untreated tumours; however, resistant MSCCs (n=16) showed a significant 
increase in positivity (Mann-Whitney U test, p=0.009, Figure 4.7), resulting in no significant 
difference in Ki67 positivity between the different tumour types in the resistant cohort. 
4.2.3 Reduced olaparib concentration in resistant tumours does not correlate 
with high PAR levels. 
To investigate whether the mechanism of resistance to olaparib involves the reduction in 
concentration of the drug, olaparib levels were analysed in tumours from three cohorts: (1) 
1 hour after a single dose of 100mg/kg olaparib, (2) 24 hours after a single dose of 
100mg/kg olaparib, and (3) 1 hour after the final dose of 100mg/kg olaparib in resistant 
tumours (Figure 4.8). Olaparib levels in tumours from mice treated with a single dose of 
olaparib and taken 1 hour later ranged from 0.6-0.93 µM, while those from mice treated 
with a single dose and taken 24 hours later were substantially lower (<0.007 µM, Mann-
Whitney U test p=0.03), corroborating a previous study in our laboratory, which showed 
that olaparib is rapidly removed from tumours (Hay et al. 2009). The levels of inhibitor in 
resistant tumours 1 hour after their final dose were highly variable (0.01-0.63M) and were 
significantly lower than in tumours 1 hour after a single dose, but significantly higher than in 
the tumours taken 24 hours after a single dose (Mann-Whitney U test, p<0.01 and p<0.01 
respectively). Histopathology of the resistant tumours could not distinguish between 
tumours which contained a low olaparib concentration and those with a high concentration 
(Figure 4.8), suggesting that tumour type does not affect olaparib concentration in resistant 
tumours. 
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Figure 4.6 Histopathology of tumours treated with Tariquidar or AZD2461. 
Histopathological analysis of olaparib-resistant tumours treated with either Tariquidar (A), 
AZD2461 (B) or AZD2461-resistant tumours (C). 
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Figure 4.7 Ki67 positivity in olaparib-resistant tumours. (A) Representative pictures of Ki67 staining in resistant IDC-NSTs, AMEs and MSCCs.  
(B) Comparison of percentage of positive Ki67 cells in untreated and olaparib-resistant tumour types. *p≤0.05 
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PAR is a product of PARP activity and as such the amount of PAR within a tumour can be 
indicative of the level of PARP activity. PAR levels were analysed in the same set of tumours 
discussed above, as well as from tumours 1 hour and 24 hours after a single dose of vehicle 
for olaparib (Figure 4.8). Levels of PAR in tumours from mice treated with vehicle showed 
wide variability, ranging from 15.1-139.9pg/ml, with no significant difference between the 1 
hr and 24 hr cohorts (shown in Figure 4.8 as one cohort). Tumours from mice treated with a 
single dose of olaparib and taken 1 hour later showed a significantly reduced PAR level 
compared to the overall vehicle group (Mann-Whitney U test, p<0.01) and those from mice 
treated with a single dose of olaparib and taken 24 hours later showed a significant increase 
in PAR compared to those taken 1 hour later (Mann-Whitney U test, p=0.03), correlating 
with the olaparib concentration seen in these tumours. PAR levels in olaparib-resistant 
tumours taken one hour after their final dose were significantly lower compared to the 
vehicle group and in tumours 24 hours after a single dose (Mann-Whitney U test, p<0.001 
and p=0.025 respectively) and were similar to PAR levels in tumours 1 hour after a single 
dose. This suggests that PARP activity is still low in resistant tumours, despite the variable 
concentrations of olaparib found within these tumours. 
The variation in PAR levels in the vehicle cohort suggests variable endogenous level of PARP 
activity within untreated tumours. Histopathological analysis of the tumours revealed that 
those with the highest PAR levels were IDC-NSTs (n=5), whilst those with the lowest levels 
were either AMEs (n=2) or MSCC (n=1) (Figure 4.8), suggesting that tumour type may affect 
PARP activity levels. 
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Figure 4.8 Analysis of olaparib concentration and poly(ADP-ribose) (PAR) levels in 
olaparib-resistant tumours. (A) Olaparib concentration in tumours from mice treated with a 
single dose of 100mg/kg olaparib and taken 1 hour later (1 hour olaparib) and 24 hours later 
(24 hours olaparib) were compared to those in olaparib-resistant tumours (resistant). (B) 
PAR levels were analysed and compared in the same tumours and also compared to levels in 
tumours treated with a single dose of vehicle (vehicle). Circles represent IDC-NSTs, triangles 
ASQCs, squares AMEs and diamonds MSCCs. *p≤0.05. Analysis was performed by 
AstraZeneca. 
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4.2.4 A subset of resistant tumours have EMT characteristics. 
Resistant IDC-NST and AMEs show significantly higher expression of Vimentin compared to 
untreated tumours, suggesting that the cells are undergoing EMT. Analysis of EMT markers  
in resistant IDC-NSTs showed no significant differences in E-cadherin, Twist or Slug levels 
compared to untreated tumours, although a subset of these tumours did show reduced E-
cadherin expression (2/6) and increased Twist expression (3/6) (Figure 4.9 and Figure 4.10). 
Resistant AMEs showed similar levels of E-cadherin and Slug to untreated AMEs, with a 
significant increase in Twist levels (Mann-Whitney U test, p=0.041; Figure 4.9 and Figure 
4.10). Resistant MSCCs showed no significant difference in positivity for any of the EMT 
markers compared to untreated MSCCs, retaining the high expression of Twist and low 
expression of E-cadherin (Figure 4.9 and Figure 4.10). The one ASQC also showed similar 
expression of EMT markers compared to untreated tumours (Figure 4.9 and Figure 4.10). 
qRT-PCR analysis of Snail expression in resistant IDC-NSTs and MSCCs showed no significant 
difference to untreated tumours, although resistant MSCCs did show a trend for an increase 
in Snail expression compared to untreated MSCCs (Figure 4.10D). 
This suggests that even though some resistant IDC-NSTs and AMEs look morphologically 
similar to untreated tumours, they show increases in some EMT features, which are 
characteristically high in MSCCs. 
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Figure 4.9  
Representative pictures 
of EMT markers in 
resistant tumour types. 
Immunohistochemistries 
were performed for E-
cadherin, Twist and Slug 
to analyse EMT in the 
different tumour types 
within the resistant 
cohort. Scale bars show 
100µm. 
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Figure 4.10 EMT markers in olaparib-resistant tumours. Analysis of E-cadherin (A), Twist (B) and Slug (C) immunohistochemistries, showing 
the percentage of positive tumour cells, comparing untreated and resistant tumour types. (D) qRT-PCR analysis of Snail expression in untreated 
and resistant IDC-NSTs and MSCCs. *p≤0.05. 
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4.2.5 Resistant IDC-NSTs show genetic similarities to MSCCs  
A study from Dr Matthew Smalley’s group performed a microarray to compare gene 
expression between different histopathological tumour types from mouse models of breast 
cancer (unpublished data). This data is suggestive of the genes that are characteristic for the 
different histological tumour types. qRT-PCR analysis of the expression of six of these genes 
were carried out in untreated tumours from BlgCre-Brca2f/f/p53f/f mice and were compared 
to the expression levels in resistant tumours. As there were not enough AMEs and ASQCs to 
generate statistically significant data, these tumours were excluded from the analysis. 
Using the microarray data, three genes that were characteristic for IDC-NSTs were chosen; 
Sema3b, Foxa3 and Sox8 (Figure 4.11).  Results showed that untreated IDC-NSTs (n=4) 
showed a significant upregulation of all three genes compared to untreated MSCCs (n=4, 
Mann-Whitney U test; p=0.02, p=0.03 and p=0.03, respectively) which corresponds with the 
microarray data. Interestingly, resistant IDC-NSTs (n=4) showed a significant down-
regulation in all three genes compared to untreated IDCNSTs (Mann-Whitney U test, p=0.03, 
p=0.03 and p=0.03, respectively). No significant differences were seen between untreated 
MSCCs and resistant MSCCs (n=4). This suggests that there are differences in gene 
expression between untreated and resistant IDC-NSTs.  
Three genes that were shown to be characteristic for MSCCs were chosen from the 
microarray and analysed in the same samples as above (Figure 4.11). Corresponding with 
the microarray, the expression levels of Grem1, Pcolce2 and Hmga2 were shown to be 
significantly up-regulated in untreated MSCCs compared to untreated IDC-NSTs (Mann-
Whitney U test, p=0.03, p=0.03 and p=0.03, respectively). No significant differences were 
seen between untreated MSCCs and resistant MSCCs. Resistant IDC-NSTs showed no 
significant difference in expression of Pcolce2 compared to untreated tumours but they did 
show a significant upregulation of Grem1 (Mann-Whitney U test, p=0.03) and a trend for 
higher expression of Hmga2, suggesting that resistant IDC-NSTs contain some genetic 
similarities to MSCCs.  
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Figure 4.11 Comparison of IDC-NST and MSCC characteristic gene expression in untreated 
and resistant tumours. qRT-PCR analysis of IDC-NST characteristic genes Sema3b, Foxa3 and 
Sox8 (A) and MSCC characteristic genes Grem1, Pcolce2 and Hmga2 (B), comparing 
untreated and resistant  IDC-NSTs and MSCCs. *p≤0.05 
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4.2.6 Responding and resistant tumours show a mesenchymal signature 
Results in this project suggest that an EMT-like process correlates with resistance to PARP 
inhibitors; however, it is unclear whether this EMT-like program is limited to a small number 
of markers coupled with morphological changes or whether broad changes are occurring in 
the transcriptional programmes of tumour cells. mRNA expression levels were compared 
from tumours that were either responding well to olaparib (n=7) or had become resistant to 
treatment (n=20). All mice had been treated with daily 100mg/kg olaparib and culled one 
hour after their final dose. Histopathological analysis showed that the responding cohort 
consisted of 6 IDC-NSTs and 1 ASQC, whereas the resistant cohort was made up of 12 
MSCCs, 6 IDC-NSTs and 2 AMEs, with both cohorts showed similar staining patterns as other 
excellent responders and resistant tumours, as described previously. 
Expression of genes were individually compared in the responding and resistant cohorts for 
differential expression, and network analysis showed that the main networks of genes were 
involved in development and function of the haematological system, control of the cell 
cycle, DNA replication, recombination and repair and inflammatory response (Appendix I); 
however, as of yet, I have not had the opportunity to follow-up these results. 
Analysis of Brca2 and p53 expression showed low expression in resistant and responding 
tumours (Figure 4.12A), with no significant difference in p53 expression between the two 
cohorts. Resistant tumours did show a significant increase in Brca2 expression compared to 
responding tumours (Mann-Whitney U test, p=0.004), although the expression was still low. 
A similar pattern was also seen in Brca1 expression between the two cohorts (Mann-
Whitney U test, p<0.001; Figure 4.12A). Expression levels of 53BP1 were also analysed, and 
there was found to be no difference in expression between the two cohorts (Figure 4.12A), 
suggesting that loss of this protein in not a mechanism of resistance to olaparib in Brca2-
deficient mammary tumours, as has been shown in previously in a model of olaparib-
resistant Brca1/p53-deficient breast cancer (Jaspers et al, 2013). 
Principle component analysis of this expression data showed that the olaparib-resistant 
tumours cluster separately from the responding tumours, but also that those classified as 
resistant MSCCs clustered separately from the other resistant tumour types (Figure 4.12B), 
so we then compared gene expression between the different histopathological tumour 
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types. Compared to the resistant IDC-NSTs, resistant MSCCs showed up-regulation of the 
genes that encode Vimentin, Zeb1, and Zeb2 (Mann-Whitney U test p<0.001, p<0.001, 
p<0.001 respectively) and down-regulation of those that encode E-cadherin, CK18, Claudin 
3, Claudin 4 and Claudin 7 (Figure 4.13; Mann-Whitney U test p=0.002, p<0.001, p<0.001, 
p<0.001 respectively), corresponding with previous data that these tumours have a similar 
expression profile to claudin-low tumours.  
The responding and resistant IDC-NSTs also clustered separately in the principle component 
analysis, suggesting that even though they have the same morphology, differences in gene 
expression exist between the two cohorts. Compared to responding IDC-NSTs, resistant IDC-
NSTs showed up-regulation of the genes that encode Twist, Brca1, CD44 and -catenin 
(Figure 4.14; Mann-Whitney U test, p=0.008, p=0.005, p-0.013 and p=0.005 respectively). 
Interestingly both responding and resistant IDC-NSTs showed a mesenchymal gene 
signature (Figure 4.15), which correlates with previous data in this project which suggests 
that resistant IDC-NSTs have mesenchymal characteristics. In responding IDC-NSTs this 
mesenchymal signature may be due to the high proportion of stroma seen in these tumours, 
rather than in the epithelial cells themselves; however immunohistochemical analysis has 
shown a significant upregulation of Vimentin and Twist in epithelial cells compared to 
untreated IDC-NSTs (chapter 3).  
4.2.7 Resistant tumours show a reduction in mammosphere forming units 
Studies have shown that Claudin-low tumours have enrichment for cells with stem cell 
characteristics (Creighton et al. 2009; Hennessy et al. 2009). To investigate if olaparib-
resistant tumours show a similar enrichment we compared the mammosphere-forming 
ability of these tumours (n=8) to that of untreated tumours (n=9) (Figure 4.16).  
The percentage of mammosphere forming units (MFUs) was calculated by dividing the 
number of mammospheres formed by the number of cells seeded. In the untreated cohort 
there was a degree of variability, with MFUs ranging between 0.3-3.6% (Figure 4.16).  
Histopathological analysis of these tumours revealed that the majority (7/9) were IDC-NSTs 
with just 2 MSCCs, which accounted for two of the three lowest values of %MFUs (Figure 
4.16). Resistant tumours showed a significant decrease in the %MFUs, ranging from 0.04-
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Figure 4.12 Comparison of RNA expression levels in responding and resistant tumours. (A) RNA seq analysis compared the expression of 
Brca2, Brca1, p53 and 53BP1 in responding and resistant tumours. R.P.K.M=reads per kilobase of transcript per million mapped reads. Values 
for R.P.K.M – 0-0.5 represents very low expression, 0.5-8 represents low expression, 8-16 represents medium expression, 16-128 represents high 
expression, and above 128 represents very high expression. *p≤0.05. (B) Principle component analysis comparing responding (blue) and 
resistant (red) tumour types. Circles represent IDC-NSTs, triangles ASQCs, squares AMEs and diamonds MSCCs.  Analysis was performed by 
AstraZeneca.  
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Figure 4.13 Comparison of RNA expression levels in 
resistant IDC-NSTs and resistant MSCCs. RNA  
sequencing compared levels of Vimentin, CK18 (A), 
Zeb1, Zeb2, E-cadherin (B), and Claudins 3,4, and 7 (C) 
in resistant IDC-NSTs and MSCCs. *p≤0.05. 
RPKM=reads per kilobase of transcript per million 
mapped reads. Values for R.P.K.M – 0-0.5 represents 
very low expression, 0.5-8 represents low expression, 
8-16 represents medium expression, 16-128 
represents high expression, and above 128 represents 
very high expression. Analysis was performed by 
AstraZeneca. 
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Figure 4.14 Comparison of RNA expression levels in responding and resistant IDC-NSTs. RNA  sequencing compared levels of Twist, Brca1, 
CD44, β-catenin and CK18 in responding and resistant IDC-NSTs. *p≤0.05. RPKM=reads per kilobase of transcript per million mapped reads. 
Values for R.P.K.M – 0-0.5 represents very low expression, 0.5-8 represents low expression, 8-16 represents medium expression, 16-128 
represents high expression, and above 128 represents very high expression. Analysis was performed by AstraZeneca. 
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Figure 4.15 Analysing EMT signature of responding and resistant tumours. RNA expression profiles were compared to an in-house EMT 
signature, where positive values are associated with an epithelial profile and negative values are associated with a mesenchymal profile. Circles 
represent IDC-NSTs, triangles ASQCs, squares AMEs and diamonds MSCCs.  Analysis was performed by AstraZeneca. 
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Figure 4.16 Mammosphere forming units in untreated and resistant tumours. (A) 
Comparison of %MFUs in untreated and resistant tumours. Circles represent IDC-NSTs, 
triangles ASQCs, squares AMEs and diamonds MSCCs. *p≤0.05 (B) Representative pictures of 
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mammospheres from untreated and resistant IDC-NSTs and MSCCs. Scale bar represents 
200µm. 
0.6% (Mann-Whitney U test, p<0.01). Resistant tumours were characterised as 5 MSCCs, 2 
IDC-NSTs and 1 AME, with all tumour types showing similar %MFUs. This suggests that 
olaparib-resistant tumours have a lower number of mammosphere-producing cells than 
untreated tumours. Mammospheres were fixed and embedded in paraffin wax to allow for 
H&E and immunohistochemical staining. Immunohistochemistry on mammospheres from 
the untreated cohort revealed that they had similar staining patterns to the tumour type 
they originated from (Figure 4.17), with those from IDC-NSTs showing high CK18 and E-
cadherin levels and low CK14 and p63 levels. Those from MSCCs showing high Vimentin 
levels and low levels of CK18, CK14, p63 and E-cadherin. However, mammospheres from 
IDC-NSTs did show an higher levels of Vimentin staining, with variable staining between 
different samples (ranging from 1-60% of positive cells, Figure 4.17), compared to untreated 
tumours (<1%). Mammospheres from the resistant cohort also showed similarities in 
staining to the corresponding tumour type, with those from MSCCs showing high Vimentin 
and variable expression of CK18, CK14 and p63, those from IDC-NSTs showing high CK18 and 
E-cadherin levels and low levels of CK14 and p63, and those from the AME showing high 
Vimentin and E-cadherin positivity (Figure 4.18). In contrast to the corresponding tumour 
type, mammospheres from resistant MSCCs showed higher E-cadherin levels, those from 
resistant IDC-NSTs showed low Vimentin expression and those from the AME showed low 
levels of CK18, CK14 and p63 (Figure 4.18). This data suggests that mammospheres formed 
from different tumour types retain some of their characteristic staining patterns, but that 
they may not be truly reflective of the tumour types from which they originated. 
4.2.8 Carboplatin-resistant tumours show similarities to olaparib-resistant 
tumours 
Other studies have shown that the acquisition of EMT features is associated with 
therapeutic resistance (Li et al. 2008; Creighton et al. 2009), suggesting that the results seen 
in olaparib-resistant tumours may also occur in those resistant to other drugs. To investigate 
this, tumours from BlgCre-Brca2f/f/p53f/f mice that were treated with IP 50mg/kg 
Carboplatin once every four weeks until tumours relapsed (n=15, performed by Dr Trevor 
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Figure 4.17 Representative pictures of mammospheres 
from untreated tumours. Fixed mammospheres from 
untreated tumours were stained for H&E, CK18, CK14, 
p63, Vimentin and E-cadherin. Scale bars show 50µm. 
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Figure 4.18 Representative pictures of mammospheres 
from olaparib-resistant tumours. Fixed mammospheres 
from resistant tumours were stained for H&E, CK18, 
CK14, p63, Vimentin and E-cadherin. Scale bars show 
50µm. 
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Hay), were analysed histopathologically and for the expression of EMT markers Vimentin 
and Twist. 
The majority (67%) of carboplatin-resistant tumours were found to be IDC-NSTs, with MSCCs 
accounting for 26% and AMEs 7%, resulting in a significant difference in proportions 
compared to untreated tumours (Chi Squared, p=0.05; Figure 4.20), with a higher 
proportion of IDC-NSTs and MSCCs and a lower proportion of AMEs. These proportions are 
also significantly different to those seen in olaparib-resistant tumours (Chi Squared, p=0.05; 
Figure 4.20), which have a higher proportion of MSCCs and a lower proportion of IDC-NSTs. 
This suggests that although there is an increase in MSCCs in carboplatin-resistant tumours 
there are differences between the two therapies.  
Compared to untreated IDC-NSTs, those in the carboplatin-resistant cohort showed a 
significant reduction in CK18 staining and an increase in Vimentin and Twist staining (Mann-
Whitney U test, p=0.02, p<0.01 and p=0.026 respectively), whilst they maintained variable 
expression of CK14 (1-65%) and low expression of p63 (<1%, Figure 4.19, Figure 4.20, Figure 
4.21). These are similar staining patterns to olaparib-resistant IDC-NSTs (Figure 4.22), which 
also show a decrease in CK18 staining and an increase in Vimentin staining, with a subset 
showing an increase in Twist staining, compared to untreated tumours.  
The one AME in this cohort showed a similar staining pattern to untreated AMEs, with a 
high level of CK14 (75%) and p63 (65%), a low level of Vimentin (1%) and Twist (<1%), and 
15% positivity for CK18 (Figure 4.19, Figure 4.20, and Figure 4.21). The expression patterns 
differ to those seen in olaparib-resistant AMEs (Figure 4.22), as these show higher levels of 
positivity for Vimentin (40-50%) and Twist (5-40%). 
The MSCCs in this cohort showed variable CK18 staining, with 2 tumours showing an 
increase compared to untreated MSCCs, while retaining low expression of CK14 and p63 
(<1%, Figure 4.19 Figure 4.20 and Figure 4.21). The majority showed high Vimentin (65-80%) 
and Twist staining (40-70%), similar to the levels seen in untreated MSCCs (Figure 4.19 and 
Figure 4.21), although one tumour showed a low level of Twist (10%). MSCCs in this cohort 
showed similar CK18, p63, Vimentin and Twist staining, and a trend for a decrease in CK14 
staining compared to olaparib-resistant MSCCs (Figure 4.22). 
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Figure 4.19 Representative pictures of 
immunohistochemical stains in 
Carboplatin-resistant tumours. 
Carboplatin-resistant were classified by 
histopathology, with H&E staining used 
to analyse cell morphology. The 
different tumour types were analysed 
for Ck18, Ck14, p63, Vimentin and Twist 
positivity. Scale bars show 100µm. 
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Figure 4.20 Proportions of Carboplatin-resistant tumours compared to untreated and olaparib-resistant cohorts. Carboplatin- resistant 
tumours were classified by histopathology (C) and the proportions were compared to those from untreated (A) and olaparib-resistant cohorts 
(B). Carboplatin-resistant tumours were analysed for CK18 (D) and CK14 (E) positivity, and compared to untreated tumours. *p≤0.05 
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Figure 4.22 Comparison between Olaparib- and Carboplatin-resistant tumours. Levels of CK18 (A), CK14 (B), p63 (C), Vimentin (D) and Twist 
(E) positivity in carboplatin-resistant tumours (carboplatin) were compared to those seen in olaparib-resistant tumours (olaparib). *p≤0.05 
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These results suggest, as with olaparib-resistant tumours, that the majority of carboplatin-
resistant tumours show mesenchymal features, either by the presence of morphologically-
recognisable spindle cells or by changes in various protein levels. 
4.3 Discussion 
4.3.1 Tumours from BlgCre-Brca2f/f/p53f/f mice are showing a novel mechanism 
of olaparib resistance 
Results from the work described in this chapter suggest that the three currently proposed 
mechanisms of resistance to PARP inhibitors in HR-deficient cancers do not account for the 
resistance to olaparib seen in our BlgCre-Brca2f/f/p53f/f breast cancer model.  
The first of these involves up-regulation of P-gps, which are members of the multi-drug 
resistance protein (MDR) family and are transmembrane protein pumps that actively efflux 
drugs. It is well established that over-expression of MDRs are involved in resistance to a 
number of drugs (reviewed in Gottesman 2002), for example a study in a mouse model of 
BRCA1-mutated breast cancer showed that resistance to doxorubicin was due to 
upregulation of P-gps (Pajic et al. 2009). Previous studies in Brca2- and Brca1-deficient 
mammary tumours that became resistant to olaparib in a subset of tumours was associated 
with a significant up-regulation of P-gps compared to untreated tumours, suggesting that 
this may be a mechanism of olaparib resistance (Rottenberg et al. 2008; Hay et al. 2009). 
Here, it has been shown that the addition of the P-gp inhibitor Tariquidar to mice with 
olaparib-resistant tumours had no effect on tumour relapse, correlating with unpublished 
data from our group, in which resistant tumours were treated with the novel PARP inhibitor 
AZD2461, which has a lower affinity for P-gps, and also showed no effect on tumour relapse 
(Hay et al. unpublished). These two pieces of experimental data suggest that the previously 
reported up-regulation of P-gps is simply a characteristic of resistant tumours, rather than a 
mechanism of resistance. This differs from studies in a mouse model of Brca1/p53 mutant 
breast cancer, where sensitivity to olaparib was at least partially restored upon inhibition of 
P-gps with Tariquidar or by treatment with AZD2461 (Rottenberg et al. 2008; Jaspers et al. 
2013). however tumours from a similar mouse model, which contained additional P-gp null 
alleles, were treated with olaparib and eventually developed relapsed, showing that 
olaparib resistance can develop in the absence of P-pgs (Jaspers et al. 2013).  
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These results suggest that there may be differences in the mechanisms of resistance to 
PARP inhibition between the Brca1- and Brca2-deficient mouse models and clearly there are 
important clinical implications if such differences were replicated in BRCA1- and BRCA2-
mutated human breast cancers.  
Analysis of olaparib concentration in olaparib-resistant tumours show a significant reduction 
1 hour after the final treatment compared to tumours 1 hour after a single dose, suggesting 
that the up-regulation of P-gps may be having an effect on olaparib levels. However, in 
these same tumours PARP activity is still suppressed, which would explain why inhibition of 
the P-gps in these tumours had no effect on tumour relapse. In this study results showed 
that tumours treated with a single dose of vehicle showed variable levels of PARP activity, 
and that the variability correlated with tumour type. Other studies have shown that PARP 
expression is heterogeneous in human breast tumours and that certain molecular subtypes 
show increased levels compared to others (Goncalves et al. 2011; Prat and Perou 2011). This 
suggests that different tumour types have different endogenous levels of PAR, which may 
contribute to the differences in response to olaparib therapy (chapter 3), and therefore has 
clinical implications. 
The second proposed mechanism of resistance involves the protein 53BP1. In a subset of 
olaparib-resistant tumours from a Brca1-deficient mouse model it was shown that loss of 
53BP1 leads to restoration of the HR pathway (Jaspers et al. 2013). RNA expression data 
from tumours from the BlgCre-Brca2f/f/p53f/f model showed no significant difference in 
53BP1 levels between responding and resistant tumours. Taken together with the fact that 
53BP1 is known to interact with BRCA1 but not BRCA2 (Bouwman et al. 2010), it therefore 
seems unlikely that modulation of 53BP1 levels is a mechanism of resistance in BRCA2-
mutated breast cancer.  
The third established mechanism of resistance involves secondary activating mutations in 
the BRCA2 gene.  Preclinical and clinical studies have shown that olaparib-resistant tumours 
contain such mutations, resulting in the re-activation of the protein and restoration of the 
HR pathway (Edwards et al. 2008; Barber et al. 2013). Similar results have been seen in 
tumours that become resistant to carboplatin and cisplatin (Edwards et al. 2008; Sakai et al. 
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2008). Analysis of Brca2 mRNA levels in BlgCre-Brca2f/f/p53f/f mice showed a significant 
increase in resistant tumours compared to responding tumours, although expression was 
still low, and Brca1 mRNA levels were also shown to be significantly increased in resistant 
tumours. This suggests that resistant tumours may be trying to up-regulate genes involved 
in the HR pathway to overcome the synthetic lethality; however, given the large deletion of 
the Brca2 coding sequence upon Blg-Cre activated recombination, we hypothesis that the 
HR pathway is inactive in these tumours, suggesting that the differences in Brca levels do 
not have a role in olaparib resistance. 
It therefore seems clear that resistance to olaparib in our model falls out with the current 
proposed pre-clinical and clinical mechanisms and that there must be other novel 
mechanisms which account for the tumour relapse seen in our tumours.  
4.3.2 Olaparib-resistant tumours have mesenchymal features 
Following extensive histopathological and immunohistochemical analysis described in this 
chapter, olaparib-resistant tumours in our model were shown to be predominantly MSCCs, 
which make up a much smaller proportion of untreated tumours. Results from chapter 3 
suggest that these tumours are similar to claudin-low tumours, and mRNA analysis in this 
chapter supports this suggestion, by showing up-regulation of Vim, Zeb1, and Zeb2, and 
down-regulation of Cdh1, CK18 and the genes that encode Claudins 3, 4 and 7. RNA analysis 
also showed that MSCCs arising in this BlgCre-Brca2f/f/p53f/f mouse model have similar 
expression to MSCCs from other mouse models by showing a significant up-regulation of 
Grem1, Pcolce2 and Hmga2 and a down-regulation of the IDC-NST associated genes 
Sema3b, Foxa3 and Sox8 (Smalley et al. unpublished) compared to untreated IDC-NSTs. The 
Grem1 and Hmga2 proteins are hypothesised to play a role in EMT (Carvajal et al. 2008; 
Thuault et al. 2008), and Pcolce2 is involved in the cleavage of pro-collagen (Steiglitz et al. 
2002), possibly explaining why these genes are specific to this mesenchymal-like tumour 
type. Currently there are no studies explaining the link between the three IDC-NST 
associated genes and breast cancer, although Foxa3’s family member Foxa1 has been shown 
to be a luminal lineage-specific gene (Yamaguchi et al. 2008), corresponding with the 
luminal genetic profile of these tumours. 
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The high proportion of MSCCs in the resistant cohort correlates with other studies that 
suggest that metaplastic carcinomas are associated with treatment resistance (Al Sayed et 
al. 2006; Hennessy et al. 2009). Olaparib-resistant tumours treated with either AZD2461 or 
Tariquidar and AZD2461-resistant tumours showed similar proportions to olaparib-resistant 
tumours, adding weight to the suggestion that olaparib resistance in a BRCA2 setting may 
occur following spindle cell metaplasia to generate spindle cell carcinomas which are 
refractory to PARP inhibitor therapy. It is not really surprising that the tumours which were 
given the follow-up therapies are so similar, as initial treatment regimes were identical and 
the follow-up had no effect in either case, but it is interesting to note that treatment with 
the alternative PARP inhibitor had the same effect as treatment with olaparib.  Currently 
there are no extensive studies that show that olaparib-resistant Brca1-deficient mammary 
tumours show an increase in MSCCs; however, one such AZD2461-resistant tumour was 
shown to have an EMT phenotype (Jaspers et al. 2013), suggesting that EMT may be 
associated with resistance to PARP inhibitors in both Brca1- and Brca2-deficient tumours.  
Resistant tumours characterised as IDC-NSTs show an EMT gene signature, including 
increased expression of EMT markers/associated genes Vimentin, Twist and Grem1, and a 
decreased expression of IDC-NST/luminal genes CK18, Sema3b, Fox3a and Sox8, compared 
to untreated IDC-NSTs. This suggests that even though olaparib-resistant tumours show 
different morphologies they all show EMT characteristics, which correlates with other 
studies where the acquisition of EMT features has been associated with therapeutic 
resistance (Creighton et al. 2009; Liu et al. 2013). RNA analysis also showed that resistant 
IDC-NSTs have a significant increase in the β-catenin and CD44 mRNA expression compared 
to responding IDC-NSTs, suggesting that these tumours have an increase in Wnt signalling.  
Wnt signalling has been shown to induce EMT, through the regulation of Snail (Yook et al. 
2005), suggesting a role for this pathway in olaparib resistance. CD44, as well as being a Wnt 
target gene, is also a cancer stem cell marker in human mammary tumours. Stem-like cells 
from breast cancer cells can be sorted from mixed populations in humans by the 
CD44+/CD24-/low markers (Al-Hajj et al. 2003), suggesting that resistant IDC-NSTs may 
contain more cells with stem-cell characteristics, however, the mammosphere experiment 
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in this chapter showed a decrease in MFUs compared to untreated tumours, so the 
increased expression of CD44 may be due to Wnt signalling.  
Resistant MSCCs show very similar immunohistochemical staining patterns and gene 
expression to untreated MSCCs; however, they do show a significant increase in CK18 
positive cells and a significant increase in proliferating cells, resulting in a proliferation rate 
that is similar to the other tumour types, suggesting that they have some luminal 
characteristics. Some of them also contain epithelial sections which show characteristic 
staining patterns of IDC-NSTs or AMEs, which is similar to what is seen in moderately-
responding MSCCs on daily olaparib therapy at 30 days into treatment. The presence of 
epithelial sections and spindle cells that are CK18-positive in MSCCs, and epithelial tumour 
types with EMT features, suggest that resistant tumours result from olaparib therapy either 
by cellular conversion or clonal expansion (Figure 4.23). The former would suggest that 
epithelial cells acquire mesenchymal characteristics (through EMT) during olaparib therapy, 
resulting in resistance to the drug. This could be linked to cancer stem cells as studies have 
shown that the induction of EMT in mammary epithelial cells in vitro results in the 
expression of stem cell markers (Mani et al. 2008) and that non-cancer stem cells can 
convert to cancer stem cells by the induction of ZEB1 expression (Chaffer et al. 2013). Other 
studies have shown treatment-induced EMT, with cisplatin treatment in ovarian cancer cell 
lines (Ahmed et al. 2010; Latifi et al. 2011), cyclosporine A treatment in renal proximal 
tubular epithelial cells (McMorrow et al. 2005), and Adriamycin treatment in a breast cancer 
cell line (Li et al. 2009), suggesting that EMT conversion may occur in response to a variety 
of different drugs. The clonal expansion theory would suggest that cells which are 
intrinsically resistant to olaparib, possibly those with EMT features and/or stem cell-like 
properties, would remain during treatment, with their outgrowth resulting in tumour 
relapse. A study by Li and colleagues suggests that cancer stem cells are resistant to 
conventional cancer therapies, as they showed in patients that have undergone 12 weeks of 
chemotherapy, that there is an increase in the percentage of cells with stem cell markers 
and stem cell-like properties (Li et al. 2008), so these cells may also be resistant to other  
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Figure 4.23 Clonal expansion and cellular conversion theory of olaparib resistance. (A) In mammary tumours both epithelial and spindle cells 
exist, and are able to interconvert through EMT and MET. During olaparib therapy epithelial cells are placed under selective pressure, resulting 
in (B) the conversion to mesenchymal-like cells or (C) to stem-like cells, which both have EMT features. (D) Another possibility is that the 
epithelial cells are depleted, whilst the mesenchymal-like cells survive, resulting in clonal expansion and tumour relapse.  
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cancer treatments such as olaparib. This theory would also correlate with other studies that 
show that cells with EMT features are resistant to treatment, for example studies by 
Arumugam et al. and Tryndak et al., showed that pancreatic cancer cell lines with high Zeb-1 
and low E-cadherin expression were resistant to gemcitabine and cisplatin (Arumugam et al. 
2009), and that ZEB-1 disruption in breast cancer cell lines increased sensitivity to 
doxorubicin (Tryndyak et al. 2010). 
4.3.3 EMT phenotype did not correlate with an increase in mammosphere 
forming units 
Previous studies have shown that Claudin-low tumours show an increase in stem-cell 
markers in comparison to other tumour types, suggesting that they may be enriched for 
cancer stem cells (Creighton et al. 2009; Hennessy et al. 2009). The mammosphere assay is 
an in vitro technique that is used to measure stem cell/progenitor cell frequency in a mixed 
population (Ponti et al. 2005; Liao et al. 2007). Single cells are cultured in suspension and 
stem cells survive, developing into 3D, non-adherent, multicellular structures.  
As MSCCs have a similar gene expression profile to Claudin-low tumours, and given that an 
EMT signature is associated with cancer stem cells (Mani et al. 2008; Creighton et al. 2009; 
Prat et al. 2010), this suggested that olaparib-resistant tumours may have an increase in 
MFUs compared to untreated tumours. In contrast to this theory, results showed that 
resistant tumours show a significant decrease in MFUs, suggesting that they contain fewer 
cells with stem-cell properties. Another explanation could be the difference in proliferative 
activity of the stem cells. Results from a study by Liu et al. suggested that breast cancer 
stem cells that were characterised as mesenchymal-like were quiescent, whilst those that 
were epithelial-like were proliferative (Liu et al. 2014), suggesting that the higher number of 
MFUs in the untreated IDC-NSTs could be due to an epithelial phenotype, whereas the 
reduction of MFUs in resistant tumours could be due to mesenchymal characteristics. 
Further studies need to be performed to analyse the self-renewal capacity of the 
mammospheres formed from these tumours, which can be assessed by serial passage. 
As there was no clear difference in MFUs between the different tumour types in the 
resistant cohort, this is further evidence that olaparib-resistant tumours exhibit 
characteristics that are independent of morphology.  
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4.3.4 Carboplatin-resistant tumours also show mesenchymal characteristics 
Correlating with other studies that show that metaplastic tumours and tumours with EMT 
features are associated with treatment resistance (Al Sayed et al. 2006; Li et al. 2008; 
Creighton et al. 2009; Hennessy et al. 2009), carboplatin-resistant tumours from BlgCre-
Brca2f/f/p53f/f mice show an increase in proportion of MSCCs, as well as IDC-NSTs with 
significantly higher levels of Vimentin and Twist staining, suggestive of EMT. These staining 
patterns are similar to those seen in olaparib-resistant tumours, suggesting that 
mesenchymal-like tumours may be involved in resistance to multiple drugs, and therefore 
may have broader clinical implications. In support of this another study also showed an 
association between EMT and carboplatin resistance, by finding that biopsies from resistant 
epithelial ovarian tumours had an EMT phenotype (Marchini et al. 2013).  
4.4 Summary 
In conclusion these results suggest that resistance to olaparib in a BlgCre-Brca2f/f/p53f/f 
mouse model is not caused by any of the currently proposed mechanisms for PARP inhibitor 
resistance, but instead it may be due to a dramatic shift in phenotype to mesenchymal-like 
tumours.  
4.5 Further work 
4.5.1 Investigate HR re-activation 
Two of the proposed mechanisms of resistance to olaparib involve re-activation of the HR 
pathway. To investigate if the increased levels of Brca2 and Brca1 in resistant tumours has 
an effect on the HR pathway it would be interesting to analyse the HR pathway in these 
tumours. This could be performed by analysing Rad51 foci formation and γH2AX levels in 
resistant tumours. 
4.5.2 Confirmation of Tariquidar inhibition 
To ensure that the administration of Tariquidar has no effect on tumour relapse 
experiments need to be performed to confirm that the drug is inhibiting P-gps in the 
tumours from this mouse model. A previous experiment, using drug resistant cell lines, 
confirmed the action of Tariquidar by measuring the efflux of a fluorescent substrate (Mistry 
et al. 2001). A similar experiment could be performed using 2D cultured primary cells from 
tumour from BlgCre-Brca2f/f/p53f/f mice. 
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4.5.3 Analyse PARP-1 levels in tumours 
Results show that resistant tumours have low PAR levels, suggesting that PARP-1 is still 
inhibited in these tumours. Another theory could be that resistant tumours have reduced 
PARP-1 expression. A study showed that in vitro PARP-1-deficient cells are resistant to 
olaparib (Pettitt et al. 2013) so it would be interesting to analyse PARP-1 levels in resistant 
tumours and compare them to levels in untreated tumours.  
The variation in PAR levels in the vehicle cohort suggests that PARP-1 activity varies 
between different tumour types, and could explain the different responses of Brca2-
deficient tumours to olaparib therapy. It would therefore be interesting to also analyse 
PARP-1 levels in the different tumour types. 
4.5.4 Change in tumour type due to conversion or clonal expansion 
Olaparib-resistant tumours show an increase in MSCCs; however it is not yet clear whether 
this occurs by cellular conversion or clonal expansion. This could be investigated by 
producing specific fluorescent reporters for spindle cells and epithelial cells (using data from 
Dr Matthew Smalley’s microarray) and transfecting primary cells in vitro where changes in 
morphology and reporter expression could be analysed by time-lapse microscopy, after the 
addition of olaparib. These fluorescent reporters could also be utilised in vivo to create a 
mouse model to be used for intravital imaging (Kedrin et al. 2008), which would enable real-
time visualisation of the effect of olaparib treatment. 
4.5.5 Target mesenchymal tumours 
This work suggests that EMT/mesenchymal features may be involved in resistance to 
olaparib. It would be interesting to treat olaparib-resistant tumours with an anti-spindle cell 
or anti-mesenchymal cell therapy and analyse the effect on tumour relapse. It will also be 
important to identify which of these features is important for resistance in order to target 
the resistance. The effect of the loss of E-cadherin in Brca2-deficient tumours and olaparib 
treatment is investigated in chapter 5. 
4.5.6 Investigate the roles of fibroblasts in resistance 
This study has concentrated on analysing the epithelial cells within the mammary tumours. 
Other studies are now showing the importance of the interactions between the epithelial 
cells and the tumour-associated stroma in tumourigenesis. Cancer-associated fibroblasts 
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can be analysed by the expression of SMA, and release TGF-β, which activates TGF-β 
signalling in adjacent epithelial cells, suggesting that these cells could be contributing to the 
EMT phenotype seen in the resistant tumours, therefore it would be interesting to see if 
there is a difference in these cells in untreated and resistant tumour types. 
4.5.7 Investigate other mechanisms of resistance 
There are also other common mechanisms of drug resistance that could be investigated. 
Other pathways of DNA repair could be involved in olaparib resistance, for example the 
NHEJ pathway. These could be investigated by analysing the expression of the genes 
involved in the pathways, or analysing the repair of DSBs. A decrease in vascularisation 
within the tumours, resulting in hypoxia, can lead to a decrease in drug concentration. 
Vascularisation of olaparib-tumours could be analysed by staining for endothelial markers 
(e.g. CD31), and compared to untreated tumours. These other mechanisms could also be 
investigated by further analysis of the RNA sequencing study, which compared responding 
and resistant tumours, which could be complimented by exome sequencing and proteomic 
analysis.  
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5. Investigating the effect of E-cadherin loss in Brca2/p53-
deficient tumours 
 
5.1 Introduction 
The maintenance of epithelial layers is accomplished by cell-cell and cell-matrix contacts. 
Adheren junctions, tight junctions and desmosomes are the three major types of contacts 
that mediate cellular layer integrity. In the mammary gland, cell-cell contacts give stability 
to the ductal structure and maintain cellular polarity of the luminal cells. Adheren junctions 
are mediated by E-cadherin, a single-pass, transmembrane glycoprotein (reviewed in 
Harstock and Nelson 2008). E-cadherin forms Ca2+-dependent homo-dimers with E-cadherin 
molecules on neighbouring cells in the intercellular space. The cytoplasmic domain of E-
cadherin binds to β-catenin and p120-catenin, which links to the actin cytoskeleton through 
interaction with α-catenin. Deletion of E-cadherin has been shown to promote invasive and 
metastatic behaviour in tumours from mouse models of breast and pancreatic cancer (Perl 
et al. 1998; Derksen et al. 2006), suggesting that the loss of E-cadherin leads to a 
mesenchymal phenotype, thereby making it easier for cells to detach from the primary 
tumour and metastasise.  
The loss of E-cadherin is thought to be a hallmark of EMT, resulting in cytoskeletal 
reorganisation, breakdown of adheren junctions, and acquisition of mesenchymal 
characteristics, suggesting that it is an important caretaker of the epithelial phenotype 
(reviewed in Christiansen and Rajasekaran 2006). An EMT gene signature associates with 
Claudin-low and metaplastic breast tumours in humans and certain genes within this cluster 
are correlated with poor survival (Taube et al. 2010). Previous results in this study suggest 
that MSCCs have a poor response to olaparib therapy and may be involved in olaparib 
resistance. These tumours have EMT characteristics, with mesenchymal morphology, high 
levels of Vimentin and Twist expression and very low percentage of E-cadherin positive 
epithelial cells. As loss of E-cadherin is thought to be a critical step in EMT, we hypothesize 
that a high proportion of tumours that originate from cells that have enforced loss of E-
cadherin expression will be MSCCs, and therefore not respond well to olaparib therapy. 
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To investigate whether loss of E-cadherin drives EMT, and thereby affects histological 
tumour type, tumours from conditional Brca2/p53/Cdh1 floxed mice (Reed et al, 
unpublished) were classified by histopathology. Mice harbouring such tumours were also 
treated with the daily 100mg/kg olaparib therapy to investigate whether loss of E-cadherin 
had any effect on tumour response. 
5.2 Results 
5.2.1 BlgCre-Brca2f/f/p53f/f/Cdh1f/f untreated tumours show differences in 
tumour proportion and characteristic staining patterns compared to 
BlgCre-Brca2f/f/p53f/f tumours 
Although no metastatic sites were observed in organ samples BlgCre-Brca2f/f/p53f/f/Cdh1f/f 
tumour-bearing mice, they did show a significantly earlier age of tumour onset compared to 
BlgCre-Brca2f/f/p53f/f mice, with a median age of 246 days compared to 290 days (Wilcoxon, 
p=0.009; Figure 5.1), suggesting that loss of E-cadherin promotes initiation of mammary 
tumour growth, rather than metastasis, in this mouse model.  
Examination of a cohort of 15 untreated tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice 
revealed the presence of three histological types (Figure 5.2). The majority (13) were IDC-
NSTs with 1 AME and 1 ASQC, resulting in a significant difference in proportions compared 
to untreated tumours from BlgCre-Brca2f/f/p53f/f mice (Chi Squared, p=0.05; Figure 5.3A-B). 
Compared to IDC-NSTs from BlgCre-Brca2f/f/p53f/f mice, those in this cohort showed a 
significant up-regulation of CK14 and p63 and a significant down-regulation of CK18 (Mann-
Whitney U test, p=0.037, p=0.045 and p<0.01 respectively; Figure 5.2 and Figure 5.3C-D). 
The AME and ASQC in this cohort showed similar staining patterns to the same tumour 
types from BlgCre-Brca2f/f/p53f/f mice, with high expression of p63 and CK14; however, the 
AME had a low level of CK18 staining (Figure 5.2 and Figure 5.3C-D). As with the BlgCre-
Brca2f/f/p53f/f mouse model, all tumours were ERα negative (Figure 5.4). 
Immunohistochemical analysis of E-cadherin in untreated BlgCre-Brca2f/f/p53f/f/Cdh1f/f 
tumours showed low levels of expression, with the majority showing up to 10% positivity 
and 1 at 30% (Figure 5.5). IDC-NSTs from this cohort showed 0-30% positivity, which is a 
significant reduction from IDC-NSTs in BlgCre-Brca2f/f/p53f/f mice, which show 40-85% 
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(Mann-Whitney U test, p<0.01). The AME and ASQC in this cohort both showed low (<1%) 
levels of E-cadherin staining compared to tumours from BlgCre-Brca2f/f/p53f/f mice (45-85% 
and 60-65% respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Loss of E-cadherin promotes tumour initiation in Blg-cre Brca2f/f p53f/f model. 
Ages of tumour onset in BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice and BlgCre-Brca2f/f/p53f/f mice. 
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Figure 5.2 Representative pictures of untreated tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Tumours were stained with H&E to analyse 
cell morphology, and CK18, CK14 and p63 to analyse the luminal and basal populations.  
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Figure 5.3 Histopathology of tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Proportions of histopathological tumour types in BlgCre-
Brca2f/f/p53f/f/Cdh1f/f (E-cadf/f) mice (A) and BlgCre-Brca2f/f/p53f/f mice (E-cad+/+) (B). Tumours were analysed for CK18 (C), CK14 (D) and p63 (E). * p≤0.05 
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Figure 5.4 Representative pictures of ERα positivity in tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Immunohistochemistry for ERα in 
tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Immunohistochemistry performed by Jarrad Jenkins. 
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Figure 5.5 E-cadherin levels in tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. (A) Representative pictures of E-cadherin staining in the different tumour 
types. (B) Tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice (E-cadf/f) were analysed for E-cadherin positivity and compared to those from BlgCre-
Brca2f/f/p53f/f mice (E-cad+/+). * p≤0.05. E-cadherin immunohistochemistry performed by Jarrad Jenkins.  
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5.2.2 Loss of E-cadherin does not lead to an increase in EMT markers 
As the loss of E-cadherin is thought to be an important step in EMT, EMT markers were 
analysed in tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice (Figure 5.6 and Figure 5.7). IDC-
NSTs showed a significant increase in Slug positivity (Mann-Whitney U test, p=0.04), a trend 
for an increase in Vimentin staining (<1-20% compared to 0-<1%), and no significant 
difference in Twist levels compared to IDC-NSTs from BlgCre-Brca2f/f/p53f/f mice. qRT-PCR 
analysis of Snail expression showed no significant difference between IDC-NSTs from the 
two mouse models (Figure 5.7D). The AME and ASQC showed no differences in EMT marker 
expression compared to tumours from BlgCre-Brca2f/f/p53f/f mice, retaining the low 
expression of Twist and Vimentin and high expression of Slug. These results show that 
tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice have low expression of Twist and Vimentin 
and high expression of Slug. 
5.2.3 BlgCre-Brca2f/f/p53f/f/Cdh1f/f olaparib-resistant tumours show similarities 
to BlgCre-Brca2f/f/p53f/f resistant tumours 
To investigate the effect of E-cadherin loss on response to olaparib therapy, 13 tumour-
bearing BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice were treated with daily IP 100mg/kg olaparib and 
tumour volumes were measured bi-weekly during treatment (Figure 5.8A). The same range 
of responses was seen as in tumours from BlgCre-Brca2f/f/p53f/f mice, with the majority 
showing a moderate or excellent response, and tumours that initially responded well 
relapsing with long-term treatment (Figure 5.8B-C).  
Histopathological analysis of olaparib-resistant BlgCre-Brca2f/f/p53f/f/Cdh1f/f tumours (n=12) 
showed the presence of three of the same tumour types as in the BlgCre-Brca2f/f/p53f/f 
mice, with the majority (58%) being IDC-NSTs, 25% MSCCs and 17% AMEs, resulting in a 
significant difference in proportions compared to untreated tumours, where there is a 
higher proportion of IDC-NSTs and ASQCs, a lower proportion of AMEs and the absence of 
MSCCs (Chi Squared, p=0.05; Figure 5.8D-E). The proportions are also significantly different 
compared to resistant tumours from BlgCre-Brca2f/f/p53f/f mice, which show higher 
proportions of MSCCs and ASQCs, and lower proportions of IDC-NSTs and AMEs (Chi 
Squared, p=0.05; Figure 5.8F).  
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Figure 5.6 Representative pictures of EMT markers in untreated tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Tumours were stained for EMT markers 
Vimentin, Twist and Slug.  
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Figure 5.7 EMT markers in tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Vimentin (A),Twist (B) and Slug (C) expression were analysed in tumours from 
BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice (E-cadf/f) and compared to  tumours from BlgCre-Brca2f/f/p53f/f mice (E-cad+/+).  (D) Snail expression was analysed 
by qRT-PCR in IDC-NSTs from the two mouse models.  qRT-PCR performed by Jarrad Jenkins. * p≤0.05. 
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Figure 5.8 The effect of E-cadherin loss on olaparib therapy. (A) BlgCre-
Brca2f/f/p53f/f/Cdh1f/f mice were treated with daily 100mg/kg olaparib therapy and tumours 
(n=14) showed similar range of responses compared to tumours from BlgCre-Brca2f/f/p53f/f 
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mice, and long-term treatment resulted in tumour relapse. Response to therapy in BlgCre-
Brca2f/f/p53f/f/Cdh1f/f mice (B) and BlgCre-Brca2f/f/p53f/f mice (C) was classified into three 
groups: poor, moderate and excellent. Olaparib-resistant tumours from BlgCre-
Brca2f/f/p53f/f/Cdh1f/f mice were classified by histopathology (E) and the proportions were 
compared to untreated tumours (D), and olaparib-resistant tumours from BlgCre-
Brca2f/f/p53f/f mice (F).  
IDC-NSTs from the resistant cohort (n=7) show a significant reduction in p63 staining 
compared to untreated IDC-NSTs (Mann-Whitney U test, p=0.04), while retaining variable 
expression of CK14 and CK18 (Figure 5.9 and Figure 5.10). Resistant AMEs (n=2) showed 
similar staining to the 1 untreated AME, with high p63 and CK14 expression and low CK18 
expression (Figure 5.9 and Figure 5.10), although the low numbers of this tumour type in 
both cohorts make it difficult to draw any firm conclusions. Comparison of staining patterns 
in resistant tumours from either the E-cadherin+ or E-cadherin- models showed that IDC-
NSTs in the BlgCre-Brca2f/f/p53f/f/Cdh1f/f cohort had a significant reduction in CK18 
expression (Mann-Whitney U test, p=0.03), and similar p63 and CK14 levels (Figure 5.11). 
Resistant AMEs also showed a reduction in CK18 staining compared to those from BlgCre-
Brca2f/f/p53f/f mice, although again the low number of tumours means that statistical 
significance was not reached (Figure 5.11). Resistant MSCCs from both cohorts  showed 
similar staining for all three markers (Figure 5.9 and Figure 5.11) and as before these 
tumours contained epithelial sections that showed staining patterns similar to IDC-NSTs or 
AMEs, with AME sections showing p63 and CK14 positivity and IDC-NST sections showing 
CK18 positivity.   
All resistant IDC-NSTs and AMEs showed low levels of E-cadherin staining (0-10%;  untreated 
tumours. Resistant MSCCs showed <30% E-cadherin positivity (Figure 5.12), which 
correlated with the epithelial sections.  
Analysis of EMT markers in resistant tumours showed that IDC-NSTs had a significant 
increase in Vimentin and Twist staining compared to untreated IDC-NSTs (Mann-Whitney U 
test, p=0.04 and p=0.01 respectively), and the 2 resistant AMEs also showed higher levels of 
Vimentin staining over the 1 untreated AME (Figure 5.13 and Figure 5.14). These results are 
similar to resistant IDC-NSTs and AMEs from BlgCre-Brca2f/f/p53f/f mice which also show 
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Figure 5.9 Representative pictures of olaparib-resistant tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Resistant tumours were stained with H&E and 
immunohistochemistries for CK18, CK14 and p63 were performed.  
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Figure 5.10 Comparison of luminal and basal marker expression in untreated and olaparib-resistant tumours from BlgCre-
Brca2f/f/p53f/f/Cdh1f/f mice. Tumours were analysed for expression of CK18 (A), CK14 (B) and p63 (C). * p≤0.05 
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Figure 5.11 Comparison of luminal and basal markers between olaparib-resistant tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice (E-cadf/f) 
and BlgCre-Brca2f/f/p53f/f mice (E-cad+/+). Tumours were analysed for CK18 (A), CK14 (B) and p63 (C). * p≤0.05. 
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Figure 5.12 E-cadherin levels in olaparib-resistant tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. (A) Representative pictures of E-cadherin 
staining in the olaparib-resistant tumour types. (B) E-cadherin positivity in resistant tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice.  
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higher levels of Vimentin and Twist positivity compared to untreated tumours (chapter 4), 
adding weight to the suggestion that olaparib-resistant tumours with epithelial morphology 
have mesenchymal-like gene expression. The IDC-NSTs and AME also showed a trend for a 
decrease in Slug staining, compared to untreated tumours (Figure 5.14). The MSCCs showed 
high levels of all three EMT markers (Figure 5.13 and Figure 5.15). Comparison between 
BlgCre-Brca2f/f/p53f/f/Cdh1f/f resistant tumours and BlgCre-Brca2f/f/p53f/f resistant tumours 
showed that the MSCCs and IDC-NSTs had similar staining patterns for Vimentin, Twist and 
Slug (Figure 5.15). Resistant AMEs from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice showed a 
decrease in Vimentin and Twist expression compared to BlgCre-Brca2f/f/p53f/f resistant AME 
tumours (Figure 5.15), although again this may be due to the low numbers in these cohorts. 
5.2.4 Characterisation of initial response to olaparib therapy 
Of 15 tumours that received daily IP 100mg/kg olaparib therapy, 13 became resistant 
following either an excellent or moderate response, 1 had a poor response and continued 
growing, and one was harvested during a moderate response due to resistance in a second 
tumour on the same mouse. The poor responder was classified as an AME, which had 
similar staining patterns to the untreated AME from the same mouse model, with high 
expression of p63, CK14 and Slug, and low expression of Vimentin, CK18 and Twist; 
however, it showed a high level of E-cadherin staining in comparison to the 1 untreated 
AME (45% compared to <1%; Figure 5.16 and Figure 5.17). As only one tumour has been 
analysed, firm conclusions cannot be made, but it is interesting that it differs to the BlgCre-
Brca2f/f/p53f/f model, in which tumours that had a poor response to olaparib therapy were 
all classified as MSCCs (n=16, chapter 3). 
The moderate responder was classified as an IDC-NST, which had similar staining patterns to 
untreated IDC-NSTs from the same mouse model, apart from showing an increase in E-
cadherin staining (60% compared to 0-30%; Figure 5.16 and Figure 5.17). In the BlgCre-
Brca2f/f/p53f/f model, IDC-NSTs that are responding moderately to daily olaparib therapy 
show an increase in Vimentin and Twist expression compared to untreated IDC-NSTs; 
however, this IDC-NST retained the low expression of Vimentin and Twist seen in the 
untreated tumours. 
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Figure 5.13 Representative pictures of EMT markers in olaparib-resistant tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Resistant tumours 
were stained for Vimentin, Twist and Slug to analyse EMT. 
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Figure 5.14 Comparison of EMT markers between untreated and olaparib-resistant tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Vimentin (A), Twist (B) and Slug (C) 
positivity in resistant tumours, compared to untreated tumours. * p≤0.05. 
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Figure 5.15 Comparison of EMT markers between olaparib-resistant tumours from BlgCre-Brca2
f/f
/p53
f/f
/Cdh1
f/f
 mice (E-cad
f/f
) and BlgCre-Brca2
f/f
/p53
f/f 
mice (E-cad
+/+
). 
Vimentin (A), Twist (B) and Slug (C) positivity in resistant E-cad
f/f
 tumours, compared to resistant E-cad
+/+
 tumours. * p≤0.05. 
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
0 1 2 3 4 5 6 7
0
10
20
30
40
50
0 1 2 3 4 5 6 7
IDC-NST AME MSCC IDC-NST AME MSCC IDC-NST AME MSCC IDC-NST AME MSCC 
IDC-NST AME MSCC IDC-NST AME MSCC 
E-cad+/+ E-cadf/f E-cad+/+ E-cad
f/f 
E-cad+/+ E-cadf/f 
%
 V
im
en
ti
n
 p
o
si
ti
ve
 t
u
m
o
u
r 
ce
lls
 
%
 T
w
is
t 
p
o
si
ti
ve
 t
u
m
o
u
r 
ce
lls
 
%
 S
lu
g 
p
o
si
ti
ve
 t
u
m
o
u
r 
ce
lls
 
A B 
C 
* 
* * 
* 
* * 
143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 Representative pictures of a poor and moderate responder to daily olaparib therapy. The poor and moderate responder to daily 
100mg/kg olaparib treatment from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice were characterised by staining for CK18, CK14 and p63. 
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Figure 5.17 Representative pictures of EMT markers in a poor and moderate responder to daily olaparib therapy. The poor and moderate 
responder to daily 100mg/kg olaparib treatment from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice were analysed for EMT by staining for E-cadherin, 
Vimentin, Twist and Slug.  
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5.3 Discussion 
5.3.1 Loss of E-cadherin in Brca2/p53-deficient mammary tumours leads to 
earlier age of tumour onset 
Previous studies have shown that loss of E-cadherin in mouse models of breast and prostate 
cancer promotes cancer progression (Perl et al. 1998; Derksen et al. 2006). In this study, 
BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice showed a significantly earlier age of tumour onset 
compared to BlgCre-Brca2f/f/p53f/f mice. Correlating with this, a study in 
K14Cre;Cdh1f/f/p53f/f mouse model suggested that loss of E-cadherin gives a selective 
advantage during tumour initiation (Derksen et al. 2006). This suggests that the loss of E-
cadherin may promote the growth of mammary tumours in these mouse models, possibly 
by producing a more tumour permissive environment, allowing neoplastic cells to grow out 
and form tumours at earlier time points. 
Other studies investigating E-cadherin loss in mammary tumours, using the K14Cre, have 
shown that it leads to metastasis, with the presence of CK18/CK14 positive epithelial cells in 
a number of organs (Derksen et al. 2006; Derksen et al. 2011). No secondary lesions were 
observed during the dissection and histological analysis of organs from mammary-tumour-
bearing BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice in this study. This could be due to differences in 
the mouse models, for example the different promoters for Cre expression, or the inclusion 
of Brca2f/f in our model; however, it would be interesting to investigate whether any 
CK18/CK14 positive cells are present in the organs described in the previous reports. 
5.3.2 Loss of E-cadherin does not result in high proportions of MSCCs 
MSCC tumours from the BlgCre-Brca2f/f/p53f/f model show EMT features, with mesenchymal 
morphology, high Vimentin and Twist staining and low E-cadherin expression. As loss of E-
cadherin is thought to be critical in EMT, it was hypothesised that additional deletion of E-
cadherin in Brca2/p53-deficient mammary tumours would lead to an increase in the 
proportion of MSCCs; however this study showed the absence of MSCCs in these mice, with 
the majority of tumours being IDC-NSTs. A cohort of tumours from BlgCre-
Brca2f/f/p53f/f/Cdh1f/f mice did show differences in the relative proportions of tumour types 
compared to those from the BlgCre-Brca2f/f/p53f/f model, with an increase in IDC-NSTs, a 
decrease in AMEs and the absence of MSCCs. The absence of MSCCs suggests therefore that 
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loss of E-cadherin is not a driving step in the formation of MSCC tumours in the BlgCre-
Brca2f/f/p53f/f model, and that it is possibly the other roles of the transcription factors that 
regulate EMT that are critical for the initiation of the process. This corresponds with a study 
by Derksen and colleagues, where mammary tumours from K14Cre-Cdh1f/f/p53f/f mice were 
found to be mainly invasive lobular carcinomas, which express the luminal marker CK8, have 
variable expression of CK14 and are negative for Vimentin (Derksen et al. 2006). An 
interesting study by Lombaerts and colleagues investigated the effects of different 
mechanisms of loss of E-cadherin expression in a panel of human mammary cell lines and 
showed that cells with rounded morphology and luminal characteristics contained Cdh1 
gene mutations, whilst cells with mesenchymal morphology and EMT characteristics had 
methylation of the E-cadherin promoter (Lombaerts et al. 2006). This may explain the 
absence of MSCCs in the cohort of tumours from the BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice and 
suggests that MSCCs from the BlgCre-Brca2f/f/p53f/f model and olaparib-resistant tumours 
have low E-cadherin expression due to promoter methylation rather than gene mutation.  
Although three of the same tumour types that are present in the BlgCre-Brca2f/f/p53f/f 
model were observed, tumours showed differences in staining patterns. The IDC-NSTs 
showed a significant down-regulation of CK18 and up-regulation of p63 and CK14, and, 
although there were low numbers of AMEs and ASQCs, they also showed a reduction in 
CK18 staining, suggesting that although loss of E-cadherin does not lead to changes in 
morphology, it results in changes in gene expression, with tumours showing a reduction in 
luminal markers and an increase in basal markers. This correlates with other studies that 
have also shown that reduction of E-cadherin is associated with a basal phenotype, for 
example an investigation in human invasive breast carcinomas showed that a reduction in E-
cadherin was associated with CK5/6 and CK17 positivity and triple negative phenotypes 
(Mahler-Araujo et al. 2008), and analysis of different types of human breast tumours 
showed that EMT, including reduction of E-cadherin, related to basal-like tumours (Sarrio et 
al. 2008). 
5.3.3 Loss of E-cadherin does not drive EMT in Brca2/p53-deficient tumours 
Transcriptional repression of E-cadherin is thought to be a critical step in EMT. To 
investigate if the loss of E-cadherin expression drives this process in the BlgCre-
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Brca2f/f/p53f/f model, EMT markers were analysed in tumours from BlgCre-
Brca2f/f/p53f/f/Cdh1f/f mice. The majority of tumours showed ≥1% positivity for Vimentin and 
Twist, with levels no different to those observed in BlgCre-Brca2f/f/p53f/f tumours. The 
majority also showed high levels of Slug staining, which is characteristic for AMEs and 
ASQCs, but low levels are observed in IDC-NSTs from BlgCre-Brca2f/f/p53f/f mice. This high 
level of Slug staining corresponds with high p63 staining, which correlates with previous 
observations in this study (chapter 3). This data suggests that loss of E-cadherin does not 
drive tumour cells to undergo EMT, corresponding with the absence of mesenchymal 
morphology in these tumours.  Although some reports indicate that transcriptional 
repression of E-cadherin can induce EMT (Cano et al. 2000; Bolos et al. 2003), others have 
shown that loss of E-cadherin alone is not essential for EMT; for example, a study by 
Hollestelle and colleagues analysed the loss of E-cadherin expression in different breast 
cancer cell lines and found that not all that had undergone EMT showed loss of E-cadherin 
(Hollestelle et al. 2013). They also investigated the effect of re-introducing E-cadherin cDNA 
into a spindle breast cancer cell line, where they showed no changes in expression and that 
the cells retained their spindle-cell morphology, suggesting that loss of E-cadherin is not a 
critical step in EMT. An in vitro study by Maeda et al (Maeda et al. 2005) induced EMT in 
mammary epithelial cell lines showed that the morphological changes of EMT preceded the 
down-regulation of E-cadherin, again suggesting that loss of E-cadherin is not essential for 
mesenchymal morphology, which could explain why the genetic loss of E-cadherin alone in 
mammary tumours from BlgCre-Brca2f/f/p53f/f mice does not result in mesenchymal 
morphology. 
5.3.4 Loss of E-cadherin has no effect on olaparib treatment and resistance 
We hypothesised that as loss of E-cadherin would lead to a high proportion of MSCCs, 
therefore a poor response to olaparib therapy, as these tumours have been implicated in 
both poor response and resistance to olaparib (chapters 3 and 4). In contrast this study 
showed an absence of MSCCs in these mice, which correlated with daily olaparib treatment 
in tumours from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice showing similar initial responses to those 
seen in BlgCre-Brca2f/f/p53f/f tumours, with the majority showing either an excellent or 
moderate response, with poor response being rare, suggesting that loss of E-cadherin has 
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little or no effect on the initial response to olaparib therapy. Long-term olaparib treatment 
also resulted in tumour relapse, on a similar timescale to that seen in mice with BlgCre-
Brca2f/f/p53f/f tumours. This contrasts with studies in human bladder and pancreatic cancers 
which show that tumours with reduced E-cadherin expression have worse progression free 
survival and overall survival (Fondrevelle et al. 2009; Hong et al. 2011). A study investigating 
E-cadherin expression in human gastric carcinomas, did show that there was no relation to 
response to chemotherapy; however patients with reduced expression did show worse 
survival (Graziano et al. 2004b). 
As seen in resistant tumours from BlgCre-Brca2f/f/p53f/f mice, olaparib-resistant BlgCre-
Brca2f/f/p53f/f/Cdh1f/f tumours showed an increase in the proportion of MSCCs (25%) 
compared to the untreated cohort (0%), re-enforcing the idea that this tumour type is 
involved in the process of olaparib resistance in Brca2-deficient breast cancer. However, the 
predominant tumour type was still found to be IDC-NST, as seen in the untreated cohort. 
Analysis of luminal and basal markers in resistant AMEs showed no significant differences to 
untreated tumours, retaining the low expression of CK18 and high expression of CK14 and 
p63, although due to the low numbers in these cohorts no firm conclusions can be made. 
Resistant IDC-NSTs showed similar CK18 expression to untreated tumours, but showed a 
significant reduction in p63 staining and a trend for a decrease in CK14 staining, suggesting 
that they have lower expression of basal-like genes. As such, they show similar levels of 
basal markers to olaparib-resistant IDC-NSTs from BlgCre-Brca2f/f/p53f/f mice. Taken 
together with the analysis of resistant MSCCs in this mouse model, which showed similar 
expression of CK18, CK14 and p63 compared to resistant MSCCs from BlgCre-Brca2f/f/p53f/f 
mice, this suggests that loss of E-cadherin does not affect levels of these histological 
markers in olaparib-resistant tumours. 
Resistant IDC-NSTs and AMEs from BlgCre-Brca2f/f/p53f/f mice show similarities in EMT 
marker expression to MSCCs, with an increase in Vimentin and Twist staining. The resistant 
MSCCs from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice also had high Vimentin (60-80%) and Twist 
(35-45%) levels, showing that MSCCs from the two mouse models have similar EMT 
expression patterns. Resistant IDC-NSTs from BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice showed a 
significant increase in both Vimentin and Twist levels and resistant AMEs also showed 
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increased levels of Vimentin compared to untreated tumours, suggesting that additional loss 
of E-cadherin does not alter the mesenchymal-like gene expression of olaparib-resistant 
BlgCre-Brca2f/f/p53f/f tumours.  
Two of the tumours treated with daily olaparib did not become resistant as they had to be 
taken at earlier time points. One showed a poor response to olaparib therapy, and was 
characterised as an AME, which differs to the results from BlgCre-Brca2f/f/p53f/f tumours, 
where it was shown poor responders were exclusively MSCCs, suggesting that this tumour 
type has an intrinsic resistance (chapter 3). This resistant AME showed low levels of the EMT 
markers Vimentin and Twist, suggesting that it did not have MSCC characteristics, and 
showed similar staining patterns to the untreated AME from the same mouse model, apart 
from a higher level of E-cadherin staining (45% compared to <1%). This suggests that there 
may be other factors involved in the poor response to olaparib therapy.  
The high expression of E-cadherin in this AME was unusual, as all other untreated and 
resistant tumours analysed showed low expression (0-30%). Interestingly, analysis of a 
moderately-responding BlgCre-Brca2f/f/p53f/f/Cdh1f/f tumour also showed high expression of 
E-cadherin (60%). This tumour was classified as an IDC-NST, which showed similar staining 
patterns to untreated IDC-NSTs from the same mouse model, but did not show an increase 
in Vimentin and Twist staining as seen in moderately responding IDC-NSTs from BlgCre-
Brca2f/f/p53f/f mice, suggesting that in the E-cadherin- model, olaparib therapy may not 
induce Vimentin and Twist expression. These results suggest that further investigation into 
the early responses to olaparib therapy is needed in this mouse model, as there may be 
clinically significant differences from those seen in tumours from BlgCre-Brca2f/f/p53f/f mice. 
5.4 Summary 
Results presented in this chapter suggest that the additional genetic loss of E-cadherin in 
BlgCre-Brca2f/f/p53f/f tumours does not drive EMT and increase the number of MSCCs. In 
contrast, tumours show a reduction in the luminal marker CK18 and high expression of basal 
markers. In addition, loss of E-cadherin did not markedly alter the response to olaparib 
treatment or the development of resistance. Results also give further evidence that 
EMT/mesenchymal characteristics are involved in resistance to olaparib, with resistant 
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tumour cohorts showing an increase in the proportion of MSCCs and other resistant tumour 
types showing an increase in at least some EMT markers. 
5.5 Further Work 
Work presented in this chapter has investigated the effect of additional genetic loss of E-
cadherin in BlgCre-Brca2f/f/p53f/f tumours. It would be interesting to also investigate the 
effect of perturbing expression of other EMT markers in these tumours and analysing 
tumour histology and formation, as well as response and resistance to olaparib. This could 
be done in vivo, by creating new mouse models, or in vitro, using primary cell culture. Of 
particular interest would be loss of Vimentin, as analysis of expression in tumours from 
BlgCre-Brca2f/f/p53f/f mice suggest that it is induced by olaparib treatment, resistant 
tumours show high expression, and MSCCs, which have shown to have a poor response to 
olaparib therapy (chapter 3), show high levels of vimentin staining. 
As mentioned previously, as other studies have suggested that loss of E-cadherin in 
mammary tumours leads to metastasis (Derksen et al. 2006; Derksen et al. 2011), it would 
be interesting to investigate if tumours cells have metastasised in BlgCre-
Brca2f/f/p53f/f/Cdh1f/f mice, by observing if there are CK18/CK14 positive cells in other 
organs. 
It would also be interesting to carry out a more in-depth analysis of the initial responses of 
BlgCre-Brca2f/f/p53f/f/Cdh1f/f tumours to olaparib therapy. This could be done by analysing 
tumours at early time points during olaparib therapy, for example 1 hour and 24 hours after 
a single dose, and tumours showing different responses to daily olaparib therapy after 
around 30 days, similar to the study on BlgCre-Brca2f/f/p53f/f tumours performed in chapter 
3, thereby allowing comparison of early response between the two genetically-distinct 
tumour types. 
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6. General Discussion 
 
6.1 Analysing initial response to olaparib 
Breast cancer is the most common cancer in the UK and, despite increases in survival rates, 
is still the second most common cause of cancer death in women in the UK, 
(http://www.cancerresearchuk.org). Conventional chemotherapies target highly 
proliferating cells, resulting in systemic toxicity, particularly at sites such as hair follicles and 
the small intestine. In order to try to reduce this toxicity in cancer patients, a plethora of 
targeted therapies are in various stages of development, which are designed such that they 
target specific signalling pathways, thereby causing selective death of cancer cells. As breast 
cancer is such a heterogeneous disease, with multiple classification systems and intrinsic 
subgroups, targeted therapies may be critical in the treatment of this disease, thereby 
allowing for personalised therapy to be developed, which is where the patient receives a 
specific tailored treatment based on the genetic/signalling perturbations in their particular 
cancer.  
One strategy for targeted therapy is that of synthetic lethality. First proposed by Theodore 
Dobzhansky in the 1940’s, this is a process where a cell can survive with a deficiency in 
either of two specific proteins, but will die if both are absent (Dobzhansky 1946). PARP 
inhibitors harness the synthetic lethality between deficiencies in the HR pathway (such as 
the BRCA proteins) and deficiency in PARP-1. They cause selective toxicity to BRCA-deficient 
cells (Bryant et al. 2005; Farmer et al. 2005), resulting in low systemic toxicity, making them 
an excellent potential personalised therapy for patients with BRCA mutations that cause 
breast, ovarian and other types of cancers (Audeh et al. 2010; Gelmon et al. 2011). Other 
studies have also suggested that their therapeutic potential may be broadened to other 
subgroups of breast cancer, such as triple-negative breast cancer (Turner and Reis-Filho 
2006). 
As breast cancer is a very heterogeneous disease, precise stratification will be essential for 
patients selected for targeted therapies. PARP inhibitors have been shown to cause 
selective toxicity to BRCA-deficient cells (Bryant et al. 2005; Farmer et al. 2005); however, 
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clinical trials have shown that not all patients with BRCA-deficient breast tumours respond 
to olaparib treatment. A phase I trial in which patients were given doses of olaparib ranging 
from 10mg once daily for two weeks to 600mg twice daily for three weeks, showed a 47% 
response rate in patients with BRCA-mutated tumours (Fong et al. 2009), and a follow-up 
phase II trial showed a 41% response rate in patients with BRCA mutations that were given 
400mg twice daily (Tutt et al. 2010). Preclinical studies in BlgCre-Brca2f/f/p53f/f mice have 
also shown a range of responses to daily olaparib therapy (Hay et al. 2009).  
6.1.1 Investigating if tumour type correlates with different responses to olaparib 
The aim of the work presented in the first chapter of this thesis was to conduct the first in 
vivo study to investigate if tumour type is associated with response to olaparib therapy in a 
BRCA2-mutant setting. Tumour-bearing BlgCre-Brca2f/f/p53f/f mice were treated with daily 
100mg/kg olaparib for 30 days. The responses to olaparib were classified into three groups: 
poor, moderate and excellent, and the tumours classified by histopathology. 
Previous studies have shown that different tumour types have different clinical behaviours 
(Perou et al. 2000a; Sorlie et al. 2003; Reis-Filho and Pusztai 2011), and the presence of four 
different histopathological tumour types in this model indicates that tumour type may 
stratify the response to olaparib therapy. The majority of tumours showed either an 
excellent or a moderate response, with only 20% showing a poor response. Tumours 
showing an excellent response were characterised as ASQCs and IDC-NSTs, whilst moderate 
responders were either AMEs, MSCCs or IDC-NSTs, and poor/non- responders were 
exclusively MSCCs. This variation in responses between the different types of tumours 
suggests that there is indeed a correlation between tumour type and response to olaparib 
therapy. This is important for the clinic, as it suggests that further stratification will be 
needed to determine maximum patient benefit. 
The presence of IDC-NSTs in two different response groups may be explained by the 
significant differences in vimentin staining seen between the groups. Those in the moderate 
responder cohort showed higher levels of vimentin staining, suggesting that vimentin levels 
may be indicative of response. This was also shown to be true independent of tumour type, 
with the tumours in the excellent responder cohort showing low levels of Vimentin-positive 
epithelial cells, whilst moderate responders contained significantly higher levels when 
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compared to excellent responders. In addition, poor responders showed significantly higher 
levels than moderate responders. Other studies have also shown correlations between 
Vimentin expression and sensitivity to therapy, for example gefitinib-resistant cell lines of 
head and neck squamous cell carcinoma and NSCLC were found to express Vimentin, as well 
as other EMT markers, whilst expression was absent in sensitive lines (Frederick et al. 2007). 
Untreated IDC-NSTs show very low levels of Vimentin staining, suggesting that Vimentin 
expression is induced during olaparib treatment. This is supported by the significant 
increase in Vimentin positive cells in IDC-NSTs treated with a single dose of olaparib and 
taken 1 hour later, compared to untreated tumours. The study by Li et al. showed that 
Adriamycin treatment on MCF7 cells induced EMT in a subpopulation (Li et al. 2009), 
suggesting that other cancer therapeutics also induce EMT. 
The significant increase of Vimentin positive cells in IDC-NSTs 1 hour after a single dose of 
olaparib suggests that it has a secondary role of driving EMT/mesenchymal phenotype in 
these tumours. A study analysing olaparib therapy in breast cancer cells in vitro showed that 
treatment induced expression of phosphorylated ERK (Shimo et al. 2014), and they conclude 
that cell death is induced by this pathway. The ERK pathway has also shown to induce ZEB1 
and TWIST expression, suggesting that in a subset of cells olaparib induces EMT via the 
expression of ZEB1 and/or TWIST. This would correlate with the increase in Twist positive 
cells in IDC-NSTs 1 hour after a single dose of olaparib seen in this study. This induction 
could then drive plasticity to eventually form olaparib resistance, resulting in tumour 
relapse. This mechanism may have a broader relevance for cancer therapy, as cisplatin has 
also been shown to induce EMT in ovarian cancer cell lines (Ahmed et al. 2010) and 
carboplatin-resistant tumours in this study classified as IDC-NSTs show a significant increase 
in Vimentin- and Twist-positive cells.    
MSCCs were also found in two different response groups: moderate and poor. Those in the 
poor responder group showed identical morphological and immunohistochemical staining 
patterns to untreated MSCCs, but those in the moderate responder group contained small 
regions of epitheloid morphology, which had similar immunohistochemical staining to IDC-
NSTs or AMEs. This feature was also seen in resistant MSCCs, suggesting that at 30 days of 
treatment, tumours may be starting to show signs of resistance. 
154 
 
In contrast, 2 tumours taken between 18 and 40 days of olaparib therapy from BlgCre-
Brca2f/f/p53f/f/Cdh1f/f mice showed differences to BlgCre-Brca2f/f/p53f/f mice, with a poor 
responder characterised as an AME, and a moderate responder characterised as an IDC-NST, 
with both tumours showing low Vimentin positivity. Because there were only 2 tumours, no 
firm conclusions can be formed, but it suggests that there may be differences between the 
two models which may warrant further investigation. 
6.1.2 MSCCs may be intrinsically resistant 
Poor responders were found to be exclusively MSCCs, showing identical morphology and 
immunohistochemical staining patterns as untreated MSCCs. This suggests that this tumour 
type may have an intrinsic resistance to PARP inhibition, and correlates with studies in 
human breast tumours, which show that metaplastic carcinomas have a poor prognosis (Al 
Sayed et al. 2006; Hennessy et al. 2009). This is interesting as the majority of tumours in our 
model which became resistance during treatment are also MSCCs, or display MSCC 
characteristics, suggesting that the endpoint of acquired resistance in many tumours may be 
the same as those which are intrinsically resistant, or that the tumours which initially 
responded had a low level of intrinsically-resistant cells at treatment outset, which survived 
and were selected for during therapy. EMT features are also associated with resistance to 
other drugs, such as gemcitabine and cisplatin (Arumugam et al. 2009). 
The possibility that MSCCs have an intrinsic resistance to olaparib is very important for the 
clinic, as it suggests that patients with this tumour type will not benefit from olaparib 
therapy, thereby suggesting that the histopathology of tumours should be taken into 
account when stratifying patients for olaparib treatment. Although MSCCs are very rare in 
humans, the intrinsic resistance may also apply to tumours with MSCC features, for example 
the presence of mesenchymal morphology or those with similar expression profiles, 
therefore widening the clinical implications. 
6.2 Investigating the mechanism of resistance to olaparib 
Unfortunately, a recurring problem with cancer treatment is that of drug resistance. Pre-
clinical studies with the PARP inhibitor olaparib in Brca1 and Brca2 conditional knockout 
mice have shown that long-term treatment invariably results in tumour relapse (Rottenberg 
et al. 2008; Hay et al. 2009), and clinical resistance has also been reported (Barber et al. 
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2013). Tumour resistance is highly detrimental in the clinic, hence it is imperative that the 
mechanisms of drug resistance are discovered and explored to ensure the effectiveness of 
cancer drugs.  
The main objective of the work presented in chapter 4 was to discover the mechanism(s) of 
olaparib resistance in a Brca2 conditional knockout mouse model. Olaparib resistance has 
been investigated by other laboratories in vitro and in a Brca1 conditional knockout mouse 
model, making this the first study of an in vivo investigation in a mutant Brca2 setting. Two 
strategies were taken to investigate the mechanism of resistance; firstly by analysing the 
current proposed mechanisms, and secondly by assessing whether histopathological tumour 
type impacts on resistance.  
6.2.1 Investigating proposed mechanisms of resistance 
The rationale behind utilising the P-gp inhibitor Tariquidar in combination with olaparib on 
relapsed tumours from olaparib-treated BlgCre-Brca2f/f/p53f/f mice came from previous 
work in which such olaparib-resistant tumours showed a significant up-regulation of these 
efflux pumps in comparison to untreated tumours (Hay et al. 2009), suggesting that it was 
likely to be a major mechanism of resistance. However, the addition of Tariquidar to 
olaparib-resistant tumours had no effect on tumour relapse and resistant tumours retained 
low PAR levels 1 hour after treatment, suggesting that PARP-1 is still effectively inhibited in 
resistant tumours, despite the up-regulation of P-gps. In addition, it corroborates previous 
work in this model with the AstraZeneca PARP inhibitor AZD2461, which was designed to be 
a lower substrate for P-gps, which found that resistant tumours did not respond to this 
follow-up therapy either (Hay et al. unpublished). This differs from studies in a mouse model 
of Brca1/p53 mutant breast cancer, where sensitivity to olaparib was at least partially 
restored upon inhibition of P-gps with Tariquidar or by treatment with AZD2461 (Rottenberg 
et al. 2008; Jaspers et al. 2013). Tariquidar has also been shown to reverse the resistant 
phenotype of Brca1-deficient mouse mammary tumours to doxorubicin (Pajic et al. 2009). 
Analysis of 53BP1 levels in resistant tumours showed no significant difference to tumours 
that were responding to daily olaparib treatment, suggesting that, unlike in Brca1-deficient 
tumours (Jaspers et al. 2013), loss of this protein is not involved in olaparib resistance. 
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These results show that there are differences in the mechanisms of resistance to PARP 
inhibition between these two genetically distinct mouse models and this will have important 
clinical implications if such differences are replicated in BRCA1- and BRCA2-mutated human 
cancers. Consequently, this would suggest that targeting of resistant tumours from patients 
with BRCA1- and BRCA2-mutated breast cancers will require different therapeutic 
strategies; therefore further studies are needed to investigate the reasons behind the 
differences. It would be interesting to investigate if a similar phenomenon is seen with 
resistance to other drugs, such as carboplatin and cisplatin. 
Results from in vitro and clinical studies investigating olaparib resistance in a BRCA2 setting 
have suggested that secondary mutations in the gene, causing the re-activation of the HR 
pathway, is a mechanism of resistance (Edwards et al. 2008; Barber et al. 2013). Analysis of 
Brca2 expression in resistant tumours in this study showed low expression, suggesting that 
the re-activation of the protein does not occur in this mouse model. However, to fully 
investigate this possibility, sequencing of the Brca2 gene should be performed in resistant 
tumours and re-activation of the HR pathway should be analysed in more detail.  
This is the first study to suggest that olaparib-resistance in a mutant BRCA2 setting is not 
due to these already proposed mechanisms, therefore a novel mechanism or mechanisms 
must be involved.  
6.2.2 Analysing  olaparib-resistant tumour types 
The rationale behind analysing olaparib-resistant tumours by histopathology was due to 
previous studies suggesting that certain breast tumour subtypes are resistance to traditional 
chemotherapeutics (Al Sayed et al. 2006; Hennessy et al. 2009). The majority of olaparib-
resistant Brca2/p53-mutant tumours in this study were characterised as MSCCs, which only 
account for a small proportion of untreated tumours. They are mesenchymal tumours, with 
spindle morphology and high expression of EMT genes such as Vimentin and Twist. 
Interestingly, although other types of resistant tumours showed epitheloid morphology, 
they also exhibited similar expression profiles to MSCCs, with increased expression of EMT 
markers and a decrease in luminal characteristics. This suggests that the mesenchymal/EMT 
features may be important in causing resistance to olaparib in this model, correlating with 
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other studies that show that EMT features are associated with resistance to 
chemotherapeutics (Creighton et al. 2009; Liu et al. 2013). The presence of resistant 
tumours with epitheloid morphology suggests that mesenchymal morphology is not 
necessary for olaparib resistance, rather it is down to the genetic changes, which could be 
termed as partial EMT, and this is the first in vivo study to suggest this. Histological analysis 
of human olaparib-resistant tumours will be critical to see if the results seen in the mouse 
model are recapitulated in humans. This work has important implications for research into 
olaparib therapy as it suggests that relapsed tumours in patients may have EMT features, 
and therefore further studies are needed to investigate whether these features are critical 
for resistance. It will also be important to investigate the processes that lead to the EMT 
features, so that therapies can be developed to prevent resistance to PARP inhibitors. 
Current theories include clonal expansion of cells with intrinsic resistance, or conversion of 
epitheloid cells to more mesenchymal-like cells (Figure 4.23), possibly through partial or full 
EMT. To further this study it would have been beneficial to analyse matched, sequential 
biopsies of initially sensitive and subsequently resistant tumours from the mouse model. 
This would have allowed us to analyse if the same tumour has changed histopathological 
type during treatment. Unfortunately this is impractical in the mouse model due to Home 
Office regulations, the small amount of tumour material that is available in these models, 
and the wound response may also impact the results. 
One further possible hypothesis for the mechanism of resistance is loss of PARP-1 
expression. A previous study has shown that in vitro PARP-1-deficient cells are resistant to 
olaparib (Pettitt et al. 2013), and work in this thesis has shown that PAR levels in resistant 
tumours were low, indicating low PARP activity, which could be due to the loss of PARP-1 
expression. This would correlate with the theory that PARP inhibitors trap PARP-1 at sites of 
damaged DNA, which is cytotoxic to the cell, resulting in cell death (Murai et al. 2012), 
therefore the loss of PARP-1 would prevent the toxicity. As mentioned previously, MSCCs 
may have an intrinsic resistance to olaparib. 2 MSCCs that were treated with vehicle showed 
lower PAR levels compared to IDC-NSTs, suggesting that these tumours have lower PARP-1 
expression, which could lead to intrinsic resistance. 
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6.2.3 Role of E-cadherin 
To further investigate if/which EMT characteristics are important for resistance to olaparib, 
the response to olaparib therapy and tumour histopathology was analysed in tumours from 
BlgCre-Brca2f/f/p53f/f/Cdh1f/f mice. Histopathological analysis of untreated tumours showed 
that the majority had high expression of basal markers and low expression of luminal 
markers, but no difference in EMT associated genes or the presence of mesenchymal 
morphology, suggesting that the genetic loss of E-cadherin does not drive EMT and the 
formation of MSCCs. These results are comparable to those in previous studies performed in 
a similar mouse model (Derksen et al. 2006) and in human breast tumours (Mahler-Araujo 
et al. 2008). Daily olaparib treatment also showed no clear differences compared to BlgCre-
Brca2f/f/p53f/f mice, with the same range of initial responses and relapse with long term 
treatment. This may be because genetic loss of E-cadherin does not seem to drive EMT in 
this model. Resistant tumours showed similar morphological and expression profiles to 
those in BlgCre-Brca2f/f/p53f/f mice, suggesting that EMT is involved in olaparib resistance 
and that the loss of E-cadherin is not critical for resistance. This is probably not surprising as 
resistant IDC-NSTs and AMEs from BlgCre-Brca2f/f/p53f/f mice do not show loss of E-
cadherin. This is important as it eliminates genetic loss of E-cadherin as a possible target for 
therapeutic intervention of olaparib resistance; however other studies suggest that 
mesenchymal morphology correlates with loss of E-cadherin by methylation of the 
promoter (Lombaerts et al. 2006), suggesting that methylation, rather than mutations are 
important for EMT and mesenchymal characteristics. This would correlate with a study in 
human gastric carcinomas which showed that hypermethylation of CDH1 was associated 
with worse prognosis and reduced 5-year survival rate (Graziano et al. 2004a) This means 
that loss of E-cadherin by methylation may be important for olaparib resistance, and 
requires further investigation. 
6.3 Summary of olaparib therapy in a mouse model of BRCA2-
mutated breast cancer  
Daily olaparib therapy has shown to cause regression of BRCA-deficient tumours in 
preclinical studies (Rottenberg et al. 2008; Hay et al. 2009) and clinical trials (Fong et al. 
2009; Tutt et al. 2010); however these studies have also shown that not all BRCA-deficient 
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tumours respond to the treatment. The work in this thesis suggests that tumours with 
mesenchymal features have an intrinsic resistance to olaparib therapy, which would mean 
that further patient stratification is required when deciding on whether this therapy may be 
suitable, and may explain why not all patients with BRCA-mutated breast cancer have 
benefitted from olaparib therapy in current clinical trials. 
Investigating resistance to olaparib therapy in this thesis suggests that tumours which 
initially respond to olaparib therapy harness or acquire certain mesenchymal characteristics 
in order to develop resistance during treatment. This is a novel mechanism of resistance to 
olaparib therapy, and requires further investigation into the specific mechanisms and 
molecular pathways involved in order to target resistance, and prolong clinical benefit. The 
presence of mesenchymal characteristics in carboplatin-resistant tumours from the same 
mouse model suggests that this mechanism could be involved in resistance to other cancer 
treatments, therefore widening the potential benefit of targeting this mechanism. 
Although it is difficult to calculate precisely how many cancer patients will be impacted by 
this research, it has the potential to further stratify BRCA-mutated patients for olaparib 
therapy, thereby impacting patients with tumours that do not have mesenchymal features, 
which the percentage of breast cancer cases is currently unknown.. Tumours with 
mesenchymal features have shown here to have a poorer response to olaparib therapy, this 
suggests that histology, or Vimentin expression in the tumours, could be used to further 
stratify patients for treatment. This work also allows future research to focus on discovering 
the mechanisms that govern this poorer response in order to re-sensitise these tumours, 
therefore potentially improving patient responses. Pre-clinical studies have shown that all 
BRCA-deficient tumours on continuous olaparib therapy relapse, suggesting that a similar 
effect will be seen in humans. This work suggests that majority of these relapsed tumours 
will have mesenchymal features. By discovering the mechanisms of this, and investigating if 
they are critical for tumour relapse, will provide the clinic with a way of combating olaparib 
resistance, therefore possibly impacting the majority of patients with BRCA2- mutated 
breast cancer, that have initially responded to olaparib. 
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Appendix I.  
Networks of genes differentially expressed in “resistant” cohort relative to “responding” cohort.  
Genes in network Functions 
Genes upregulated Genes downregulated  
- BLK, CARD11, CD5, CD6, CD19, CD22, CD27, 
CD180, CD79A, CD79B, FCRLA, ICOS, IGJ, 
IK2F3, LAX1, MS4A1, PIGR, POU2F2, PPP2R2C, 
SH2D1A, SLAMF1, SP1B, TNFRSF13C, TRAT1, 
UBASH3A 
Haematological system development and function, 
humoral immune response, tissue morphology 
AURKA, AUKB, BUB1, CENPA, CENP1, CKAP2, 
DLL4,HIST1H2AB/HIST1H2AE, 
HIST1H2BJ/HIST1H2BK, KIF20A, KIF4A, MAD2L1, 
NCAPG, NDC80, NUF2, PRC1, RACGAP1, SEPT1, 
SHCBP1, UBE2C 
AGAP2, CD226, FYB, GIMAP5 Cell cycle, cellular assembly and organisation, DNA 
replication, recombination andn repair 
BCAT1, CCNA2, CCNB2, CDC25C, CDKN3, CEP55, 
CK51B, DUSP9, HIST1H1A, HIST1H1B, HMGA2, 
KIF22, PLK1, PTPN22, STEAP1, TTK 
ANO3, CTLA4, FREM1 Cellular assembly and organisation, DNA replication, 
recombination and repair, cell cycle 
HMGA2, POU4F2 BTLA, CD19, CEL, CLEC2D, FAM26F, GNA14, 
HAAO, HEPACAM2, IPCEF1, SLAMF6, STAP1 
Inflammatory response, cell-to-cell signalling and 
interaction, haematological system development 
and function 
LGALS1, TOP2A CD2, CD4,CD247,CD3E, CD3G, CD8A, DPP4, 
DTX1, FCRL3, GRAP2, ITK, KYNU, PTPRCAP, 
SH2D2A, THEMIS, ZAP70 
Cellular development, cellualr growth and 
proliferation, haematological system development 
and function 
ASF1B, BIRC5, CCND1, DEPDC1, FAM83D, HAS2, 
MNS1, PHF19, STC1 
GDF6, HLA-DQA1, IKZF1, IKZF4, MUC1, SOX6 Lymphoid tissue structure and development, organ 
morphology, cancer 
POU4F2, STEAP2 AKNA, APOD, ATP8A2, BTLA, CD28, CD40LG, 
COL15A1, FOXP3, HMCN1, IL2RC, IL7R, 
LAMA2, MMP11 
Cellular development, cellualr growth and 
proliferation, haematological system development 
and function 
DNPH1, HIST2H2AB, ADIG, CACNA1E, CYP2D6, CYP4B1, H2-T24, Energy production, endocrine system disorders, 
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HLA-DOA, HLA-DOB, MS4A1, PAMR1, SOX14, 
TOX 
gastrointestinal disease 
KIAA0101, TUBB6 ATP2A3, CD74, CYFIP3, FAAH, ITGA4, KLF15, 
PRKAA2, WIPF3 
Carbohydrate metabolism, cell morphology, organ 
morphology 
BOK C5, CCR6, CCR8, CCR9, CXCR6, CYGB, GPR18, 
GSTA3, HMGCS2, PRG2 
Cell signalling, molecular transport, vitamin and 
mineral  
 
 
 
 
 
 
 
 
 
 
 
 
